No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d1yimA_, 1.0000, 0.00, 1.000, 245, 245, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 4
2, d1xp9A_, 0.9990, 0.18, 1.000, 245, 245, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 18
3, d1xp1A_, 0.9984, 0.24, 1.000, 245, 245, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 15
4, d1xpcA_, 0.9982, 0.25, 1.000, 245, 245, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 19
5, d1xp6A_, 0.9980, 0.27, 1.000, 245, 245, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 16
6, d1sj0A_, 0.9889, 0.32, 1.000, 243, 243, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE ANTAGONIST LIGAND 4-D
7, d2iogA_, 0.9867, 0.43, 1.000, 243, 243, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 11F
8, d1qktA_, 0.9862, 1.00, 0.988, 248, 245, MUTANT ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
9, p6chwA_, 0.9859, 0.82, 0.988, 246, 245, ESTROGEN RECEPTOR ALPHA Y537S COVALENTLY BOUND TO ANTAGONIST H3B-5942.
10, p6chzA_, 0.9843, 1.01, 0.988, 246, 245, ESTROGEN RECEPTOR ALPHA Y537S BOUND TO ANTAGONIST H3B-9224.
11, d2ouzA_, 0.9838, 1.05, 1.000, 246, 245, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA-LASOFOXIFENE COMPLEX
12, d1yinA_, 0.9810, 0.31, 1.000, 241, 241, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 3F
13, d3ertA_, 0.9781, 1.15, 1.000, 246, 245, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 4- HYDROXYTAMOXIFEN
14, d2ertA_, 0.9781, 1.15, 1.000, 246, 245,  
15, d2ayrA1, 0.9740, 0.87, 0.988, 242, 242, A SERM DESIGNED FOR THE TREATMENT OF UTERINE LEIOMYOMA WITH UNIQUE TISSUE SPECIFICITY FOR UTERUS AND OVARIES IN RATS
16, d5fqpA_, 0.9689, 1.12, 0.988, 242, 242, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 1.
17, d5w9dA_, 0.9562, 1.37, 0.979, 242, 242, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S C417S C530S MUTANT IN COMPLEX WITH ENDOXIFEN
18, d3dt3B_, 0.9484, 1.39, 0.992, 240, 239, HUMAN ESTROGEN RECEPTOR ALPHA LBD WITH GW368
19, d3dt3A_, 0.9474, 0.73, 0.991, 236, 235, HUMAN ESTROGEN RECEPTOR ALPHA LBD WITH GW368
20, p5ufwA_, 0.9423, 1.27, 0.983, 237, 237, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1154
21, d2pogA_, 0.9404, 0.52, 0.991, 233, 232, BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR B AGONISTS (SERBAS). PART 2: STRUCTURE ACTIVITY RELATIONSHIP STUDIES ON THE BENZOPYRAN SCAFFOLD.
22, d2q70A_, 0.9403, 0.97, 0.987, 235, 234, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLXED TO A BENZOPYRAN LIGAND
23, d5w9dB_, 0.9395, 1.27, 0.983, 237, 237, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S C417S C530S MUTANT IN COMPLEX WITH ENDOXIFEN
24, d2r6yA_, 0.9362, 0.50, 0.991, 232, 231, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SERM
25, d1uomA_, 0.9362, 0.50, 0.991, 231, 231, THE STRUCTURE OF ESTROGEN RECEPTOR IN COMPLEX WITH A SELECTIVE AND POTENT TETRAHYDROISOCHIOLIN LIGAND.
26, p5w9cB_, 0.9343, 1.14, 0.983, 234, 234, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
27, d2qxsA_, 0.9343, 1.24, 0.953, 236, 235, CRYSTAL STRUCTURE OF ANTAGONIZING MUTANT 536S OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO RALOXIFENE
28, d5fqvA_, 0.9329, 1.14, 0.987, 233, 233, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 5.
29, d5fqsA_, 0.9329, 1.14, 0.987, 233, 233, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 3.
30, d5fqtA_, 0.9325, 1.14, 0.987, 233, 233, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 4.
31, p5ufxA_, 0.9316, 1.25, 0.970, 234, 234, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1074
32, p6c42A_, 0.9309, 1.26, 0.970, 234, 234, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1156
33, d3os8A_, 0.9279, 1.54, 0.962, 240, 237, ESTROGEN RECEPTOR
34, d3os8B_, 0.9271, 1.55, 0.962, 240, 237, ESTROGEN RECEPTOR
35, p5w9cA_, 0.9270, 1.27, 0.970, 233, 233, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
36, d3osaA_, 0.9264, 1.55, 0.958, 239, 237, ESTROGEN RECEPTOR
37, d3osaB_, 0.9253, 1.57, 0.962, 239, 237, ESTROGEN RECEPTOR
38, d5fqrA_, 0.9236, 0.63, 0.982, 228, 228, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 2.
39, d4xi3C_, 0.9235, 1.39, 0.962, 236, 234, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
40, d2r6wA_, 0.9234, 0.61, 0.991, 229, 228, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO A SERM
41, d5accA_, 0.9229, 0.64, 0.982, 228, 228, A NOVEL ORAL SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATOR AZD9496 DRIVES TUMOUR GROWTH INHIBITION IN ESTROGEN RECEPTOR POSITIVE AND ESR1 MUTANT MODELS
42, d3os9A_, 0.9220, 1.19, 0.961, 233, 232, ESTROGEN RECEPTOR
43, d3os8C_, 0.9218, 1.24, 0.987, 234, 232, ESTROGEN RECEPTOR
44, d4xi3B_, 0.9188, 1.30, 0.957, 233, 232, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
45, d2i0jB_, 0.9174, 0.44, 0.991, 227, 226, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
46, p5ufxB_, 0.9165, 1.20, 0.983, 231, 230, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1074
47, d4xi3A_, 0.9165, 1.07, 0.983, 230, 229, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
48, d2iokB_, 0.9135, 0.71, 1.000, 228, 227, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 1D
49, d1r5kA_, 0.9130, 1.73, 0.957, 236, 234, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH GW5638
50, p5didB_, 0.9115, 1.80, 0.923, 245, 233, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(23-DIFLUORO-4-HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1- OL
51, p5w9cD_, 0.9106, 0.95, 0.969, 227, 227, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
52, p5di7B_, 0.9103, 1.81, 0.923, 245, 233, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN METHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(4-HYDROXY-2-METHYLPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
53, p5ufwB_, 0.9101, 1.16, 0.974, 229, 228, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1154
54, d2i0jD_, 0.9097, 0.42, 0.991, 225, 224, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
55, d2qabB_, 0.9089, 1.85, 0.923, 245, 233, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH AN ETHYL INDAZOLE COMPOUND
56, d3osaC_, 0.9075, 1.19, 0.982, 230, 228, ESTROGEN RECEPTOR
57, p5w9cC_, 0.9073, 1.28, 0.987, 228, 228, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
58, d2iokA_, 0.9069, 0.84, 0.991, 227, 226, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 1D
59, d5tnbD_, 0.9068, 0.77, 0.987, 227, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
60, d2yjaB_, 0.9068, 1.92, 0.923, 245, 233, STAPLED PEPTIDES BINDING TO ESTROGEN RECEPTOR ALPHA.
61, d1r5kB_, 0.9067, 1.78, 0.957, 235, 233, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH GW5638
62, d1r5kC_, 0.9065, 1.75, 0.957, 235, 233, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH GW5638
63, d3os8D_, 0.9058, 1.27, 0.987, 230, 228, ESTROGEN RECEPTOR
64, d3erdA_, 0.9048, 1.85, 0.914, 245, 232, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DIETHYLSTILBESTROL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
65, d1pcgB_, 0.9048, 1.89, 0.914, 243, 232, HELIX-STABILIZED CYCLIC PEPTIDES AS SELECTIVE INHIBITORS OF STEROID RECEPTOR-COACTIVATOR INTERACTIONS
66, d1qkuA_, 0.9043, 1.92, 0.923, 250, 233, WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
67, p5tm7B_, 0.9039, 1.93, 0.931, 240, 233, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)HEPTANOIC ACID
68, d3uucC_, 0.9038, 1.23, 0.987, 228, 227, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
69, d1g50A_, 0.9038, 1.94, 0.923, 247, 233, CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
70, p5didA_, 0.9035, 1.82, 0.922, 244, 231, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(23-DIFLUORO-4-HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1- OL
71, d2qa6A_, 0.9035, 1.81, 0.918, 243, 231, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA MUTANT 537S COMPLEXED WITH 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-13-DIOL
72, p5tmlB_, 0.9034, 1.94, 0.931, 241, 233, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND (E)-6-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)HEX-5-ENOIC ACID
73, d1g50B_, 0.9033, 1.94, 0.923, 246, 233, CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
74, d1qkuB_, 0.9032, 1.93, 0.923, 247, 233, WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
75, p4iwcB_, 0.9029, 1.82, 0.905, 240, 231, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC THIOPHENE-DERIVATIVE
76, p5tn1B_, 0.9028, 1.82, 0.922, 245, 231, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14SE)-17-((4- ISOPROPYLPHENYL)IMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
77, p5tlvB_, 0.9024, 1.83, 0.926, 242, 231, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(THIOPHENE-23-DIYL)BIS(3-FLUOROPHENOL)
78, p5digB_, 0.9013, 1.78, 0.909, 242, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUOROMETHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S 3AR5S7AS)-5-[4-HYDROXY-2-(TRIFLUOROMETHYL)PHENYL]-7A- METHYLOCTAHYDRO-1H-INDEN-1-OL
79, d1qkuC_, 0.9008, 1.98, 0.923, 247, 233, WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
80, d1g50C_, 0.9006, 1.99, 0.923, 244, 233, CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
81, d2qa6B_, 0.9003, 1.82, 0.922, 242, 230, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA MUTANT 537S COMPLEXED WITH 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-13-DIOL
82, p5di7A_, 0.9002, 1.81, 0.909, 241, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN METHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(4-HYDROXY-2-METHYLPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
83, d2qr9B_, 0.9002, 1.82, 0.922, 242, 230, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DERIVATIVE COMPOUND
84, d2qseB_, 0.9000, 1.81, 0.922, 242, 230, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH BURNED MEAT COMPOUND 4-OH-PHIP
85, d3q95A_, 0.8995, 1.82, 0.913, 243, 230, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND ESTRIOL
86, d2qxmB_, 0.8995, 1.82, 0.922, 242, 230, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO BURNED MEAT COMPOUND PHIP
87, p5tn1A_, 0.8993, 1.83, 0.935, 245, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14SE)-17-((4- ISOPROPYLPHENYL)IMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
88, d5u2bC_, 0.8992, 1.81, 0.930, 244, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
89, d5u2bA_, 0.8989, 1.91, 0.957, 242, 231, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
90, d5tnbC_, 0.8989, 1.26, 0.956, 229, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
91, d2p15B_, 0.8989, 1.83, 0.922, 242, 230, CRYSTAL STRUCTURE OF THE ER ALPHA LIGAND BINDING DOMAIN WITH THE AGONIST ORTHO-TRIFLUOROMETHYLPHENYLVINYL ESTRADIOL
92, p5tm6B_, 0.8988, 1.89, 0.913, 243, 231, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEXANOIC ACID
93, p5tlxB_, 0.8987, 1.88, 0.926, 242, 231, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
94, p5tmzB_, 0.8986, 1.88, 0.926, 243, 231, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S17S)-16-(3- METHOXYBENZYL)-13-METHYL-78911121314151617-DECAHYDRO-6H- CYCLOPENTA[A]PHENANTHRENE-317-DIOL
95, d2qgwB_, 0.8982, 1.83, 0.922, 242, 230, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH A CHLORO-INDAZOLE COMPOUND
96, d3os9B_, 0.8980, 1.20, 0.960, 228, 226, ESTROGEN RECEPTOR
97, p5tn4B_, 0.8979, 1.88, 0.926, 243, 231, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ACD-RING ESTROGEN (S)-5-(4-HYDROXY-35- DIMETHYLPHENYL)-23-DIHYDRO-1H-INDEN-1-OL
98, p5drjB_, 0.8976, 1.85, 0.913, 242, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 3-METHYL 25-DIARYLTHIOPHENE-CORE LIGAND 44 -(3-METHYLTHIENE-25-DIYL)BIS(3-CHLOROPHENOL)
99, d2i0jC_, 0.8975, 0.60, 0.991, 223, 222, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
100, p5tm3B_, 0.8972, 1.85, 0.917, 243, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 23-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
101, p5kceB_, 0.8971, 1.98, 0.923, 239, 233, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL 2-CHLOROBENZYL OBHS-N DERIVATIVE
102, p5e1cB_, 0.8970, 1.82, 0.913, 241, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE DIMETHYL {(1S)-3-[BIS(4- HYDROXYPHENYL)METHYLIDENE]CYCLOHEXYL}PROPANEDIOATE
103, d2qr9A_, 0.8966, 1.85, 0.930, 242, 230, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DERIVATIVE COMPOUND
104, p5tn3B_, 0.8964, 1.85, 0.926, 243, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S)-17-((4- ISOPROPYLPHENYL)AMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
105, p5tmvB_, 0.8964, 1.87, 0.917, 239, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS ANALOG 4-IODOPHENYL (1S2R4S)-56-BIS(4- HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
106, p5tmrA_, 0.8963, 1.85, 0.909, 242, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (CYCLOHEXYLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
107, p5tmqB_, 0.8963, 1.87, 0.913, 243, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE 4-BROMOPHENYL 44  - DIHYDROXY-[11 :2 1  -TERPHENYL]-4 -SULFONATE
108, p4tuzB_, 0.8961, 1.88, 0.909, 241, 230, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALENOL
109, p3uuaA_, 0.8961, 1.86, 0.913, 241, 230, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-AF
110, d1xqcC_, 0.8961, 0.96, 0.991, 224, 224, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
111, p4mg5A_, 0.8954, 1.87, 0.922, 239, 230, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH CHLORDECONE
112, p5dziB_, 0.8952, 1.83, 0.913, 239, 229, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
113, p5u2dA_, 0.8949, 1.88, 0.926, 246, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
114, d2q6jA_, 0.8948, 1.96, 0.922, 242, 231, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED TO A B-N SUBSTITUTED LIGAND
115, p5dl4B_, 0.8946, 1.82, 0.917, 240, 229, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(PHENYLAMINO)PHENYL]PROP-1-ENE-11-DIYL}DIPHENOL
116, p4mg9A_, 0.8946, 1.90, 0.917, 241, 230, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BUTYLPARABEN
117, p5tmuA_, 0.8945, 1.90, 0.922, 241, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(CYCLOHEPTYLIDENEMETHYLENE)DIPHENOL
118, d2p15A_, 0.8937, 1.91, 0.922, 242, 230, CRYSTAL STRUCTURE OF THE ER ALPHA LIGAND BINDING DOMAIN WITH THE AGONIST ORTHO-TRIFLUOROMETHYLPHENYLVINYL ESTRADIOL
119, d5aauA1, 0.8936, 1.10, 0.955, 225, 224, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
120, d1xqcA_, 0.8934, 1.02, 0.991, 224, 224, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
121, d2r6yB_, 0.8933, 0.43, 0.991, 221, 220, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SERM
122, p5krmB_, 0.8931, 1.79, 0.917, 240, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(25-DIFLUORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
123, d1gwqA_, 0.8927, 1.83, 0.930, 243, 228, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE CORE AND TIF2 NRBOX2 PEPTIDE
124, p4mg8A_, 0.8924, 1.87, 0.921, 240, 229, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALANOL
125, p3uudA_, 0.8923, 1.87, 0.908, 240, 229, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ESTRADIOL
126, p5tmsB_, 0.8922, 1.87, 0.926, 243, 229, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (BICYCLO[3.3.1]NONAN-9-YLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
127, p5dueB_, 0.8922, 1.85, 0.913, 242, 229, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PARA-HYDROXYL-SUBSTITUTED SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG 4-HYDROXYPHENYL (1S2S4S5S6R 7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7-THIABICYCLO[2.2.1]HEPTANE-2- SULFONATE 7-OXIDE
128, p5t1zA_, 0.8921, 1.82, 0.917, 240, 228, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ETHOXYTRIPHENYLETHYLENE AND GRIP PEPTIDE
129, p6c42B_, 0.8920, 1.22, 0.987, 225, 224, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1156
130, d3q97A_, 0.8915, 1.83, 0.921, 243, 228, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND TWO ISOMERS OF ETHOXY TRIPHENYLETHYLENE
131, p5dkgB_, 0.8914, 1.98, 0.926, 240, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A T-BUTYL-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 - [2-(4-TERT-BUTYLPHENYL)PROP-1-ENE-11-DIYL]DIPHENOL
132, d3osaD_, 0.8913, 1.22, 0.987, 226, 224, ESTROGEN RECEPTOR
133, d5tnbA_, 0.8911, 1.27, 0.960, 227, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
134, d1a52A_, 0.8911, 1.50, 0.973, 239, 225, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO ESTRADIOL
135, p5tmwB_, 0.8909, 1.93, 0.939, 240, 229, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS DERIVATIVE 4-ACETAMIDOPHENYL (1S2R4S)-56- BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
136, d3uucD_, 0.8909, 1.72, 0.965, 231, 229, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
137, d1a52B_, 0.8909, 1.54, 0.973, 240, 225, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO ESTRADIOL
138, d2qgtB_, 0.8908, 1.83, 0.912, 239, 228, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO AN ETHER ESTRADIOL COMPOUND
139, p5drmB_, 0.8907, 1.88, 0.952, 235, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 25-DIARYLTHIOPHENE-CORE LIGAND 44 - THIENE-25-DIYLBIS(3-CHLOROPHENOL)
140, d3q97B_, 0.8907, 1.82, 0.912, 240, 228, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND TWO ISOMERS OF ETHOXY TRIPHENYLETHYLENE
141, d1gwrB_, 0.8906, 1.85, 0.917, 239, 228, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-OESTRADIOL AND TIF2 NRBOX3 PEPTIDE
142, d3hlvA_, 0.8905, 1.97, 0.948, 240, 229, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND 16-ALPHA-HYDROXY-ESTRONE ((8S9R13S14R 16R)-316-DIHYDROXY-13-METHYL-78911121415 16-OCTAHYDRO-6H- CYCLOPENTA[A]PHENANTHREN-17-ONE
143, d2r6wB_, 0.8904, 0.85, 0.991, 223, 222, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO A SERM
144, d1gwqB_, 0.8901, 1.94, 0.943, 242, 228, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE CORE AND TIF2 NRBOX2 PEPTIDE
145, p5tm5A_, 0.8900, 1.84, 0.917, 239, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 5-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)PENTANOIC ACID
146, d1xqcB_, 0.8899, 0.72, 0.986, 221, 221, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
147, d2qxsB_, 0.8898, 1.26, 0.982, 225, 224, CRYSTAL STRUCTURE OF ANTAGONIZING MUTANT 536S OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO RALOXIFENE
148, p4znuA_, 0.8897, 1.89, 0.917, 235, 229, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHYL-SUBSTITUTED OBHS DERIVATIVE
149, d2i0jA_, 0.8897, 0.60, 0.991, 221, 220, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
150, p5tlyB_, 0.8895, 1.88, 0.921, 236, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
151, d3hlvB_, 0.8893, 1.87, 0.917, 240, 228, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND 16-ALPHA-HYDROXY-ESTRONE ((8S9R13S14R 16R)-316-DIHYDROXY-13-METHYL-78911121415 16-OCTAHYDRO-6H- CYCLOPENTA[A]PHENANTHREN-17-ONE
152, d5ak2A1, 0.8891, 1.11, 0.960, 224, 223, OXYPHENYLPROPENOIC ACIDS AS ORAL SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS.
153, p4znsB_, 0.8891, 1.87, 0.917, 236, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-FLUORO-SUBSTITUTED OBHS DERIVATIVE
154, p5t1zB_, 0.8890, 1.81, 0.912, 238, 227, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ETHOXYTRIPHENYLETHYLENE AND GRIP PEPTIDE
155, p5tmoB_, 0.8888, 1.88, 0.917, 239, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE PHENYL 44  -DIHYDROXY- [11 :2 1  -TERPHENYL]-4 -SULFONATE
156, p5drmA_, 0.8888, 1.87, 0.912, 239, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 25-DIARYLTHIOPHENE-CORE LIGAND 44 - THIENE-25-DIYLBIS(3-CHLOROPHENOL)
157, d3l03B_, 0.8887, 2.12, 0.904, 242, 230, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTETROL (ESTRA-135(10)-TRIENE-315 ALPHA 16ALPHA17BETA-TETROL)
158, d5aavA1, 0.8885, 1.52, 0.960, 228, 227, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
159, p5e14B_, 0.8882, 1.89, 0.908, 237, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- PHENYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
160, p5tm8A_, 0.8878, 1.90, 0.925, 235, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEPTANOIC ACID
161, d5aauB_, 0.8878, 1.11, 0.977, 222, 222, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
162, p4znvB_, 0.8873, 1.88, 0.917, 243, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHOXY-SUBSTITUTED OBHS DERIVATIVE
163, d1gwrA_, 0.8873, 1.66, 0.929, 238, 226, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-OESTRADIOL AND TIF2 NRBOX3 PEPTIDE
164, d2qseA_, 0.8871, 1.76, 0.929, 238, 226, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH BURNED MEAT COMPOUND 4-OH-PHIP
165, p5dz1B_, 0.8868, 1.98, 0.904, 241, 230, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-ETHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
166, d1errA_, 0.8867, 1.18, 0.978, 224, 223, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE
167, p4zntB_, 0.8865, 1.94, 0.917, 233, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-BROMO-SUBSTITUTED OBHS DERIVATIVE
168, p4ppsA_, 0.8864, 1.84, 0.916, 238, 227, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN A-CD RING ESTROGEN DERIVATIVE
169, p4mgdA_, 0.8864, 1.91, 0.912, 240, 228, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH HPTE
170, p5e0wA_, 0.8861, 1.96, 0.925, 234, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-HYDROXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
171, p5tltB_, 0.8858, 1.88, 0.904, 240, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OCTANE-18-DIYL BIS(23-BIS(4-HYDROXYPHENYL)PENTANOATE)
172, p5gs4A_, 0.8855, 1.98, 0.943, 236, 227, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA IN COMPLEX WITH A STABILIZED PEPTIDE ANTAGONIST
173, p5tlvA_, 0.8854, 1.85, 0.925, 239, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(THIOPHENE-23-DIYL)BIS(3-FLUOROPHENOL)
174, p5dxmB_, 0.8852, 1.84, 0.921, 237, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 3-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(4-HYDROXYPHENYL)METHYL]PHENOL
175, p4mgbA_, 0.8850, 2.02, 0.939, 239, 229, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH TCBPA
176, p4mgaA_, 0.8850, 1.92, 0.895, 239, 228, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH 4-TERT- OCTYLPHENOL
177, d1x7rA_, 0.8850, 1.97, 0.938, 235, 227, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH GENISTEIN
178, p5kraB_, 0.8847, 1.92, 0.921, 240, 228, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
179, d2qgtA_, 0.8845, 1.82, 0.920, 237, 226, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO AN ETHER ESTRADIOL COMPOUND
180, p5e19B_, 0.8842, 1.87, 0.912, 238, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE METHYL {4-[BIS(4-HYDROXYPHENYL) METHYLIDENE]CYCLOHEXYL}ACETATE
181, p5dxkB_, 0.8840, 1.88, 0.921, 239, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(9S)-BICYCLO[3.3.1]NON-9- YLMETHANEDIYL]DIPHENOL
182, p5dtvB_, 0.8840, 1.87, 0.925, 238, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIMETHYL-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
183, p5digA_, 0.8838, 1.83, 0.920, 241, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUOROMETHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S 3AR5S7AS)-5-[4-HYDROXY-2-(TRIFLUOROMETHYL)PHENYL]-7A- METHYLOCTAHYDRO-1H-INDEN-1-OL
184, p4znhA_, 0.8836, 1.83, 0.925, 239, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-FLUORO-SUBSTITUTED OBHS DERIVATIVE
185, d1ndeA_, 0.8835, 1.86, 0.576, 231, 231, ESTROGEN RECEPTOR BETA WITH SELECTIVE TRIAZINE MODULATOR
186, d2jfaB_, 0.8834, 0.95, 1.000, 222, 221, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH AN AFFINITY- SELECTED COREPRESSOR PEPTIDE
187, d5tn9C_, 0.8823, 1.27, 0.937, 224, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
188, p5dlrB_, 0.8822, 1.88, 0.916, 240, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-ETHYLENE COMPOUND 44 -(2-PHENYLETHENE-11-DIYL) DIPHENOL
189, d1xqcD_, 0.8821, 0.94, 0.986, 221, 221, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
190, d1errB_, 0.8821, 1.10, 1.000, 222, 221, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE
191, p4iw8A_, 0.8820, 1.91, 0.890, 239, 228, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 9A
192, p3uu7A_, 0.8817, 1.87, 0.916, 237, 226, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-A
193, d3os9C_, 0.8817, 0.77, 0.982, 221, 219, ESTROGEN RECEPTOR
194, p5gtrA_, 0.8815, 2.03, 0.943, 236, 227, ESTROGEN RECEPTOR ALPHA IN COMPLEX WITH A STABILIZED PEPTIDE ANTAGONIST 6
195, p5du5B_, 0.8813, 1.86, 0.920, 235, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
196, p4pppB_, 0.8812, 1.87, 0.912, 235, 226, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH FLUORO-RESVERATROL
197, p5tn8B_, 0.8811, 1.89, 0.920, 235, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-4-OLATE
198, p5tm2B_, 0.8810, 1.97, 0.934, 231, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
199, p4dmaA_, 0.8808, 1.89, 0.920, 238, 226, CRYSTAL STRUCTURE OF ERA LBD IN COMPLEX WITH RU100132
200, d2qabA_, 0.8808, 1.80, 0.920, 236, 225, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH AN ETHYL INDAZOLE COMPOUND
201, p5krlA_, 0.8806, 1.83, 0.920, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(2-CHLORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
202, d2b1vB_, 0.8806, 2.10, 0.912, 241, 228, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
203, p5dieB_, 0.8804, 1.83, 0.902, 235, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR 5S7AS)-7A-METHYL-5-(235-TRIFLUORO-4-HYDROXYPHENYL)OCTAHYDRO-1H- INDEN-1-OL
204, d4q50F_, 0.8804, 0.98, 0.986, 220, 220, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
205, p4ivwB_, 0.8804, 1.86, 0.920, 238, 226, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 6B
206, d3l03A_, 0.8804, 1.82, 0.920, 235, 225, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTETROL (ESTRA-135(10)-TRIENE-315 ALPHA 16ALPHA17BETA-TETROL)
207, p5tlfB_, 0.8803, 1.87, 0.912, 235, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CONSTRAINED WAY DERIVATIVE 4-(2-(3-METHYLBUT-2-EN- 1-YL)-7-(TRIFLUOROMETHYL)-2H-INDAZOL-3-YL)BENZENE-13-DIOL
208, p5kccA_, 0.8803, 1.88, 0.916, 237, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONAMIDE (OBHS-N)
209, d2qgwA_, 0.8803, 1.81, 0.920, 236, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH A CHLORO-INDAZOLE COMPOUND
210, d3uucB_, 0.8802, 1.61, 0.964, 229, 225, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
211, d1zkyB_, 0.8802, 2.11, 0.912, 242, 228, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-3M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
212, p5krmA_, 0.8801, 1.82, 0.920, 237, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(25-DIFLUORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
213, p5duhA_, 0.8801, 1.83, 0.924, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-3 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-3-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
214, p4ppsB_, 0.8801, 1.83, 0.920, 236, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN A-CD RING ESTROGEN DERIVATIVE
215, p5tn7A_, 0.8800, 1.82, 0.920, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-3 -FLUORO-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[1 1 -BIPHENYL]-4-OLATE
216, p5tluB_, 0.8800, 1.86, 0.916, 238, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PEG-LINKED DIMERIC ESTROGEN EE2-(EG)6-EE2-AMINE
217, p5dieA_, 0.8799, 1.84, 0.920, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR 5S7AS)-7A-METHYL-5-(235-TRIFLUORO-4-HYDROXYPHENYL)OCTAHYDRO-1H- INDEN-1-OL
218, p5tmtA_, 0.8797, 1.88, 0.903, 237, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((13-DIHYDRO-2H-INDEN-2-YLIDENE)METHYLENE)DIPHENOL
219, p5tldB_, 0.8796, 1.91, 0.925, 235, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL
220, p4iwfA_, 0.8796, 1.84, 0.920, 236, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC OXIME-DERIVATIVE
221, p4mgcA_, 0.8795, 1.93, 0.938, 235, 226, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZOPHENONE-2
222, p5tn6A_, 0.8794, 1.85, 0.920, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE SPIRO BC-ESTRADIOL (1S1 S3A S7A S)-7A -METHYL- 1 22 33 3A 4 6 7 7A -DECAHYDRO-15 -SPIROBI[INDENE]-1 5- DIOL
223, p5tmwA_, 0.8791, 1.92, 0.920, 240, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS DERIVATIVE 4-ACETAMIDOPHENYL (1S2R4S)-56- BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
224, p5krhB_, 0.8791, 1.86, 0.916, 237, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16-BENZYLIDENE ESTRONE
225, p5tn7B_, 0.8790, 1.85, 0.929, 235, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-3 -FLUORO-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[1 1 -BIPHENYL]-4-OLATE
226, p5krcB_, 0.8790, 1.84, 0.924, 238, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH ZEARALENONE
227, p5dz3B_, 0.8790, 1.90, 0.903, 238, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(FLUOROMETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
228, p5dk9B_, 0.8790, 1.88, 0.916, 235, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 4 4 -{2-[3-(PHENYLAMINO)PHENYL]BUT-1-ENE-11-DIYL}DIPHENOL
229, p4iv2B_, 0.8790, 1.93, 0.916, 238, 227, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 5A
230, p5tlgB_, 0.8784, 1.84, 0.916, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-44  -DIHYDROXY-3 -((HYDROXYIMINIO)METHYL)-[11 :2  1  -TERPHENYL]-4 -OLATE
231, d2qzoB_, 0.8783, 1.86, 0.920, 235, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH WAY-169916
232, d1x7eB_, 0.8782, 1.96, 0.916, 238, 226, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH WAY-244
233, d1ereC_, 0.8782, 1.96, 0.938, 235, 225, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
234, p4zn7B_, 0.8781, 1.86, 0.929, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DIETHYLSTILBESTROL
235, p4iwcA_, 0.8781, 1.87, 0.924, 236, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC THIOPHENE-DERIVATIVE
236, d1ereF_, 0.8781, 1.96, 0.942, 235, 225, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
237, d1ereB_, 0.8781, 1.96, 0.942, 235, 225, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
238, d1ereA_, 0.8781, 1.96, 0.942, 235, 225, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
239, d4q50C_, 0.8780, 0.93, 0.973, 220, 219, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
240, d2faiB_, 0.8779, 2.14, 0.912, 242, 228, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-2M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
241, d1ereE_, 0.8779, 1.96, 0.938, 235, 225, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
242, d1ereD_, 0.8778, 1.96, 0.942, 235, 225, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
243, d1x7eA_, 0.8777, 1.97, 0.916, 238, 226, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH WAY-244
244, p4mg7A_, 0.8776, 1.91, 0.912, 238, 226, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH FERUTININE
245, p5dxrB_, 0.8775, 1.84, 0.916, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- METHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
246, d4q50G_, 0.8775, 0.99, 0.977, 219, 219, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
247, p5tn3A_, 0.8774, 1.86, 0.924, 238, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S)-17-((4- ISOPROPYLPHENYL)AMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
248, d3q95B_, 0.8770, 2.16, 0.912, 251, 228, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND ESTRIOL
249, d2b1zB_, 0.8769, 2.16, 0.912, 251, 228, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17METHYL-17ALPHA-DIHYDROEQUILENIN AND A GLUCOC INTERACTING PROTEIN 1 NR BOX II PEPTIDE
250, p5tmrB_, 0.8768, 1.97, 0.907, 235, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (CYCLOHEXYLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
251, p5kriB_, 0.8766, 1.88, 0.924, 237, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16B-BENZYL 17B-ESTRADIOL
252, p4tuzA_, 0.8766, 1.88, 0.929, 233, 225, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALENOL
253, p5dmfA_, 0.8764, 1.82, 0.920, 235, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}PROP-1-ENE-11- DIYL)DIPHENOL
254, d3erdB_, 0.8764, 1.87, 0.924, 236, 225, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DIETHYLSTILBESTROL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
255, d1zkyA_, 0.8759, 1.90, 0.920, 237, 225, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-3M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
256, d5tn9D_, 0.8755, 1.84, 0.920, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
257, p5tn5B_, 0.8755, 0.73, 0.986, 219, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE AC-RING ESTROGEN (1S3AS5S7AS)-5-(4- HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
258, d1qknA_, 0.8755, 1.84, 0.915, 235, 224, RAT OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH ANTAGONIST RALOXIFENE
259, p5dydB_, 0.8754, 1.72, 0.577, 228, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(METHYLSULFANYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
260, p5tllA_, 0.8751, 1.85, 0.911, 231, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-2-CHLORO-4 -HYDROXY-4-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-3-OLATE
261, d2g5oA_, 0.8745, 1.85, 0.924, 235, 224, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 2- (BUT-1-ENYL)-17BETA-ESTRADIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
262, p5krjB_, 0.8744, 1.85, 0.911, 235, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN A-NAPHTHYL SUBSTITUTED OBHS DERIVATIVE
263, p5kcuB_, 0.8743, 1.78, 0.929, 229, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL ALPHA-NAPHTHYL OBHS-N DERIVATIVE
264, p4iu7B_, 0.8740, 1.57, 0.924, 227, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 2B
265, p5tlpA_, 0.8737, 2.01, 0.938, 237, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-BSC ANALOG 3-FLUOROPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE AND 3-METHYL-6-PHENYL-3H- IMIDAZO[45-B]PYRIDIN-2-AMINE
266, p5kriA_, 0.8737, 1.83, 0.928, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16B-BENZYL 17B-ESTRADIOL
267, d2g44A_, 0.8736, 1.80, 0.928, 234, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M-G AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
268, p5tmzA_, 0.8734, 1.87, 0.920, 234, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S17S)-16-(3- METHOXYBENZYL)-13-METHYL-78911121314151617-DECAHYDRO-6H- CYCLOPENTA[A]PHENANTHRENE-317-DIOL
269, p5tm7A_, 0.8734, 1.87, 0.924, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)HEPTANOIC ACID
270, p5kraF_, 0.8734, 1.93, 0.929, 234, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
271, p5e1cA_, 0.8734, 1.91, 0.902, 237, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE DIMETHYL {(1S)-3-[BIS(4- HYDROXYPHENYL)METHYLIDENE]CYCLOHEXYL}PROPANEDIOATE
272, p5dugA_, 0.8732, 1.85, 0.924, 237, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
273, p5e0xA_, 0.8731, 1.88, 0.920, 234, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-METHOXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
274, p5dueA_, 0.8729, 1.89, 0.929, 230, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PARA-HYDROXYL-SUBSTITUTED SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG 4-HYDROXYPHENYL (1S2S4S5S6R 7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7-THIABICYCLO[2.2.1]HEPTANE-2- SULFONATE 7-OXIDE
275, d4q50E_, 0.8725, 1.87, 0.920, 235, 224, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
276, p5tlfA_, 0.8724, 0.86, 0.991, 218, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CONSTRAINED WAY DERIVATIVE 4-(2-(3-METHYLBUT-2-EN- 1-YL)-7-(TRIFLUOROMETHYL)-2H-INDAZOL-3-YL)BENZENE-13-DIOL
277, d2jfaA_, 0.8724, 1.97, 0.924, 237, 225, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH AN AFFINITY- SELECTED COREPRESSOR PEPTIDE
278, p5dl4A_, 0.8723, 0.98, 0.986, 221, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(PHENYLAMINO)PHENYL]PROP-1-ENE-11-DIYL}DIPHENOL
279, d4q50H_, 0.8722, 1.82, 0.933, 237, 223, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
280, p4iw6B_, 0.8721, 1.02, 0.982, 218, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 7B
281, p5tllB_, 0.8720, 1.90, 0.911, 235, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-2-CHLORO-4 -HYDROXY-4-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-3-OLATE
282, p4tv1A_, 0.8720, 1.83, 0.924, 234, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH PROPYLPARABEN
283, p4pp6A_, 0.8717, 1.83, 0.919, 233, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RESVERATROL
284, p4mgcB_, 0.8717, 1.83, 0.919, 234, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZOPHENONE-2
285, d2faiA_, 0.8715, 1.83, 0.919, 234, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-2M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
286, d3hm1A_, 0.8714, 1.86, 0.919, 233, 223, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTRONE ((8R9S13S14S)-3-HYDROXY-13-METHYL- 7891112141516-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE)
287, d2b1vA_, 0.8714, 1.84, 0.915, 232, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
288, p5dmcB_, 0.8711, 1.84, 0.919, 233, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A NITRILE-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 33-BIS(4- HYDROXYPHENYL)-2-PHENYLPROP-2-ENENITRILE
289, p5eitB_, 0.8709, 1.93, 0.920, 231, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- (TRIFLUOROMETHYL)IMIDAZO[12-A]PYRIDIN-6-OL
290, p5dxbA_, 0.8709, 1.85, 0.919, 235, 223, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P1 AND ESTRADIOL
291, d2g5oB_, 0.8709, 1.87, 0.919, 231, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 2- (BUT-1-ENYL)-17BETA-ESTRADIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
292, p5dziA_, 0.8707, 1.86, 0.915, 236, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
293, p5dx3A_, 0.8705, 1.83, 0.924, 235, 223, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P3 AND ESTRADIOL
294, p5tlxA_, 0.8703, 1.87, 0.919, 231, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
295, p5tmvA_, 0.8702, 1.90, 0.919, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS ANALOG 4-IODOPHENYL (1S2R4S)-56-BIS(4- HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
296, p5dmfB_, 0.8700, 1.94, 0.924, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}PROP-1-ENE-11- DIYL)DIPHENOL
297, p5tn5A_, 0.8699, 1.86, 0.915, 233, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE AC-RING ESTROGEN (1S3AS5S7AS)-5-(4- HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
298, p5tn4A_, 0.8699, 1.85, 0.919, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ACD-RING ESTROGEN (S)-5-(4-HYDROXY-35- DIMETHYLPHENYL)-23-DIHYDRO-1H-INDEN-1-OL
299, p5krfB_, 0.8699, 1.87, 0.919, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE DYNAMIC WAY DERIVATIVE 1A
300, p5ei1B_, 0.8698, 1.90, 0.911, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- IODANYL-IMIDAZO[12-A]PYRIDIN-6-OL
301, p5dwiB_, 0.8698, 1.93, 0.924, 233, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 2-CHLORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(2-CHLOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
302, p5kd9A_, 0.8697, 1.90, 0.928, 231, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
303, p5kd9B_, 0.8696, 1.96, 0.924, 235, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
304, p5dxkA_, 0.8695, 1.84, 0.924, 228, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(9S)-BICYCLO[3.3.1]NON-9- YLMETHANEDIYL]DIPHENOL
305, p5drjA_, 0.8694, 1.78, 0.914, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 3-METHYL 25-DIARYLTHIOPHENE-CORE LIGAND 44 -(3-METHYLTHIENE-25-DIYL)BIS(3-CHLOROPHENOL)
306, p5wgqA_, 0.8692, 1.86, 0.924, 234, 223, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-BCP1 
307, p5ei1A_, 0.8692, 1.89, 0.910, 231, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- IODANYL-IMIDAZO[12-A]PYRIDIN-6-OL
308, p5dugB_, 0.8692, 1.82, 0.919, 232, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
309, p5egvB_, 0.8691, 1.87, 0.919, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX THE 34-DIARYL-FURAN DERIVATIVE 3-CHLORANYL-4-[4-(2- CHLORANYL-4-OXIDANYL-PHENYL)FURAN-3-YL]PHENOL
310, p5dkbA_, 0.8691, 1.91, 0.919, 232, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-METHYLPHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(3-METHYLPHENYL)AMINO]PHENYL}BUT-1-ENE-11- DIYL)DIPHENOL
311, p5dkeB_, 0.8689, 1.87, 0.928, 230, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-NAPHTHYL-SUBSTITUTED METHYL CIS-DIARYL-ETHYLENE COMPOUND 44 -[2-(NAPHTHALEN-2-YL)PROP-1-ENE-11-DIYL]DIPHENOL
312, p5tmsA_, 0.8687, 1.84, 0.933, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (BICYCLO[3.3.1]NONAN-9-YLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
313, p5tmqA_, 0.8687, 1.89, 0.924, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE 4-BROMOPHENYL 44  - DIHYDROXY-[11 :2 1  -TERPHENYL]-4 -SULFONATE
314, d4xi3D_, 0.8687, 1.89, 0.924, 234, 223, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
315, d1l2iA_, 0.8687, 1.20, 0.991, 219, 218, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH (RR)-511-CIS-DIETHYL-561112- TETRAHYDROCHRYSENE-28-DIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
316, d2b1zA_, 0.8685, 1.83, 0.910, 233, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17METHYL-17ALPHA-DIHYDROEQUILENIN AND A GLUCOC INTERACTING PROTEIN 1 NR BOX II PEPTIDE
317, p5tm4A_, 0.8682, 1.83, 0.919, 232, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG 5-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)PENTANOIC ACID
318, p5tm1B_, 0.8682, 1.91, 0.928, 228, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
319, p4zn7A_, 0.8682, 1.94, 0.937, 226, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DIETHYLSTILBESTROL
320, p5dkgA_, 0.8680, 1.88, 0.919, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A T-BUTYL-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 - [2-(4-TERT-BUTYLPHENYL)PROP-1-ENE-11-DIYL]DIPHENOL
321, d3uucA_, 0.8680, 1.88, 0.928, 231, 223, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
322, d5tn9A_, 0.8679, 1.19, 0.982, 220, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
323, p5dvsA_, 0.8678, 1.40, 0.955, 222, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-METHYL-SUBSTITUTED TRIARYL-IMINE 44 -[(2-METHYLPHENYL) CARBONIMIDOYL]DIPHENOL
324, p5dxmA_, 0.8676, 1.82, 0.928, 231, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 3-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(4-HYDROXYPHENYL)METHYL]PHENOL
325, d3hm1B_, 0.8676, 1.93, 0.924, 234, 223, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTRONE ((8R9S13S14S)-3-HYDROXY-13-METHYL- 7891112141516-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE)
326, p5dzhB_, 0.8675, 1.85, 0.919, 236, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
327, p5tmoA_, 0.8674, 1.96, 0.911, 235, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE PHENYL 44  -DIHYDROXY- [11 :2 1  -TERPHENYL]-4 -SULFONATE
328, p5dkbB_, 0.8674, 1.93, 0.924, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-METHYLPHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(3-METHYLPHENYL)AMINO]PHENYL}BUT-1-ENE-11- DIYL)DIPHENOL
329, p5tmuB_, 0.8672, 1.89, 0.919, 232, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(CYCLOHEPTYLIDENEMETHYLENE)DIPHENOL
330, p5tm6A_, 0.8672, 1.93, 0.928, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEXANOIC ACID
331, p5eitA_, 0.8672, 1.99, 0.937, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- (TRIFLUOROMETHYL)IMIDAZO[12-A]PYRIDIN-6-OL
332, d1l2jA_, 0.8671, 1.85, 0.919, 234, 222, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH (R R)-511-CIS-DIETHYL-561112-TETRAHYDROCHRYSENE-28-DIOL
333, p4mg6A_, 0.8668, 1.87, 0.539, 232, 228, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZYLBUTYLPHTALATE
334, p5kr9B_, 0.8666, 1.91, 0.915, 233, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH COUMESTROL
335, p5dy8B_, 0.8664, 1.85, 0.919, 233, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3- ETHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
336, p5dybB_, 0.8663, 1.90, 0.915, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -(34-DIHYDRONAPHTHALEN-2(1H)- YLIDENEMETHANEDIYL)DIPHENOL
337, p5dxrA_, 0.8663, 1.92, 0.910, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- METHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
338, p5duhB_, 0.8662, 1.93, 0.928, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-3 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-3-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
339, p5tlyA_, 0.8660, 1.91, 0.928, 233, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
340, p5kr9A_, 0.8660, 1.81, 0.923, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH COUMESTROL
341, p5dwiA_, 0.8658, 1.94, 0.919, 236, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 2-CHLORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(2-CHLOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
342, p5hyrA_, 0.8656, 1.90, 0.941, 232, 222, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-SP2 AND ESTRADIOL
343, p5krcA_, 0.8654, 1.88, 0.919, 231, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH ZEARALENONE
344, p4tv1B_, 0.8654, 1.82, 0.919, 233, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH PROPYLPARABEN
345, p5e15B_, 0.8653, 1.91, 0.941, 231, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
346, p5dxpB_, 0.8653, 2.00, 0.924, 233, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 4-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(PHENYL)METHYL]PHENOL
347, p2bj4A_, 0.8651, 1.78, 0.932, 230, 221, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A PHAGE-DISPLAY DERIVED PEPTIDE ANTAGONIST
348, p5dksB_, 0.8650, 0.88, 0.986, 218, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-NAPHTHYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(NAPHTHALEN-1-YLAMINO)PHENYL]BUT-1-ENE-11- DIYL}DIPHENOL
349, p5ehjB_, 0.8647, 1.93, 0.924, 227, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4AR8AR)-OCTAHYDRONAPHTHALEN- 2(1H)-YLIDENEMETHANEDIYL]DIPHENOL
350, d2qxmA_, 0.8647, 2.04, 0.915, 234, 224, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO BURNED MEAT COMPOUND PHIP
351, p5tmlA_, 0.8645, 1.82, 0.923, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND (E)-6-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)HEX-5-ENOIC ACID
352, p5dz0A_, 0.8645, 1.99, 0.933, 235, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-METHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
353, d2qh6A_, 0.8644, 2.05, 0.924, 236, 224, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DIARYLETHYLENE COMPOUND
354, p5kctA_, 0.8643, 1.83, 0.923, 232, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
355, d4q50D_, 0.8642, 1.98, 0.924, 236, 223, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
356, d2qa8B_, 0.8642, 0.76, 0.981, 216, 215, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH GENISTEIN
357, d2g44B_, 0.8640, 1.89, 0.914, 234, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M-G AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
358, p4mg5B_, 0.8636, 1.84, 0.919, 234, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH CHLORDECONE
359, d1qkmA_, 0.8636, 1.92, 0.919, 234, 222, HUMAN OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST GENISTEIN
360, p5dweA_, 0.8633, 2.00, 0.542, 230, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-CHLORO-SUBSTITUTED TRIARYL-IMINE ANALOG 44 -[(2- CHLOROPHENYL)CARBONIMIDOYL]DIPHENOL
361, p4mgdB_, 0.8628, 1.99, 0.932, 236, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH HPTE
362, p5tloB_, 0.8627, 1.94, 0.928, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A SQUARIC ACID-LINKED DIMERIC ESTROGEN
363, p5dz0B_, 0.8626, 1.85, 0.928, 232, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-METHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
364, p5dxeA_, 0.8626, 1.93, 0.883, 234, 222, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P4 AND ESTRADIOL
365, p5du5A_, 0.8626, 1.87, 0.919, 228, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
366, p5e14A_, 0.8623, 1.93, 0.946, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- PHENYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
367, p5tloA_, 0.8621, 2.00, 0.941, 232, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A SQUARIC ACID-LINKED DIMERIC ESTROGEN
368, p4iu7A_, 0.8621, 1.96, 0.928, 229, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 2B
369, p4dmaB_, 0.8621, 2.01, 0.928, 235, 223, CRYSTAL STRUCTURE OF ERA LBD IN COMPLEX WITH RU100132
370, p5tm3A_, 0.8620, 1.93, 0.919, 235, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 23-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
371, p5kctB_, 0.8620, 1.96, 0.937, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
372, p5e19A_, 0.8620, 1.88, 0.910, 226, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE METHYL {4-[BIS(4-HYDROXYPHENYL) METHYLIDENE]CYCLOHEXYL}ACETATE
373, p3uu7B_, 0.8619, 1.86, 0.914, 233, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-A
374, d1l2iB_, 0.8615, 1.88, 0.919, 232, 221, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH (RR)-511-CIS-DIETHYL-561112- TETRAHYDROCHRYSENE-28-DIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
375, p5tm5B_, 0.8614, 1.89, 0.919, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 5-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)PENTANOIC ACID
376, p5kcwA_, 0.8613, 1.88, 0.923, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL OBHS-N DERIVATIVE
377, p5wgdA_, 0.8610, 1.89, 0.923, 233, 221, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-LP1 
378, p4znsA_, 0.8610, 1.83, 0.918, 228, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-FLUORO-SUBSTITUTED OBHS DERIVATIVE
379, d2q6jB_, 0.8610, 1.96, 0.946, 231, 221, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED TO A B-N SUBSTITUTED LIGAND
380, p2bj4B_, 0.8610, 1.95, 0.919, 233, 222, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A PHAGE-DISPLAY DERIVED PEPTIDE ANTAGONIST
381, d2qa8A_, 0.8607, 1.47, 1.000, 221, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH GENISTEIN
382, p5kcfB_, 0.8606, 1.93, 0.941, 229, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-METHOXYBENZYL OBHS-N DERIVATIVE
383, p5dwjA_, 0.8606, 1.98, 0.914, 227, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 4-FLUORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(4-FLUOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
384, d2b23B_, 0.8606, 1.96, 0.946, 231, 221, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
385, p5kroB_, 0.8602, 1.90, 0.914, 230, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE METHYL(PHENYL)AMINO-SUBSTITUTED ESTROGEN (8R9S 13S14S17S)-13-METHYL-17-(METHYL(PHENYL)AMINO)-7891112131415 1617-DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
386, d5jmmB_, 0.8601, 1.94, 0.932, 228, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BIOCHANIN A
387, p5tmtB_, 0.8600, 2.00, 0.919, 233, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((13-DIHYDRO-2H-INDEN-2-YLIDENE)METHYLENE)DIPHENOL
388, p3uudB_, 0.8600, 1.98, 0.928, 234, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ESTRADIOL
389, p5krhA_, 0.8598, 1.90, 0.923, 235, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16-BENZYLIDENE ESTRONE
390, p5kcfA_, 0.8598, 1.81, 0.923, 231, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-METHOXYBENZYL OBHS-N DERIVATIVE
391, p5dxgA_, 0.8598, 1.99, 0.923, 236, 222, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P5
392, p4znwB_, 0.8598, 1.84, 0.918, 228, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 4-BROMO-SUBSTITUTED OBHS DERIVATIVE
393, p5dk9A_, 0.8597, 1.91, 0.928, 228, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 4 4 -{2-[3-(PHENYLAMINO)PHENYL]BUT-1-ENE-11-DIYL}DIPHENOL
394, p4mg8B_, 0.8597, 1.89, 0.923, 230, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALANOL
395, p4pxmA_, 0.8596, 1.91, 0.928, 234, 221, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH ESTRADIOL AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
396, p5tn6B_, 0.8594, 1.81, 0.918, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE SPIRO BC-ESTRADIOL (1S1 S3A S7A S)-7A -METHYL- 1 22 33 3A 4 6 7 7A -DECAHYDRO-15 -SPIROBI[INDENE]-1 5- DIOL
397, d1pcgA_, 0.8594, 1.92, 0.941, 230, 220, HELIX-STABILIZED CYCLIC PEPTIDES AS SELECTIVE INHIBITORS OF STEROID RECEPTOR-COACTIVATOR INTERACTIONS
398, p5kcdA_, 0.8593, 1.96, 0.905, 232, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL SUBSTITUTED OBHS-N DERIVATIVE
399, p5dzhA_, 0.8592, 1.86, 0.923, 231, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
400, p4iv4B_, 0.8591, 1.99, 0.923, 235, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 5B
401, p4mgaB_, 0.8586, 1.91, 0.910, 232, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH 4-TERT- OCTYLPHENOL
402, p4ivyB_, 0.8586, 1.94, 0.928, 233, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 7A
403, p5dp0B_, 0.8582, 1.90, 0.923, 232, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 4 4 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}ETHENE-11-DIYL)DIPHENOL
404, p4mg6B_, 0.8582, 1.91, 0.910, 232, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZYLBUTYLPHTALATE
405, p5wgqB_, 0.8581, 2.02, 0.919, 234, 222, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-BCP1 
406, p5kroA_, 0.8581, 1.82, 0.927, 229, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE METHYL(PHENYL)AMINO-SUBSTITUTED ESTROGEN (8R9S 13S14S17S)-13-METHYL-17-(METHYL(PHENYL)AMINO)-7891112131415 1617-DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
407, d5tnbB_, 0.8579, 1.81, 0.922, 229, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
408, p5tm8B_, 0.8579, 0.79, 0.986, 215, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEPTANOIC ACID
409, p5tldA_, 0.8578, 1.95, 0.941, 228, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL
410, p5dtvA_, 0.8578, 1.81, 0.927, 230, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIMETHYL-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
411, p5tlgA_, 0.8576, 1.93, 0.945, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-44  -DIHYDROXY-3 -((HYDROXYIMINIO)METHYL)-[11 :2  1  -TERPHENYL]-4 -OLATE
412, p5krfA_, 0.8575, 1.89, 0.941, 229, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE DYNAMIC WAY DERIVATIVE 1A
413, d2z4bB_, 0.8575, 2.03, 0.923, 234, 222, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
414, p5e0xB_, 0.8574, 1.86, 0.540, 224, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-METHOXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
415, d2jj3B_, 0.8574, 1.84, 0.927, 230, 219, ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
416, p5kcuA_, 0.8573, 1.95, 0.542, 226, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL ALPHA-NAPHTHYL OBHS-N DERIVATIVE
417, p4znwA_, 0.8572, 1.83, 0.936, 226, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 4-BROMO-SUBSTITUTED OBHS DERIVATIVE
418, p4zntA_, 0.8572, 1.97, 0.923, 234, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-BROMO-SUBSTITUTED OBHS DERIVATIVE
419, p5kraE_, 0.8569, 1.94, 0.945, 229, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
420, p5dxqB_, 0.8569, 1.88, 0.950, 228, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENEMETHANEDIYL]DIPHENOL
421, p4zn9A_, 0.8569, 1.89, 0.923, 232, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
422, p4mgbB_, 0.8569, 1.90, 0.918, 237, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH TCBPA
423, d5jmmA_, 0.8568, 1.93, 0.918, 232, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BIOCHANIN A
424, p4pp6B_, 0.8568, 1.89, 0.918, 230, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RESVERATROL
425, p5dlrA_, 0.8565, 1.94, 0.936, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-ETHYLENE COMPOUND 44 -(2-PHENYLETHENE-11-DIYL) DIPHENOL
426, d2giuA_, 0.8565, 1.99, 0.928, 233, 221, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 45
427, p5krjA_, 0.8562, 1.95, 0.533, 225, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN A-NAPHTHYL SUBSTITUTED OBHS DERIVATIVE
428, p4mg9B_, 0.8562, 1.95, 0.936, 231, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BUTYLPARABEN
429, p5krlB_, 0.8561, 1.98, 0.945, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(2-CHLORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
430, p4znhB_, 0.8560, 1.90, 0.950, 228, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-FLUORO-SUBSTITUTED OBHS DERIVATIVE
431, p5dksA_, 0.8556, 1.90, 0.941, 227, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-NAPHTHYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(NAPHTHALEN-1-YLAMINO)PHENYL]BUT-1-ENE-11- DIYL}DIPHENOL
432, p4ivwA_, 0.8556, 1.84, 0.922, 225, 219, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 6B
433, p5dxqA_, 0.8552, 2.00, 0.923, 234, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENEMETHANEDIYL]DIPHENOL
434, p4q13A_, 0.8552, 1.94, 0.945, 227, 219, APO ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT WITH A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
435, p4iw6A_, 0.8551, 2.00, 0.936, 226, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 7B
436, p4iwfB_, 0.8550, 2.01, 0.928, 233, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC OXIME-DERIVATIVE
437, p5dy8A_, 0.8549, 1.92, 0.945, 228, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3- ETHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
438, p5tlmA_, 0.8548, 2.02, 0.928, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 4  -(THIOPHENE-235-TRIYL)TRIPHENOL
439, p5tltA_, 0.8546, 1.89, 0.932, 226, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OCTANE-18-DIYL BIS(23-BIS(4-HYDROXYPHENYL)PENTANOATE)
440, p4znvA_, 0.8545, 2.02, 0.923, 234, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHOXY-SUBSTITUTED OBHS DERIVATIVE
441, d2qh6B_, 0.8544, 2.03, 0.910, 237, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DIARYLETHYLENE COMPOUND
442, p3uuaB_, 0.8540, 1.95, 0.941, 228, 219, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-AF
443, p5tluA_, 0.8530, 1.96, 0.941, 228, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PEG-LINKED DIMERIC ESTROGEN EE2-(EG)6-EE2-AMINE
444, d5toaB_, 0.8529, 1.96, 0.945, 229, 219, CRYSTAL STRUCTURE OF ER BETA BOUND TO ESTRADIOL
445, p6cbzA_, 0.8528, 2.27, 0.524, 232, 227, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ESTRADIOL AND GRIP PEPTIDE
446, p4pppA_, 0.8528, 1.84, 0.917, 227, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH FLUORO-RESVERATROL
447, d3ollA_, 0.8528, 1.91, 0.940, 228, 218, CRYSTAL STRUCTURE OF PHOSPHORYLATED ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
448, d2qtuB_, 0.8527, 2.22, 0.527, 234, 226, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
449, p5krkA_, 0.8526, 1.79, 0.545, 222, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((5-BROMO-23-DIHYDRO-1H-INDEN-1-YLIDENE) METHYLENE)DIPHENOL
450, p5u2dB_, 0.8525, 1.85, 0.931, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
451, d5toaA_, 0.8525, 2.07, 0.914, 239, 221, CRYSTAL STRUCTURE OF ER BETA BOUND TO ESTRADIOL
452, d2q70B_, 0.8525, 2.15, 0.529, 230, 225, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLXED TO A BENZOPYRAN LIGAND
453, p5egvA_, 0.8524, 0.43, 0.990, 211, 210, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX THE 34-DIARYL-FURAN DERIVATIVE 3-CHLORANYL-4-[4-(2- CHLORANYL-4-OXIDANYL-PHENYL)FURAN-3-YL]PHENOL
454, p4q13B_, 0.8523, 1.92, 0.940, 229, 218, APO ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT WITH A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
455, d2i0gB_, 0.8522, 1.91, 0.940, 226, 218, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
456, d2pogB_, 0.8521, 1.83, 0.545, 222, 222, BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR B AGONISTS (SERBAS). PART 2: STRUCTURE ACTIVITY RELATIONSHIP STUDIES ON THE BENZOPYRAN SCAFFOLD.
457, d2ocfA_, 0.8518, 0.45, 0.990, 211, 210, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND THE E2#23 FN3 MONOBODY
458, p2ylyB_, 0.8517, 1.96, 0.914, 231, 220, SULFONAMIDES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS.
459, d2jj3A_, 0.8517, 1.70, 0.577, 221, 220, ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
460, p4mg7B_, 0.8516, 1.83, 0.550, 223, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH FERUTININE
461, p5kcwB_, 0.8513, 2.00, 0.927, 232, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL OBHS-N DERIVATIVE
462, p2jf9A_, 0.8512, 1.95, 0.913, 224, 219, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN- SPECIFIC PEPTIDE ANTAGONIST
463, p4iw8B_, 0.8504, 0.90, 0.976, 215, 212, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 9A
464, p5tn8A_, 0.8500, 2.08, 0.923, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-4-OLATE
465, p5dz1A_, 0.8500, 2.01, 0.940, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-ETHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
466, d2i0gA_, 0.8499, 2.02, 0.923, 232, 220, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
467, d2ewpA_, 0.8499, 1.80, 0.548, 221, 221, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
468, d3ollB_, 0.8495, 1.84, 0.350, 224, 223, CRYSTAL STRUCTURE OF PHOSPHORYLATED ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
469, d2z4bA_, 0.8495, 2.20, 0.529, 233, 225, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
470, d2ewpB_, 0.8495, 1.81, 0.548, 221, 221, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
471, p4iv4A_, 0.8494, 1.80, 0.350, 224, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 5B
472, p5tmmB_, 0.8492, 2.02, 0.922, 229, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENYL)HEX-5-ENOIC ACID
473, p5e0wB_, 0.8489, 1.86, 0.945, 222, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-HYDROXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
474, p4iv2A_, 0.8488, 2.01, 0.918, 230, 219, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 5A
475, p5tmmA_, 0.8487, 2.06, 0.923, 231, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENYL)HEX-5-ENOIC ACID
476, p4znuB_, 0.8485, 2.00, 0.945, 223, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHYL-SUBSTITUTED OBHS DERIVATIVE
477, d5u2bB_, 0.8482, 1.83, 0.931, 226, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
478, p5dp0A_, 0.8482, 1.80, 0.935, 228, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 4 4 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}ETHENE-11-DIYL)DIPHENOL
479, p5krkB_, 0.8479, 1.89, 0.917, 229, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((5-BROMO-23-DIHYDRO-1H-INDEN-1-YLIDENE) METHYLENE)DIPHENOL
480, p5dwjB_, 0.8478, 1.96, 0.913, 221, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 4-FLUORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(4-FLUOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
481, d5u2bE_, 0.8477, 1.95, 0.931, 229, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
482, d2ewpC_, 0.8475, 1.94, 0.945, 221, 218, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
483, p5dz3A_, 0.8468, 1.74, 0.351, 223, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(FLUOROMETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
484, p5dweB_, 0.8468, 2.05, 0.927, 231, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-CHLORO-SUBSTITUTED TRIARYL-IMINE ANALOG 44 -[(2- CHLOROPHENYL)CARBONIMIDOYL]DIPHENOL
485, p5tm9A_, 0.8466, 1.99, 0.931, 229, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-3-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)ACRYLIC ACID
486, p5dydA_, 0.8465, 1.10, 0.972, 215, 212, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(METHYLSULFANYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
487, p5dxbB_, 0.8464, 1.96, 0.945, 225, 217, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P1 AND ESTRADIOL
488, p4pxmB_, 0.8462, 1.97, 0.945, 224, 217, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH ESTRADIOL AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
489, p4zn9B_, 0.8457, 1.90, 0.940, 226, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
490, d2b23A_, 0.8456, 1.96, 0.922, 235, 218, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
491, d5u2bF_, 0.8450, 1.98, 0.940, 226, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
492, d2qtuA_, 0.8447, 1.85, 0.954, 225, 216, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
493, p5kccB_, 0.8446, 1.73, 0.553, 219, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONAMIDE (OBHS-N)
494, p5dybA_, 0.8445, 1.97, 0.940, 227, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -(34-DIHYDRONAPHTHALEN-2(1H)- YLIDENEMETHANEDIYL)DIPHENOL
495, p5tm1A_, 0.8441, 2.02, 0.917, 229, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
496, p5dwgA_, 0.8441, 1.94, 0.954, 220, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE TRIARYL-SUBSTITUTED IMINE ANALOG 4-{(E)-(4-HYDROXYPHENYL) [(2-METHYLPHENYL)IMINO]METHYL}BENZENE-13-DIOL
497, d5u2bD_, 0.8440, 1.93, 0.944, 225, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
498, p5ehjA_, 0.8439, 1.74, 0.949, 226, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4AR8AR)-OCTAHYDRONAPHTHALEN- 2(1H)-YLIDENEMETHANEDIYL]DIPHENOL
499, p5dx3B_, 0.8438, 1.98, 0.917, 229, 218, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P3 AND ESTRADIOL
500, p5hyrB_, 0.8435, 1.95, 0.944, 224, 216, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-SP2 AND ESTRADIOL
501, d2gpuA_, 0.8435, 1.94, 0.940, 223, 216, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN
502, p5kraA_, 0.8433, 1.78, 0.348, 222, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
503, d3olsA_, 0.8433, 1.90, 0.949, 226, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
504, d1u3rA_, 0.8431, 2.02, 0.534, 229, 221, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-338
505, d5tn9B_, 0.8429, 2.16, 0.545, 231, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
506, d5ak2B_, 0.8429, 0.74, 0.976, 211, 209, OXYPHENYLPROPENOIC ACIDS AS ORAL SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS.
507, p5dmcA_, 0.8428, 0.98, 0.990, 210, 210, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A NITRILE-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 33-BIS(4- HYDROXYPHENYL)-2-PHENYLPROP-2-ENENITRILE
508, d3omqA_, 0.8425, 1.91, 0.944, 223, 216, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
509, d3ompA_, 0.8423, 2.04, 0.534, 229, 221, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
510, d3omoA_, 0.8423, 2.05, 0.538, 229, 221, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
511, d1u3qA_, 0.8423, 2.04, 0.538, 229, 221, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
512, d1u3sA_, 0.8421, 2.03, 0.534, 226, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-797
513, p5kcdB_, 0.8420, 2.12, 0.548, 227, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL SUBSTITUTED OBHS-N DERIVATIVE
514, d4q50B_, 0.8417, 1.96, 0.944, 226, 216, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
515, p4j26B_, 0.8410, 0.70, 0.990, 209, 209, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
516, p5tlmB_, 0.8402, 1.99, 0.532, 229, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 4  -(THIOPHENE-235-TRIYL)TRIPHENOL
517, d4q50A_, 0.8402, 2.06, 0.945, 227, 218, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
518, d2ewpD_, 0.8399, 0.98, 0.976, 210, 210, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
519, p6cbzB_, 0.8397, 1.75, 0.350, 221, 220, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ESTRADIOL AND GRIP PEPTIDE
520, d1zafB_, 0.8396, 1.92, 0.930, 223, 215, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 3-BROMO-6-HYDROXY-2-(4-HYDROXY-PHENYL)-INDEN-1-ONE
521, d1u3qC_, 0.8394, 2.14, 0.532, 228, 220, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
522, d1l2jB1, 0.8393, 2.04, 0.539, 226, 219, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH (R R)-511-CIS-DIETHYL-561112-TETRAHYDROCHRYSENE-28-DIOL
523, d1x76B_, 0.8388, 1.64, 0.546, 222, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697
524, p5dxeB_, 0.8387, 1.94, 0.537, 225, 218, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P4 AND ESTRADIOL
525, d2j7xA_, 0.8387, 1.95, 0.935, 222, 215, STRUCTURE OF ESTRADIOL-BOUND ESTROGEN RECEPTOR BETA LBD IN COMPLEX WITH LXXLL MOTIF FROM NCOA5
526, p5tm4B_, 0.8386, 2.13, 0.545, 228, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG 5-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)PENTANOIC ACID
527, p5dvsB_, 0.8385, 1.88, 0.958, 218, 214, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-METHYL-SUBSTITUTED TRIARYL-IMINE 44 -[(2-METHYLPHENYL) CARBONIMIDOYL]DIPHENOL
528, d1yy4B1, 0.8385, 1.91, 0.926, 223, 215, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 1-CHLORO-6-(4-HYDROXY-PHENYL)-NAPHTHALEN-2-OL
529, d1x7jB_, 0.8383, 1.99, 0.537, 225, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH GENISTEIN
530, p5wgdB_, 0.8382, 1.94, 0.537, 225, 218, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-LP1 
531, d2nv7B_, 0.8380, 1.90, 0.949, 222, 214, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-555
532, p4ivyA_, 0.8376, 1.93, 0.541, 225, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 7A
533, p4zi1A_, 0.8374, 2.04, 0.922, 229, 217, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH KB095285 AND CIA12 COACTIVATOR PEPTIDE
534, p4j24B_, 0.8373, 2.06, 0.534, 230, 219, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
535, d1x78B_, 0.8371, 2.01, 0.534, 228, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-244
536, p2jf9C_, 0.8369, 1.97, 0.537, 228, 218, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN- SPECIFIC PEPTIDE ANTAGONIST
537, d1x7bB_, 0.8368, 1.31, 0.967, 214, 211, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH ERB-041
538, d1u9eB_, 0.8367, 1.96, 0.537, 225, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-397
539, d1yyeB1, 0.8364, 1.94, 0.550, 228, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-202196
540, d1u3qD_, 0.8364, 1.93, 0.550, 224, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
541, p5dxpA_, 0.8363, 2.05, 0.543, 226, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 4-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(PHENYL)METHYL]PHENOL
542, d3os9D_, 0.8359, 1.79, 0.930, 222, 213, ESTROGEN RECEPTOR
543, p5tm2A_, 0.8353, 0.70, 0.986, 208, 207, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
544, d1u3qB_, 0.8353, 1.95, 0.949, 217, 214, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
545, p4j26A_, 0.8352, 2.06, 0.543, 227, 219, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
546, p5tm9B_, 0.8346, 2.02, 0.534, 228, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-3-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)ACRYLIC ACID
547, p2jf9B_, 0.8342, 0.94, 0.986, 211, 208, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN- SPECIFIC PEPTIDE ANTAGONIST
548, p4j24A_, 0.8340, 0.86, 1.000, 209, 207, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
549, d1yy4A1, 0.8339, 1.88, 0.546, 225, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 1-CHLORO-6-(4-HYDROXY-PHENYL)-NAPHTHALEN-2-OL
550, d2nv7A_, 0.8337, 2.15, 0.553, 225, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-555
551, d1x78A_, 0.8334, 2.10, 0.553, 228, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-244
552, d2yatA_, 0.8332, 2.12, 0.553, 228, 219, CRYSTAL STRUCTURE OF ESTRADIOL DERIVED METAL CHELATE AND ESTROGEN RECEPTOR-LIGAND BINDING DOMAIN COMPLEX
553, d1x7bA_, 0.8332, 1.81, 0.934, 227, 213, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH ERB-041
554, d1u3rB_, 0.8332, 2.13, 0.553, 228, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-338
555, p4j24C_, 0.8331, 2.14, 0.546, 227, 218, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
556, d2j7yA_, 0.8331, 1.89, 0.542, 225, 216, STRUCTURE OF 17-EPIESTRIOL-BOUND ESTROGEN RECEPTOR BETA LBD IN COMPLEX WITH LXXLL MOTIF FROM NCOA5
557, d1x76A_, 0.8329, 2.23, 0.557, 226, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697
558, d2qzoA_, 0.8328, 2.05, 0.541, 225, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH WAY-169916
559, d1x7jA_, 0.8325, 1.79, 0.925, 227, 214, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH GENISTEIN
560, d1yyeA1, 0.8322, 2.15, 0.553, 225, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-202196
561, d2yjdB_, 0.8317, 2.13, 0.553, 225, 219, STAPLED PEPTIDE BOUND TO ESTROGEN RECEPTOR BETA
562, d1zafA_, 0.8314, 1.93, 0.542, 223, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 3-BROMO-6-HYDROXY-2-(4-HYDROXY-PHENYL)-INDEN-1-ONE
563, p2yjdA_, 0.8311, 2.08, 0.546, 228, 218, STAPLED PEPTIDE BOUND TO ESTROGEN RECEPTOR BETA
564, d1u3sB_, 0.8304, 2.00, 0.542, 223, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-797
565, d5aavB_, 0.8293, 2.00, 0.542, 223, 216, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
566, p5dwgB_, 0.8287, 1.16, 0.990, 209, 208, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE TRIARYL-SUBSTITUTED IMINE ANALOG 4-{(E)-(4-HYDROXYPHENYL) [(2-METHYLPHENYL)IMINO]METHYL}BENZENE-13-DIOL
567, d4ltwA_, 0.8281, 2.00, 0.939, 216, 213, ANCESTRAL KETOSTEROID RECEPTOR-PROGESTERONE-MIFEPRISTONE COMPLEX
568, p5dkeA_, 0.8280, 2.35, 0.239, 251, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-NAPHTHYL-SUBSTITUTED METHYL CIS-DIARYL-ETHYLENE COMPOUND 44 -[2-(NAPHTHALEN-2-YL)PROP-1-ENE-11-DIYL]DIPHENOL
569, p5dxgB_, 0.8278, 1.78, 0.934, 221, 211, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P5
570, p4iuiB_, 0.8275, 1.95, 0.943, 219, 212, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY DERIVATIVE 4A
571, d3olsB_, 0.8266, 1.84, 0.934, 221, 212, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
572, d3omqB_, 0.8265, 2.13, 0.546, 224, 218, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
573, d3ompB_, 0.8262, 2.13, 0.546, 224, 218, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
574, d3omoB_, 0.8261, 2.14, 0.550, 224, 218, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
575, p5kceA_, 0.8259, 2.14, 0.550, 224, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL 2-CHLOROBENZYL OBHS-N DERIVATIVE
576, d1u9eA_, 0.8259, 1.70, 0.943, 223, 210, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-397
577, d2qe4A_, 0.8255, 2.17, 0.558, 223, 217, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
578, d2qe4B_, 0.8253, 0.86, 0.976, 207, 205, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
579, p5tlpB_, 0.8246, 0.37, 0.990, 204, 203, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-BSC ANALOG 3-FLUOROPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE AND 3-METHYL-6-PHENYL-3H- IMIDAZO[45-B]PYRIDIN-2-AMINE
580, p4fn9A_, 0.8227, 1.03, 1.000, 207, 205, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL 3-KETO STEROID RECEPTOR - PROGESTERONE COMPLEX
581, p4fneA_, 0.8207, 2.21, 0.236, 250, 220, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL 3-KETO STEROID RECEPTOR - DOC COMPLEX
582, p4fn9B_, 0.8198, 2.16, 0.233, 247, 219, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL 3-KETO STEROID RECEPTOR - PROGESTERONE COMPLEX
583, d2ewpE_, 0.8195, 2.23, 0.236, 249, 220, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
584, p4j24D_, 0.8193, 1.63, 0.357, 214, 213, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
585, d4n1yD_, 0.8186, 2.07, 0.542, 221, 214, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
586, d3ltxD_, 0.8177, 2.06, 0.333, 226, 216,  
587, p2ylyA_, 0.8168, 2.09, 0.333, 226, 216, SULFONAMIDES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS.
588, d4n1yB_, 0.8162, 2.03, 0.573, 219, 213, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
589, d1hg4B_, 0.8160, 2.09, 0.333, 227, 216, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
590, d3ltxB_, 0.8152, 2.26, 0.276, 240, 217,  
591, d3ltxC_, 0.8146, 2.12, 0.333, 227, 216,  
592, p5ufsA_, 0.8145, 2.12, 0.333, 227, 216, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH TRIAMCINOLONE ACETONIDE AND SHP COREGULATOR FRAGMENT
593, p5ufsB_, 0.8144, 2.23, 0.324, 224, 216, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH TRIAMCINOLONE ACETONIDE AND SHP COREGULATOR FRAGMENT
594, d4n1yC_, 0.8144, 2.39, 0.250, 248, 220, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
595, d1hg4F_, 0.8144, 2.40, 0.250, 248, 220, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
596, d1hg4A_, 0.8143, 2.07, 0.340, 224, 215, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
597, d1e3gA_, 0.8137, 2.27, 0.276, 240, 217, HUMAN ANDROGEN RECEPTOR LIGAND BINDING IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)
598, d1hg4C_, 0.8134, 2.31, 0.276, 240, 217, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
599, d4n1yA_, 0.8133, 2.31, 0.276, 240, 217, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
600, d3ltxA_, 0.8132, 2.46, 0.195, 250, 221,  
601, d5i4vA_, 0.8129, 2.27, 0.281, 238, 217, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
602, d4apuA_, 0.8127, 2.12, 0.333, 226, 216, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA-SUBSTITUTED STEROID
603, d2a3iA_, 0.8126, 2.11, 0.333, 226, 216, STRUCTURAL AND BIOCHEMICAL MECHANISMS FOR THE SPECIFICITY OF HORMONE BINDING AND COACTIVATOR ASSEMBLY BY MINERALOCORTICOID RECEPTOR
604, d4a2jB_, 0.8123, 2.57, 0.181, 260, 227, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA- SUBSTITUTED STEROIDS
605, d5jjmA_, 0.8122, 2.57, 0.181, 260, 227, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
606, d5jjmC_, 0.8120, 2.41, 0.218, 250, 220, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
607, d3zraB_, 0.8120, 2.47, 0.235, 253, 221, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
608, d3zrbA_, 0.8119, 2.47, 0.226, 250, 221, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
609, d2fszB_, 0.8119, 2.63, 0.194, 252, 222, A SECOND BINDING SITE FOR HYDROXYTAMOXIFEN WITHIN THE COACTIVATOR-BINDING GROOVE OF ESTROGEN RECEPTOR BETA
610, d1a28A_, 0.8118, 2.63, 0.198, 250, 222, HORMONE-BOUND HUMAN PROGESTERONE RECEPTOR LIGAND-BINDING DOMAIN
611, d5jjmD_, 0.8117, 2.40, 0.218, 250, 220, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
612, d2w8yB_, 0.8112, 2.40, 0.218, 250, 220, RU486 BOUND TO THE PROGESTERONE RECEPTOR IN A DESTABILIZED AGONISTIC CONFORMATION
613, d1zucA_, 0.8111, 1.85, 0.571, 227, 210, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE NONSTEROIDAL AGONIST TANAPROGET
614, d1hg4E_, 0.8108, 2.42, 0.218, 251, 220, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
615, p5g3jA_, 0.8105, 2.50, 0.199, 249, 221, DISCOVERY OF NEW SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST LEADS
616, d1e3kA_, 0.8101, 2.51, 0.226, 250, 221, HUMAN PROGESTERON RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)
617, p5dvvA_, 0.8098, 2.45, 0.218, 251, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-IMINE ANALOG 44 -(PHENYLCARBONIMIDOYL)DIPHENOL
618, d2pipL_, 0.8096, 2.33, 0.276, 240, 217, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
619, d1t7fA_, 0.8096, 2.47, 0.255, 248, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A LXXLL MOTIF
620, d1hg4D_, 0.8095, 2.45, 0.218, 251, 220, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
621, d3g8oA_, 0.8093, 1.79, 0.937, 209, 206, PROGESTERONE RECEPTOR WITH BOUND PYRROLIDINE 1
622, d2pitA_, 0.8093, 2.27, 0.201, 249, 219, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
623, p4udcA_, 0.8087, 2.56, 0.195, 250, 221, GR IN COMPLEX WITH DEXAMETHASONE
624, d1t5zA_, 0.8087, 2.37, 0.276, 238, 217, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN (LBD) WITH DHT AND A PEPTIDE DERIVED FROM ITS PHYSIOLOGICAL COACTIVATOR ARA70
625, p6el6A_, 0.8085, 2.51, 0.218, 250, 220, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH COMPOUND 4
626, p5g5wA_, 0.8085, 2.54, 0.199, 250, 221, DISCOVERY OF A NOVEL HIGHLY POTENT NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATOR SERIES MODULATORS
627, d1t79A_, 0.8085, 2.48, 0.255, 248, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXLW MOTIF
628, p5nfpA_, 0.8084, 2.56, 0.195, 250, 221, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH BUDESONIDE
629, d1t73A_, 0.8080, 2.40, 0.251, 247, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXFF MOTIF
630, d2piqA_, 0.8078, 2.41, 0.251, 247, 219, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
631, d1t7rA_, 0.8077, 2.57, 0.195, 250, 221, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXLF MOTIF
632, p5e15A_, 0.8076, 2.42, 0.251, 247, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
633, d2pioA_, 0.8076, 2.58, 0.195, 250, 221, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
634, p6el7A_, 0.8074, 2.47, 0.195, 249, 220, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH COMPOUND 31
635, d3g0wA_, 0.8074, 2.55, 0.195, 250, 221, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH AN N-ARYL-OXAZOLIDIN 2-IMINE INHIBITOR
636, d5jjmB_, 0.8073, 1.80, 0.937, 218, 206, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
637, d1s9pD_, 0.8072, 2.25, 0.197, 248, 218, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
638, d4a2jA_, 0.8071, 2.51, 0.259, 247, 220, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA- SUBSTITUTED STEROIDS
639, d1t63A_, 0.8071, 2.28, 0.201, 249, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN WITH DHT AND A PEPTIDE DERIVED FROM ITS PHYSIOLOGICAL COACTIVATOR GRIP1 NR BOX3
640, p4p6xK_, 0.8070, 2.53, 0.195, 250, 220, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
641, p4oj9A_, 0.8070, 2.40, 0.327, 225, 217, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
642, d2gppB_, 0.8070, 2.45, 0.218, 250, 220, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A RIP140 PEPTIDE AND SYNTHETIC LIGAND GSK4716
643, d1e3kB_, 0.8069, 2.59, 0.195, 250, 221, HUMAN PROGESTERON RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)
644, d4csjA_, 0.8068, 2.60, 0.240, 255, 221, THE DISCOVERY OF POTENT SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS SUITABLE FOR INHALATION
645, d2pirA_, 0.8068, 2.48, 0.195, 249, 220, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
646, d1t65A_, 0.8068, 2.39, 0.319, 224, 216, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN WITH DHT AND A PEPTIDE DERIVED FORM ITS PHYSIOLOGICAL COACTIVATOR GRIP1 NR BOX 2 BOUND IN A NON- HELICAL CONFORMATION
647, d2gp7B_, 0.8067, 2.48, 0.218, 249, 220, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
648, d1t7tA_, 0.8067, 2.52, 0.259, 247, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH 5-ALPHA DIHYDROTESTOSTERONE
649, d1t74A_, 0.8067, 2.43, 0.200, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A WXXLF MOTIF
650, d1xj7A_, 0.8065, 2.59, 0.195, 251, 221, COMPLEX ANDROGEN RECEPTOR LBD AND RAC3 PEPTIDE
651, p5nftA_, 0.8064, 2.46, 0.336, 225, 217, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH AZD5423
652, d2hvcA_, 0.8064, 2.58, 0.195, 250, 221, THE CRYSTAL STRUCTURE OF LIGAND-BINDING DOMAIN (LBD) OF HUMAN ANDROGEN RECEPTOR IN COMPLEX WITH A SELECTIVE MODULATOR LGD2226
653, d3ry9B_, 0.8063, 2.49, 0.195, 249, 220, CRYSTAL STRUCTURE OF THE RESURRECTED ANCESTRAL GLUCOCORTICOID RECEPTOR 1 IN COMPLEX WITH DOC
654, d4apuB_, 0.8062, 2.53, 0.199, 256, 221, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA-SUBSTITUTED STEROID
655, d3rljA_, 0.8060, 2.58, 0.262, 248, 221, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-22
656, d3b66A_, 0.8059, 2.50, 0.199, 250, 221, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-21
657, p4iuiA_, 0.8058, 2.28, 0.240, 247, 217, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY DERIVATIVE 4A
658, d3b5rA_, 0.8058, 2.50, 0.218, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM C-31
659, d2aaxA_, 0.8058, 2.42, 0.196, 247, 219, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND CORTISONE
660, d1tfcA_, 0.8058, 2.42, 0.196, 247, 219, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH A STEROID RECEPTOR COACTIVATOR-1 PEPTIDE
661, d2pixA_, 0.8057, 1.88, 0.956, 211, 206, AR LBD WITH SMALL MOLECULE
662, d3b65A_, 0.8056, 2.42, 0.196, 247, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-24
663, d2pklA_, 0.8056, 2.73, 0.240, 261, 221, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
664, d1t76A_, 0.8055, 2.73, 0.240, 261, 221, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A WXXVW MOTIF
665, d3zqtA_, 0.8054, 2.43, 0.336, 226, 217, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
666, d2piwA_, 0.8052, 2.42, 0.196, 248, 219, ANDROGEN RECEPTOR WITH SMALL MOLECULE
667, d2am9A_, 0.8052, 2.42, 0.196, 247, 219, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH TESTOSTERONE
668, p6el9A_, 0.8051, 2.35, 0.196, 249, 219, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH AZD9567
669, d3mnpA1, 0.8051, 2.47, 0.195, 249, 220, CRYSTAL STRUCTURE OF THE AGONIST FORM OF MOUSE GLUCOCORTICOID RECEPTOR STABILIZED BY (A611V V708A E711G) MUTATIONS AT 1.50A
670, d2w8yA_, 0.8050, 2.51, 0.195, 250, 220, RU486 BOUND TO THE PROGESTERONE RECEPTOR IN A DESTABILIZED AGONISTIC CONFORMATION
671, d3kbaB_, 0.8049, 2.43, 0.196, 248, 219, PROGESTERONE RECEPTOR BOUND TO SULFONAMIDE PYRROLIDINE PARTIAL AGONIST
672, d2aa6A_, 0.8048, 2.51, 0.195, 250, 220, MINERALOCORTICOID RECEPTOR S810L MUTANT WITH BOUND PROGESTERONE
673, p4p6xC_, 0.8047, 2.54, 0.259, 247, 220, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
674, d2piuA_, 0.8047, 2.53, 0.250, 256, 220, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
675, p4p6xG_, 0.8046, 2.48, 0.218, 250, 220, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
676, d2gp7C_, 0.8046, 2.49, 0.218, 250, 220, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
677, d1a28B_, 0.8046, 2.74, 0.240, 260, 221, HORMONE-BOUND HUMAN PROGESTERONE RECEPTOR LIGAND-BINDING DOMAIN
678, d2qpyA_, 0.8045, 2.62, 0.240, 255, 221, AR LBD WITH SMALL MOLECULE
679, d2pivA_, 0.8045, 2.45, 0.196, 248, 219, ANDROGEN RECEPTOR WITH SMALL MOLECULE
680, d2gp7D_, 0.8044, 2.62, 0.240, 254, 221, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
681, d2ab2B_, 0.8044, 2.30, 0.340, 224, 215, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND SPIRONOLACTONE
682, d2gp7A_, 0.8043, 2.49, 0.218, 249, 220, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
683, p4p6xI_, 0.8042, 2.46, 0.196, 248, 219, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
684, d3b67A_, 0.8042, 2.37, 0.196, 249, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM C-23
685, d3zr7A_, 0.8040, 2.30, 0.340, 224, 215, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
686, d2z4jA_, 0.8040, 2.66, 0.244, 259, 221, CRYSTAL STRUCTURE OF AR LBD WITH SHP PEPTIDE NR BOX 2
687, p2q1hA_, 0.8040, 2.31, 0.340, 224, 215, ANCESTRAL CORTICOID RECEPTOR IN COMPLEX WITH ALDOSTERONE
688, d2ab2A_, 0.8040, 2.61, 0.240, 255, 221, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND SPIRONOLACTONE
689, d1tfcB_, 0.8040, 2.44, 0.196, 247, 219, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH A STEROID RECEPTOR COACTIVATOR-1 PEPTIDE
690, d4u4kA_, 0.8039, 2.48, 0.218, 250, 220,  
691, d4pf3A_, 0.8037, 2.30, 0.197, 248, 218, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 37A
692, d3bqdA_, 0.8037, 2.11, 0.243, 244, 214, DOUBLING THE SIZE OF THE GLUCOCORTICOID RECEPTOR LIGAND BINDING POCKET BY DEACYLCORTIVAZOL
693, p2q3yA_, 0.8037, 2.66, 0.241, 259, 220, ANCESTRAL CORTICIOD RECEPTOR IN COMPLEX WITH DOC
694, p2q1vA_, 0.8037, 2.39, 0.319, 225, 216, ANCESTRAL CORTICOID RECEPTOR IN COMPLEX WITH CORTISOL
695, p6b0fA_, 0.8036, 2.52, 0.195, 250, 220, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH LSZ102
696, d3hq5B_, 0.8035, 2.41, 0.247, 249, 219, PROGESTERONE RECEPTOR BOUND TO AN ALKYLPYRROLIDINE LIGAND.
697, d3g8nB_, 0.8035, 2.59, 0.250, 253, 220,  
698, d2zkcA1, 0.8033, 2.12, 0.238, 244, 214, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH BISPHENOL Z
699, d4oktA_, 0.8032, 2.11, 0.243, 244, 214, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
700, d3zraA_, 0.8032, 1.48, 0.931, 204, 204, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
701, d3k23C_, 0.8032, 2.51, 0.218, 251, 220, GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11
702, d3b68A_, 0.8032, 2.51, 0.218, 251, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-4
703, p4p6wA_, 0.8031, 2.61, 0.335, 226, 218, CRYSTAL STRUCTURE OF MOMETASONE FUROATE-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
704, d2oz7A_, 0.8031, 2.48, 0.192, 248, 219, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR T877A MUTANT LIGAND- BINDING DOMAIN WITH CYPROTERONE ACETATE
705, d2gpoA_, 0.8031, 2.49, 0.218, 250, 220, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A SYNTHETIC PEPTIDE FROM RIP140
706, d1t7mA_, 0.8030, 2.66, 0.253, 246, 221, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXYF MOTIF
707, d1kv6B_, 0.8030, 2.30, 0.197, 247, 218, X-RAY STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ERR3 LIGAND- BINDING DOMAIN IN THE CONSTITUTIVELY ACTIVE CONFORMATION
708, p4uddA_, 0.8029, 2.51, 0.245, 252, 220, GR IN COMPLEX WITH DESISOBUTYRYLCICLESONIDE
709, d3zrbB_, 0.8029, 2.45, 0.201, 249, 219, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
710, d3d90A_, 0.8029, 2.36, 0.326, 224, 215, CRYSTAL STRUCTURE OF THE HUMAN PROGESTERONE RECEPTOR LIGAND- BINDING DOMAIN BOUND TO LEVONORGESTREL
711, p4p6xE_, 0.8028, 2.51, 0.195, 249, 220, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
712, d2ylqA_, 0.8028, 2.39, 0.326, 222, 215, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
713, d1sr7B_, 0.8028, 2.67, 0.262, 249, 221, PROGESTERONE RECEPTOR HORMONE BINDING DOMAIN WITH BOUND MOMETASONE FUROATE
714, d3wfgA_, 0.8027, 2.49, 0.218, 250, 220, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 2E
715, d2e2rA_, 0.8027, 2.48, 0.225, 247, 218, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH BISPHENOL A
716, d1zucB_, 0.8025, 2.65, 0.240, 255, 221, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE NONSTEROIDAL AGONIST TANAPROGET
717, d1sqnA_, 0.8025, 2.47, 0.196, 249, 219, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN WITH BOUND NORETHINDRONE
718, d1kv6A_, 0.8025, 2.53, 0.218, 249, 220, X-RAY STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ERR3 LIGAND- BINDING DOMAIN IN THE CONSTITUTIVELY ACTIVE CONFORMATION
719, d1sr7A_, 0.8024, 2.43, 0.247, 249, 219, PROGESTERONE RECEPTOR HORMONE BINDING DOMAIN WITH BOUND MOMETASONE FUROATE
720, d3k23B_, 0.8022, 2.55, 0.323, 227, 217, GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11
721, d2aa6B_, 0.8022, 2.55, 0.323, 227, 217, MINERALOCORTICOID RECEPTOR S810L MUTANT WITH BOUND PROGESTERONE
722, d3g8oB_, 0.8020, 2.52, 0.218, 251, 220, PROGESTERONE RECEPTOR WITH BOUND PYRROLIDINE 1
723, d2zasA_, 0.8018, 2.49, 0.225, 248, 218, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 4-ALPHA-CUMYLPHENOL A BISPHENOL A DERIVATIVE
724, d2fszA_, 0.8018, 2.30, 0.340, 222, 215, A SECOND BINDING SITE FOR HYDROXYTAMOXIFEN WITHIN THE COACTIVATOR-BINDING GROOVE OF ESTROGEN RECEPTOR BETA
725, d3d90B_, 0.8017, 2.52, 0.224, 249, 219, CRYSTAL STRUCTURE OF THE HUMAN PROGESTERONE RECEPTOR LIGAND- BINDING DOMAIN BOUND TO LEVONORGESTREL
726, d4ok1A_, 0.8016, 2.44, 0.253, 247, 217, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
727, d2nw4A_, 0.8016, 2.75, 0.240, 259, 221, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH BMS-564929
728, d3k22A_, 0.8015, 2.52, 0.218, 250, 220, GLUCOCORTICOID RECEPTOR WITH BOUND ALANINAMIDE 10 WITH TIF2 PEPTIDE
729, d1m2zD_, 0.8015, 2.45, 0.319, 227, 216, CRYSTAL STRUCTURE OF A DIMER COMPLEX OF THE HUMAN GLUCOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEXAMETHASONE AND A TIF2 COACTIVATOR MOTIF
730, d1sqnB_, 0.8012, 1.55, 0.576, 223, 205, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN WITH BOUND NORETHINDRONE
731, p5dvvB_, 0.8010, 2.48, 0.219, 249, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-IMINE ANALOG 44 -(PHENYLCARBONIMIDOYL)DIPHENOL
732, d2ylpA_, 0.8009, 2.51, 0.192, 249, 219, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
733, d2yloA_, 0.8009, 2.46, 0.196, 248, 219, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
734, p4p6xA_, 0.8007, 2.77, 0.257, 250, 222, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
735, d3k22B_, 0.8006, 2.63, 0.245, 253, 220, GLUCOCORTICOID RECEPTOR WITH BOUND ALANINAMIDE 10 WITH TIF2 PEPTIDE
736, d2zbsA_, 0.8005, 2.48, 0.219, 250, 219, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN APO FORM
737, d3wffA_, 0.8003, 1.71, 0.941, 210, 203, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 2B
738, d2aaxB_, 0.8003, 2.34, 0.197, 249, 218, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND CORTISONE
739, d1m2zA_, 0.8003, 2.58, 0.195, 250, 220, CRYSTAL STRUCTURE OF A DIMER COMPLEX OF THE HUMAN GLUCOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEXAMETHASONE AND A TIF2 COACTIVATOR MOTIF
740, d2p7aA_, 0.8000, 2.65, 0.249, 252, 221, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR G IN COMPLEX WITH 3-METHYL PHENOL
741, d3zr7B_, 0.7997, 2.70, 0.259, 250, 220, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
742, d1xnnA_, 0.7997, 2.56, 0.323, 227, 217, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT COMPLEX WITH (3A-ALPHA-4- ALPHA 7-ALPHA-7A-ALPHA-)-3A477A-TETRAHYDRO-2-(4-NITRO- 1-NAPHTHALENYL)-47-ETHANO-1H-ISOINDOLE-13(2H)-DIONE.
743, d2q7lA_, 0.7995, 2.98, 0.238, 258, 223, THE ANDROGEN RECEPTOR PROSTATE CANCER MUTANT H874Y LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND A TIF2 BOX3 COACTIVATOR PEPTIDE 740-753
744, d2p7gA_, 0.7995, 2.61, 0.247, 257, 219, X-RAY STRUCTURE OF ESTROGEN RELATED RECEPTOR G IN COMPLEX WITH BISPHENOL A.
745, d2yhdA_, 0.7994, 2.71, 0.253, 255, 221, HUMAN ANDROGEN RECEPTOR IN COMPLEX WITH AF2 SMALL MOLECULE INHIBITOR
746, d2gppA_, 0.7993, 2.35, 0.321, 223, 215, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A RIP140 PEPTIDE AND SYNTHETIC LIGAND GSK4716
747, d1i37A_, 0.7985, 2.46, 0.221, 246, 217, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH DIHYDROTESTOSTERONE
748, d2q7jA_, 0.7984, 2.47, 0.197, 247, 218, THE WILD TYPE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND A TIF2 BOX 3 COACTIVATOR PEPTIDE 740-753
749, d2ihqA_, 0.7977, 2.43, 0.198, 247, 217, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMIAN COMPLEX WITH AN N-ARYL- HYDROXYBICYCLOHYDANTOIN
750, d2ambA_, 0.7977, 2.41, 0.326, 222, 215, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH TETRAHYDROGESTRINONE
751, d2aa7A_, 0.7976, 2.35, 0.197, 249, 218, MINERALOCORTICOID RECEPTOR WITH BOUND DEOXYCORTICOSTERONE
752, d5t8eA_, 0.7975, 2.46, 0.319, 225, 216, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS). PART II: OPTIMIZATION OF 4-(PYRROLIDIN- 1-YL)BENZONITRILE DERIVATIVES
753, d3l3zA1, 0.7973, 2.32, 0.198, 246, 217, CRYSTAL STRUCTURE OF DHT-BOUND ANDROGEN RECEPTOR IN COMPLEX WITH THE THIRD MOTIF OF STEROID RECEPTOR COACTIVATOR 3
754, d1i38A_, 0.7973, 2.45, 0.198, 247, 217, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT COMPLEX WITH DIHYDROTESTOSTERONE
755, d5l7gA_, 0.7970, 2.46, 0.202, 248, 218, MCR IN COMPLEX WITH LIGAND
756, d3l3xA1, 0.7970, 2.38, 0.199, 246, 216, CRYSTAL STRUCTURE OF DHT-BOUND ANDROGEN RECEPTOR IN COMPLEX WITH THE FIRST MOTIF OF STEROID RECEPTOR COACTIVATOR 3
757, d1p93A_, 0.7970, 2.63, 0.248, 253, 218, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
758, d3gn8A_, 0.7964, 2.51, 0.197, 249, 218, X-RAY CRYSTAL STRUCTURE OF ANCGR2 IN COMPLEX WITH DEXAMETHASONE
759, d1p93B_, 0.7963, 2.62, 0.196, 248, 219, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
760, d1g2nA_, 0.7963, 2.36, 0.217, 247, 217, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE ULTRASPIRACLE PROTEIN USP THE ORTHOLOG OF RXRS IN INSECTS
761, p5uc3A_, 0.7962, 2.49, 0.244, 247, 217, NUCLEAR RECEPTOR
762, d5v8qA_, 0.7961, 2.60, 0.196, 249, 219, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS): PART III
763, d3mnoA1, 0.7961, 2.56, 0.248, 247, 218, CRYSTAL STRUCTURE OF THE AGONIST FORM OF MOUSE GLUCOCORTICOID RECEPTOR STABILIZED BY (A611V F608S) MUTATIONS AT 1.55A
764, d3e7cA_, 0.7961, 2.57, 0.256, 249, 219, GLUCOCORTICOID RECEPTOR LBD BOUND TO GSK866
765, d5l7hA1, 0.7960, 2.50, 0.258, 245, 217, MCR IN COMPLEX WITH LIGAND
766, p5uc3B_, 0.7958, 2.51, 0.255, 246, 216, NUCLEAR RECEPTOR
767, d1dkfA_, 0.7958, 2.51, 0.255, 246, 216, CRYSTAL STRUCTURE OF A HETERODIMERIC COMPLEX OF RAR AND RXR LIGAND-BINDING DOMAINS
768, d3k23A_, 0.7956, 2.24, 0.266, 232, 214, GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11
769, d3gn8B_, 0.7956, 2.51, 0.197, 249, 218, X-RAY CRYSTAL STRUCTURE OF ANCGR2 IN COMPLEX WITH DEXAMETHASONE
770, d5t8jA_, 0.7951, 2.54, 0.235, 254, 217, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS). PART II: OPTIMIZATION OF 4-(PYRROLIDIN- 1-YL)BENZONITRILE DERIVATIVES
771, p4e2jA_, 0.7950, 2.67, 0.264, 248, 220, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH MOMETASONE FUROATE AND TIF-2 COACTIVATOR FRAGMENT
772, d1p93C_, 0.7945, 2.50, 0.244, 247, 217, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
773, d3k6pA1, 0.7944, 2.26, 0.266, 231, 214, ESTROGEN RELATED RECEPTOR ALPHA IN COMPLEX WITH AN ETHER BASED LIGAND
774, d3hq5A_, 0.7941, 2.15, 0.304, 217, 214, PROGESTERONE RECEPTOR BOUND TO AN ALKYLPYRROLIDINE LIGAND.
775, d3g8nA_, 0.7941, 2.50, 0.265, 245, 215,  
776, d2aa5B_, 0.7941, 2.60, 0.250, 249, 220, MINERALOCORTICOID RECEPTOR WITH BOUND PROGESTERONE
777, d2aa2A_, 0.7941, 2.55, 0.197, 249, 218, MINERALOCORTICOID RECEPTOR WITH BOUND ALDOSTERONE
778, d1hj1A_, 0.7940, 2.49, 0.257, 246, 218, RAT OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH PURE ANTIOESTROGEN ICI164384
779, d1s9pB_, 0.7939, 2.53, 0.258, 247, 217, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
780, d1p93D_, 0.7936, 2.10, 0.304, 217, 214, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
781, d3ry9A_, 0.7930, 2.66, 0.217, 246, 217, CRYSTAL STRUCTURE OF THE RESURRECTED ANCESTRAL GLUCOCORTICOID RECEPTOR 1 IN COMPLEX WITH DOC
782, d3ixpA_, 0.7928, 2.66, 0.217, 246, 217, CRYSTAL STRUCTURE OF THE ECDYSONE RECEPTOR BOUND TO BYI08346
783, d1r1kA_, 0.7918, 2.58, 0.244, 255, 217, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO PONASTERONE A
784, d1gs4A_, 0.7917, 2.63, 0.244, 252, 217, STRUCTURAL BASIS FOR THE GLUCOCORTICOID RESPONSE IN A MUTANT HUMAN ANDROGEN RECEPTOR (ARCCR) DERIVED FROM AN ANDROGEN-INDEPENDENT PROSTATE CANCER
785, d3vhuA_, 0.7916, 1.35, 0.586, 204, 203, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH SPIRONOLACTONE
786, d3e7cB_, 0.7915, 2.14, 0.332, 217, 211, GLUCOCORTICOID RECEPTOR LBD BOUND TO GSK866
787, p4oarA_, 0.7914, 2.45, 0.255, 247, 216, PROGESTERONE RECEPTOR WITH BOUND ULIPRISTAL ACETATE AND A PEPTIDE FROM THE CO-REPRESSOR SMRT
788, d3mneA1, 0.7913, 2.42, 0.248, 243, 214, CRYSTAL STRUCTURE OF THE AGONIST FORM OF MOUSE GLUCOCORTICOID RECEPTOR STABILIZED BY F608S MUTATION AT 1.96A
789, d2ovhA_, 0.7913, 2.49, 0.260, 242, 215, PROGESTERONE RECEPTOR WITH BOUND ASOPRISNIL AND A PEPTIDE FROM THE CO-REPRESSOR SMRT
790, d2ovmA_, 0.7912, 2.37, 0.258, 241, 213, PROGESTERONE RECEPTOR WITH BOUND ASOPRISNIL AND A PEPTIDE FROM THE CO-REPRESSOR NCOR
791, p4e2jB_, 0.7911, 2.33, 0.200, 244, 215, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH MOMETASONE FUROATE AND TIF-2 COACTIVATOR FRAGMENT
792, d2pnuA_, 0.7911, 2.57, 0.250, 249, 216, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH EM-5744
793, p5mwyA_, 0.7910, 2.50, 0.251, 245, 215, THE STRUCTURE OF MR IN COMPLEX WITH EPLERENONE.
794, d3vhvA1, 0.7909, 2.40, 0.233, 241, 215, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH NON-STEROIDAL ANTAGONIST
795, d4udaA_, 0.7904, 2.47, 0.237, 252, 215, MR IN COMPLEX WITH DEXAMETHASONE
796, d2ax6A_, 0.7902, 2.41, 0.233, 243, 215, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT IN COMPLEX WITH HYDROXYFLUTAMIDE
797, d2ao6A_, 0.7896, 2.42, 0.233, 243, 215, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH TIF2(III) 740-753 PEPTIDE AND R1881
798, p5cj6A_, 0.7895, 2.57, 0.257, 247, 218, CRYSTAL STRUCTURE OF A SELECTIVE ANDROGEN RECEPTOR MODULATOR BOUND TO THE LIGAND BINDING DOMAIN OF THE HUMAN ANDROGEN RECEPTOR
799, d1s9pA_, 0.7893, 2.43, 0.200, 245, 215, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
800, d3kbaA_, 0.7888, 2.40, 0.238, 244, 214, PROGESTERONE RECEPTOR BOUND TO SULFONAMIDE PYRROLIDINE PARTIAL AGONIST
801, d2gpvE_, 0.7888, 2.56, 0.247, 253, 215, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
802, p3v4aA_, 0.7887, 2.27, 0.245, 241, 212, STRUCTURE OF AR LBD WITH ACTIVATOR PEPTIDE AND SARM INHIBITOR 2
803, d1s9qA_, 0.7887, 2.38, 0.201, 242, 214, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
804, d2aa5A_, 0.7886, 2.37, 0.202, 242, 213, MINERALOCORTICOID RECEPTOR WITH BOUND PROGESTERONE
805, p5vo4A_, 0.7883, 2.32, 0.215, 244, 214, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH 5-(2-FLUORO-4-HYDROXYPHENYL)-1-METHYL-1H-PYRROLE-2- CARBONITRILE
806, d2r40A_, 0.7881, 1.93, 0.335, 215, 209, CRYSTAL STRUCTURE OF 20E BOUND ECR/USP
807, d2gpvD_, 0.7881, 2.46, 0.225, 243, 213, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
808, p4ummF_, 0.7880, 1.78, 0.340, 208, 206, THE CRYO-EM STRUCTURE OF THE PALINDROMIC DNA-BOUND USP-ECR NUCLEAR RECEPTOR REVEALS AN ASYMMETRIC ORGANIZATION WITH ALLOSTERIC DOMAIN POSITIONING
809, p5mwpA_, 0.7879, 2.26, 0.202, 244, 213, THE STRUCTURE OF MR IN COMPLEX WITH AZD9977.
810, p3v49A_, 0.7879, 2.22, 0.348, 224, 210, STRUCTURE OF AR LBD WITH ACTIVATOR PEPTIDE AND SARM INHIBITOR 1
811, d1s9pC_, 0.7879, 2.69, 0.236, 255, 216, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
812, d1r20A_, 0.7879, 2.35, 0.215, 245, 214, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO THE SYNTHETIC AGONIST BYI06830
813, p4ofrA_, 0.7877, 2.19, 0.261, 238, 211, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
814, d5l7eA_, 0.7875, 1.96, 0.338, 209, 207, MCR IN COMPLEX WITH LIGAND
815, d2gpvF_, 0.7874, 2.37, 0.255, 241, 212, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
816, d1xowA_, 0.7874, 2.41, 0.235, 243, 213, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH AN ANDROGEN RECEPTOR NH2- TERMINAL PEPTIDE AR20-30 AND R1881
817, d2p7zA_, 0.7868, 2.26, 0.207, 244, 213, ESTROGEN RELATED RECEPTOR GAMMA IN COMPLEX WITH 4-HYDROXY- TAMOXIFEN
818, d4j5wD_, 0.7867, 2.17, 0.335, 219, 209, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
819, d4udbA_, 0.7863, 2.30, 0.259, 239, 212, MR IN COMPLEX WITH DESISOBUTYRYLCICLESONIDE
820, d2gpvA_, 0.7863, 2.31, 0.216, 243, 213, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
821, d1nhzA_, 0.7862, 2.41, 0.239, 243, 213, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF GLUCOCORTICOID RECEPTOR
822, p4ummG_, 0.7859, 1.80, 0.340, 208, 206, THE CRYO-EM STRUCTURE OF THE PALINDROMIC DNA-BOUND USP-ECR NUCLEAR RECEPTOR REVEALS AN ASYMMETRIC ORGANIZATION WITH ALLOSTERIC DOMAIN POSITIONING
823, d1r1kD_, 0.7859, 2.39, 0.202, 243, 213, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO PONASTERONE A
824, d1xq3A_, 0.7857, 1.75, 0.340, 207, 206, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH R1881
825, d2gpvC_, 0.7855, 2.33, 0.280, 227, 214, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
826, d2gpvB_, 0.7855, 2.42, 0.252, 244, 214, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
827, d4oghA_, 0.7850, 1.99, 0.338, 224, 207, CRYSTAL STRUCTURE OF T877A-AR-LBD
828, d4hlwA_, 0.7843, 2.42, 0.257, 239, 214, TARGETING THE BINDING FUNCTION 3 (BF3) SITE OF THE HUMAN ANDROGEN RECEPTOR THROUGH VIRTUAL SCREENING. 2. DEVELOPMENT OF 2-((2- PHENOXYETHYL) THIO)-1H-BENZOIMIDAZOLE DERIVATIVES.
829, d3cldB_, 0.7837, 2.60, 0.156, 236, 218, LIGAND BINDING DOMAIN OF THE GLUCOCORTICOID RECEPTOR COMPLEXED WITH FLUTICAZONE FUROATE
830, d4oilA_, 0.7836, 2.60, 0.156, 236, 218, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
831, d1z5xE_, 0.7834, 2.41, 0.202, 243, 213, HEMIPTERAN ECDYSONE RECEPTOR LIGAND-BINDING DOMAIN COMPLEXED WITH PONASTERONE A
832, d1s9qB_, 0.7828, 1.84, 0.340, 223, 206, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
833, d4j5xD_, 0.7827, 1.84, 0.340, 223, 206, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
834, d2amaA_, 0.7825, 2.39, 0.203, 242, 212, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH DIHYDROTESTOSTERONE
835, d4oeaA_, 0.7824, 2.35, 0.216, 244, 213, CRYSTAL STRUCTURE OF AR-LBD
836, d4ohaA_, 0.7821, 2.51, 0.257, 241, 214, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
837, d4oh5A_, 0.7817, 2.29, 0.203, 242, 212, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
838, d3cldA_, 0.7817, 2.84, 0.179, 237, 218, LIGAND BINDING DOMAIN OF THE GLUCOCORTICOID RECEPTOR COMPLEXED WITH FLUTICAZONE FUROATE
839, d4olmA_, 0.7816, 1.84, 0.337, 216, 205, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
840, d2q7kA_, 0.7813, 2.24, 0.283, 239, 212, THE ANDROGEN RECEPTOR PROSTATE CANCER MUTANT H874Y LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND AN AR 20-30 PEPTIDE
841, p4oeyA_, 0.7811, 2.24, 0.283, 239, 212, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
842, d4k7aA_, 0.7811, 2.33, 0.217, 243, 212, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH MINOXIDIL
843, d1vjbA_, 0.7811, 2.49, 0.202, 242, 213, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4- HYDROXYTAMOXIFEN
844, d1pq6B_, 0.7807, 2.40, 0.203, 242, 212, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
845, p4ofuA_, 0.7806, 2.24, 0.209, 242, 211, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
846, d1vjbB_, 0.7805, 2.65, 0.260, 243, 215, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4- HYDROXYTAMOXIFEN
847, d4oiuA_, 0.7803, 2.39, 0.199, 240, 211, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
848, p4oedA_, 0.7800, 2.26, 0.204, 242, 211, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
849, p4nqaI1, 0.7798, 2.42, 0.203, 241, 212, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
850, d2oaxF_, 0.7796, 2.34, 0.203, 242, 212, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
851, p4oezA_, 0.7789, 2.00, 0.354, 208, 206, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
852, d4ql8A_, 0.7786, 2.73, 0.178, 241, 219, CRYSTAL STRUCTURE OF ANDROGEN RECEPTOR IN COMPLEX WITH THE LIGAND
853, d1pq9B_, 0.7784, 2.44, 0.203, 241, 212, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
854, d5kyaE1, 0.7783, 1.94, 0.340, 210, 206, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
855, d3falD_, 0.7783, 2.36, 0.217, 242, 212, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
856, d1pqcB_, 0.7783, 2.36, 0.217, 242, 212, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
857, d3fc6D_, 0.7781, 2.61, 0.179, 240, 218, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
858, d2r40D_, 0.7781, 2.35, 0.248, 238, 210, CRYSTAL STRUCTURE OF 20E BOUND ECR/USP
859, d2nxxH_, 0.7778, 2.39, 0.217, 242, 212, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
860, d2nxxG_, 0.7777, 2.31, 0.218, 240, 211, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
861, d2nxxE_, 0.7777, 2.57, 0.184, 238, 217, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
862, d2nxxF_, 0.7776, 2.74, 0.178, 242, 219, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
863, d4oztE_, 0.7775, 2.55, 0.171, 242, 217, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (PONA CRYSTAL)
864, p4oh6A_, 0.7773, 2.57, 0.184, 238, 217, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
865, d4j5xC_, 0.7764, 2.57, 0.171, 241, 217, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
866, d3l0eA_, 0.7764, 2.63, 0.158, 233, 215, X-RAY CRYSTAL STRUCTURE OF A POTENT LIVER X RECEPTOR MODULATOR
867, d4okwA_, 0.7759, 2.69, 0.186, 234, 215, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
868, d2ax7A_, 0.7757, 2.70, 0.186, 233, 215, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT IN COMPLEX WITH S-1
869, d3rllA_, 0.7756, 2.70, 0.186, 234, 215, CRYSTAL STRUCTURE OF THE T877A ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH (S)-N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-(4- CYANONAPHTHALEN-1-YLOXY)-2-HYDROXY-2-METHYLPROPANAMIDE
870, d3kfcA_, 0.7754, 2.70, 0.191, 233, 215, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
871, d2axaA_, 0.7754, 2.81, 0.198, 238, 217, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH S-1
872, d1fm6U_, 0.7754, 2.81, 0.198, 238, 217, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
873, d2q7iA_, 0.7752, 2.34, 0.218, 242, 211, THE WILD TYPE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND AN AR 20-30 PEPTIDE
874, d4ojbA_, 0.7751, 2.75, 0.257, 238, 218, CRYSTAL STRUCTURE OF W741L-AR-LBD
875, d4okxA_, 0.7749, 2.88, 0.168, 243, 220, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
876, d3kfcD_, 0.7749, 2.43, 0.204, 239, 211, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
877, d3fc6B_, 0.7747, 2.40, 0.205, 238, 210, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
878, d2ax8A_, 0.7747, 2.40, 0.205, 238, 210, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN W741L MUTANT IN COMPLEX WITH S-1
879, d1p8dB_, 0.7745, 2.53, 0.185, 233, 216, X-RAY CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN WITH 24(S)25- EPOXYCHOLESTEROL
880, p4okbA_, 0.7743, 2.40, 0.205, 238, 210, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
881, d1pq6D_, 0.7743, 2.84, 0.278, 232, 216, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
882, p5t97B_, 0.7741, 2.32, 0.219, 241, 210, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- (4-{(1R)-6-HYDROXY-1-METHYL-2-[4-(PROPAN-2 -YL)PHENYL]-1234- TETRAHYDROISOQUINOLIN-1-YL}PHENYL)PROP-2-ENOIC ACID
883, p3wt6A_, 0.7741, 2.43, 0.204, 240, 211, A MIXED POPULATION OF ANTAGONIST AND AGONIST BINDING CONFORMERS IN A SINGLE CRYSTAL EXPLAINS PARTIAL AGONISM AGAINST VITAMIN D RECEPTOR: ACTIVE VITAMIN D ANALOGUES WITH 22R-ALKYL GROUP
884, d1y9rA_, 0.7741, 2.28, 0.200, 240, 210, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
885, d5kyjA1, 0.7738, 2.63, 0.180, 233, 217, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
886, d5i4vE1, 0.7737, 2.61, 0.171, 241, 217, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
887, d2aclH2, 0.7737, 2.41, 0.200, 238, 210, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
888, d2aclF2, 0.7737, 2.62, 0.180, 239, 217, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
889, p1yp0A_, 0.7737, 2.32, 0.219, 240, 210, STRUCTURE OF THE STEROIDOGENIC FACTOR-1 LIGAND BINDING DOMAIN BOUND TO PHOSPHOLIPID AND A SHP PEPTIDE MOTIF
890, d5kyaA1, 0.7735, 2.63, 0.185, 227, 216, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
891, d5hcvA_, 0.7732, 0.49, 0.995, 191, 191, IDENTIFICATION OF SPIROOXINDOLE AND DIBENZOXAZEPINE MOTIFS AS POTENT MINERALOCORTICOID RECEPTOR ANTAGONISTS
892, p4j5wB_, 0.7732, 3.07, 0.190, 239, 221, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
893, p4nqaB1, 0.7730, 2.34, 0.244, 239, 209, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
894, d2ax9A_, 0.7729, 2.80, 0.178, 242, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH R-3
895, d2aclB1, 0.7727, 2.81, 0.183, 236, 218, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
896, d1fm6A_, 0.7727, 2.66, 0.171, 243, 217, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
897, d2pjlB1, 0.7725, 2.69, 0.170, 241, 218, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR ALPHA IN COMPLEX WITH A SYNTHETIC INVERSE AGONIST REVEALS ITS NOVEL MOLECULAR MECHANISM
898, d1p8dA_, 0.7724, 2.88, 0.206, 239, 218, X-RAY CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN WITH 24(S)25- EPOXYCHOLESTEROL
899, d5hjpB1, 0.7723, 2.83, 0.183, 235, 218, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
900, d2pjlA1, 0.7722, 2.35, 0.240, 236, 208, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR ALPHA IN COMPLEX WITH A SYNTHETIC INVERSE AGONIST REVEALS ITS NOVEL MOLECULAR MECHANISM
901, d1pqcC_, 0.7722, 3.11, 0.143, 293, 224, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
902, d1k74A_, 0.7722, 2.63, 0.180, 240, 217, THE 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN PPARGAMMA AND RXRALPHA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH GW409544 AND 9-CIS RETINOIC ACID AND CO-ACTIVATOR PEPTIDES.
903, d1pq9C_, 0.7721, 2.30, 0.220, 238, 209, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
904, d1xlsC_, 0.7717, 2.84, 0.178, 241, 219, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
905, d1fm9A_, 0.7717, 2.77, 0.279, 232, 215, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES.
906, p4j5wA_, 0.7713, 2.07, 0.311, 211, 209, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
907, d1xlsB_, 0.7710, 2.59, 0.190, 240, 216, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
908, p4dk8C_, 0.7709, 2.68, 0.180, 243, 217, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST 5
909, d1xlsD_, 0.7709, 2.08, 0.311, 211, 209, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
910, d1xlsA_, 0.7709, 2.67, 0.190, 231, 216, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
911, d5hjpD1, 0.7708, 2.88, 0.282, 232, 216, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
912, d2abiB_, 0.7705, 2.66, 0.190, 231, 216, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE
913, d5kyjE1, 0.7700, 2.90, 0.282, 232, 216, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
914, d1xvpA_, 0.7698, 2.88, 0.282, 232, 216, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
915, d1mznA_, 0.7697, 3.15, 0.143, 294, 224, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
916, d1pqcA_, 0.7696, 3.15, 0.143, 294, 224, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
917, d1pq9A_, 0.7695, 2.80, 0.284, 232, 215, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
918, d1xv9C_, 0.7694, 2.64, 0.185, 229, 216, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
919, d1z95A_, 0.7692, 2.80, 0.284, 232, 215, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN W741L MUTANT COMPLEX WITH R-BICALUTAMIDE
920, d1xv9A_, 0.7692, 2.80, 0.284, 232, 215, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
921, d3falB_, 0.7691, 2.71, 0.185, 235, 216, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
922, d2hasA_, 0.7691, 2.36, 0.242, 234, 207, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA-(1- PROPOXY) CALCITRIOL
923, d1mznE_, 0.7689, 2.85, 0.183, 235, 218, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
924, d4rakB_, 0.7684, 3.01, 0.274, 232, 215, CRYSTAL STRUCTURE OF NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2 (LXRB) COMPLEXED WITH PARTIAL AGONIST
925, d2aclD2, 0.7684, 2.66, 0.275, 224, 211, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
926, d1ya3A_, 0.7684, 2.65, 0.185, 232, 216, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
927, d1dkfB_, 0.7684, 2.66, 0.185, 232, 216, CRYSTAL STRUCTURE OF A HETERODIMERIC COMPLEX OF RAR AND RXR LIGAND-BINDING DOMAINS
928, d2hamA_, 0.7683, 2.94, 0.271, 232, 214, CRYSTAL STRUCTURE OF VDR LBD COMPLEXED TO 2ALPHA-PROPYL- CALCITRIOL
929, d1yucB_, 0.7683, 2.48, 0.200, 238, 210, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO PHOSPHOLIPID AND A FRAGMENT OF HUMAN SHP
930, p5gidA_, 0.7681, 3.00, 0.274, 232, 215, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-4 (C2 FORM)
931, d1y9rB_, 0.7675, 2.71, 0.181, 238, 216, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
932, d3vhwA_, 0.7674, 2.82, 0.198, 253, 217, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 4-MP
933, d3d24C1, 0.7672, 2.67, 0.275, 224, 211, CRYSTAL STRUCTURE OF LIGAND-BINDING DOMAIN OF ESTROGEN- RELATED RECEPTOR ALPHA (ERRALPHA) IN COMPLEX WITH THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR COACTIVATOR- 1ALPHA BOX3 PEPTIDE (PGC-1ALPHA)
934, d2oaxD_, 0.7671, 2.71, 0.185, 232, 216, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
935, d3wwrA_, 0.7670, 2.78, 0.170, 241, 218, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1-((((1S2R6RZ)-26-DIHYDROXY-4-((E)-2-((1R 3AS7AR)-1-((R)-6-HYDROXY-6-METHYLHEPTAN-2-YL)-7A-METHYLHEXAHYDRO-1H- INDEN-4(2H)-YLIDENE)ETHYLIDENE)-3-METHYLENECYCLOHEXYL)OXY)METHYL) CYCLOPROPANECARBONITRILE
936, d3aurA_, 0.7669, 2.35, 0.243, 233, 206, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YNE-DIENE TYPE ANALOG OF ACTIVE 14-EPI-2BETA- METHYL-19-NORVITAMIN D3
937, p3ipuA_, 0.7667, 2.77, 0.209, 232, 215, X-RAY STRUCTURE OF BENZISOXAZOLE UREA SYNTHETIC AGONIST BOUND TO THE LXR-ALPHA
938, d1xvpC_, 0.7666, 3.06, 0.192, 253, 219, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
939, p4dorB_, 0.7664, 2.84, 0.215, 240, 214, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 IN ITS APO STATE BOUND TO A FRAGMENT OF HUMAN SHP BOX1
940, p3ctbA_, 0.7664, 3.03, 0.201, 237, 219, TETHERED PXR-LBD/SRC-1P APOPROTEIN
941, p4j5xB_, 0.7663, 2.43, 0.245, 238, 208, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
942, p5b5bD_, 0.7662, 2.88, 0.193, 254, 218, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 2-METHYLIDENE-2627- DIPHENYL-19-NOR-125-DIHYDROXYVITAMIN D3
943, d1pq6A_, 0.7662, 2.18, 0.309, 211, 204, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
944, d3x31A_, 0.7661, 2.44, 0.251, 234, 207, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 78-CIS-14-EPI-1A25-DIHYDROXY-19-NORVITAMIN D3
945, d5gt4A_, 0.7660, 3.13, 0.186, 254, 220, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH (1R2S3R5Z7E14BETA17ALPHA)-2-CYANOPROPOXY- 910-SECOCHOLESTA-5710-TRIENE-1325-TRIOL
946, p4oniB_, 0.7660, 2.84, 0.194, 253, 217, STRUCTURE OF HUMAN ORPHAN RECEPTOR LRH1 BOUND TO TWO BACTERIAL PHOSPHOLIPIDS
947, d4iteA_, 0.7659, 2.79, 0.180, 238, 217, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1ALPHA25-DIHYDROXY-2ALPHA-[2-(2H-TETRAZOL-2- YL)ETHYL]VITAMIN D3
948, p5yt2A_, 0.7658, 2.86, 0.277, 236, 213, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH (1R;2S;3R)-5-[(E)-2-{(1R;3AS;7AR)-1-[(R)-6- HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-2;3;3A;6;7;7A-HEXAHYDRO-1H- INDEN-4-YL}VINYL]-2-(3-HYDROXYPROPYL)CYCLOHEX-4-ENE-1;3-DIOL 
949, p5ysyA_, 0.7658, 2.86, 0.215, 240, 214, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH (1R;2R;3R)-5-[(E)-2-{(1R;3AS;7AR)-1-[(R)-6- HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-2;3;3A;6;7;7A-HEXAHYDRO-1H- INDEN-4-YL}VINYL]-2-(3-HYDROXYPROPYL)CYCLOHEX-4-ENE-1;3-DIOL 
950, d3x36A_, 0.7658, 3.02, 0.150, 287, 220, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 78-CIS-1A25-DIHYDROXY-19-NORVITAMIN D3
951, d3ax8A_, 0.7655, 3.21, 0.143, 293, 223, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 15ALPHA-METHOXY-1ALPHA25-DIHYDROXYVITAMIN D3
952, d2abiC_, 0.7655, 3.10, 0.200, 240, 220, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE
953, d3auqA_, 0.7654, 2.66, 0.181, 232, 215, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YNE-DIENE TYPE ANALOG OF ACTIVE 14-EPI-2ALPHA- METHYL-19-NORVITAMIN D3
954, d5jy3B_, 0.7653, 3.22, 0.181, 254, 221, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
955, p6bnsA_, 0.7652, 2.85, 0.194, 255, 217, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND 25A AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES
956, p5gicA_, 0.7652, 2.77, 0.221, 242, 213, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-2P
957, d3kfcB_, 0.7651, 2.91, 0.193, 253, 218, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
958, d2harA_, 0.7650, 2.91, 0.193, 255, 218, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2 ALPHA-(3- HYDROXY-1-PROPOXY) CALCITRIOL
959, p3hvlA_, 0.7649, 2.91, 0.193, 255, 218, TETHERED PXR-LBD/SRC-1P COMPLEXED WITH SR-12813
960, p3ctbB_, 0.7648, 2.86, 0.194, 254, 217, TETHERED PXR-LBD/SRC-1P APOPROTEIN
961, d1xlsG_, 0.7648, 2.91, 0.193, 253, 218, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
962, d1xlsF_, 0.7648, 2.45, 0.242, 234, 207, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
963, d1zh7B_, 0.7647, 2.92, 0.188, 253, 218, STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP
964, d1xlsH_, 0.7647, 2.78, 0.185, 230, 216, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
965, d1xlsE_, 0.7647, 3.06, 0.150, 286, 220, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
966, d1zh7A_, 0.7646, 3.01, 0.202, 237, 218, STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP
967, p4j5xA_, 0.7644, 2.66, 0.181, 232, 215, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
968, d4pa2A_, 0.7642, 3.06, 0.193, 252, 218,  
969, p3hvlB_, 0.7641, 3.06, 0.145, 287, 220, TETHERED PXR-LBD/SRC-1P COMPLEXED WITH SR-12813
970, p5b5bA_, 0.7639, 3.15, 0.149, 287, 221, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 2-METHYLIDENE-2627- DIPHENYL-19-NOR-125-DIHYDROXYVITAMIN D3
971, p3vt6A_, 0.7639, 3.18, 0.190, 242, 221, CRYSTAL STRUCTURE OF RAT VDR-LBD WITH 2-SUBSTITUTED-16-ENE-22-THIA- 1ALPHA25-DIHYDROXY-2627-DIMETHYL-19-NORVITAMIN D3
972, p5vqkA_, 0.7638, 3.18, 0.190, 242, 221, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH A INVERSE AGONIST AND SRC2 PEPTIDE 
973, p4q0aC_, 0.7638, 2.88, 0.229, 243, 214, VITAMIN D RECEPTOR COMPLEX WITH LITHOCHOLIC ACID
974, p3ipuB_, 0.7637, 3.18, 0.190, 242, 221, X-RAY STRUCTURE OF BENZISOXAZOLE UREA SYNTHETIC AGONIST BOUND TO THE LXR-ALPHA
975, d1s19A_, 0.7636, 3.18, 0.190, 242, 221, CRYSTAL STRUCTURE OF VDR LIGAND BINDING DOMAIN COMPLEXED TO CALCIPOTRIOL.
976, d5i4vF_, 0.7635, 2.87, 0.224, 243, 214, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
977, d1rkgA_, 0.7635, 3.24, 0.144, 293, 222, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 2MBISP AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
978, d5k13A_, 0.7634, 2.94, 0.193, 255, 218, CRYSTAL STRUCTURE OF THE RAR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST
979, d4itfA_, 0.7634, 3.19, 0.145, 289, 221, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1ALPHA25-DIHYDROXY-2ALPHA-[2-(1H-TETRAZOLE-1- YL)ETHYL]VITAMIN D3
980, d1rkhA_, 0.7634, 3.07, 0.201, 249, 219, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 2AM20R AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
981, p3wt7A_, 0.7632, 3.07, 0.201, 240, 219, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22R-BUTYL-2-METHYLIDENE- 2627-DIMETHYL-1924-DINOR-1 25-DIHYDROXYVITAMIN D3
982, d3m7rA_, 0.7629, 3.02, 0.159, 256, 220, CRYSTAL STRUCTURE OF VDR H305Q MUTANT
983, d1upvA_, 0.7629, 3.19, 0.196, 239, 219, CRYSTAL STRUCTURE OF THE HUMAN LIVER X RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST
984, p3vtdA_, 0.7628, 2.83, 0.171, 235, 216, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO A PARTIAL AGONIST 26-ADAMANTYL-23-YNE-19-NORVITAMMIN D ADTK4
985, p5b41A_, 0.7627, 2.93, 0.194, 253, 217, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 2-METHYLIDENE-19-NOR-1A 25-DIHYDROXYVITAMIN D3
986, p5xpoA_, 0.7626, 2.45, 0.284, 218, 211, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 25-(HYDROXYPHENYL)-2- METHYLIDENE-19;26;27-TRINOR-25-OXO-1-HYDROXYVITAMIN D3 
987, p3wt5A_, 0.7626, 3.18, 0.200, 241, 220, A MIXED POPULATION OF ANTAGONIST AND AGONIST BINDING CONFORMERS IN A SINGLE CRYSTAL EXPLAINS PARTIAL AGONISM AGAINST VITAMIN D RECEPTOR: ACTIVE VITAMIN D ANALOGUES WITH 22R-ALKYL GROUP
988, d2zfxA_, 0.7626, 2.97, 0.190, 235, 216, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YR301 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
989, d2hb7A_, 0.7626, 2.95, 0.188, 253, 218, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA(3- HYDROXY-1-PROPYL) CALCITRIOL
990, p4ynkA_, 0.7625, 3.09, 0.201, 242, 219, CRYSTAL STRUCTURE OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH A 19-NORVITAMIN D COMPOUND
991, d1txiA_, 0.7625, 3.10, 0.201, 240, 219, CRYSTAL STRUCTURE OF THE VDR LIGAND BINDING DOMAIN COMPLEXED TO TX522
992, d1s0zA_, 0.7625, 2.97, 0.197, 253, 218, CRYSTAL STRUCTURE OF THE VDR LBD COMPLEXED TO SEOCALCITOL.
993, d2hb8A_, 0.7624, 2.61, 0.183, 232, 213, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA-METHYL CALCITRIOL
994, d1yucA_, 0.7624, 3.05, 0.201, 240, 219, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO PHOSPHOLIPID AND A FRAGMENT OF HUMAN SHP
995, d1upwA_, 0.7624, 3.10, 0.201, 239, 219, CRYSTAL STRUCTURE OF THE HUMAN LIVER X RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST
996, p5mx7A_, 0.7623, 3.07, 0.196, 239, 219, struct.pdbx_descriptor               Vitamin D3 receptor A; Nuclear receptor coactivator 1 (E.C.2.3.1.48)  
997, d5jy3D_, 0.7623, 3.08, 0.201, 240, 219, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
998, p3w5pA_, 0.7623, 3.38, 0.194, 241, 222, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
999, p5vqlA_, 0.7622, 3.05, 0.193, 254, 218, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH A INVERSE AGONIST AND SRC2 PEPTIDE 
1000, d3afrA_, 0.7622, 3.28, 0.199, 240, 221, CRYSTAL STRUCTURE OF VDR-LBD/22S-BUTYL-1A24R-DIHYDROXYVITAMIN D3 COMPLEX
1001, d2oaxA_, 0.7622, 3.00, 0.197, 253, 218, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1002, p1zdtA_, 0.7622, 3.16, 0.187, 253, 219, THE CRYSTAL STRUCTURE OF HUMAN STEROIDOGENIC FACTOR-1
1003, d2zxnA_, 0.7621, 3.21, 0.191, 254, 220, A NEW CLASS OF VITAMIN D RECEPTOR LIGANDS THAT INDUCE STRUCTURAL REARRANGEMENT OF THE LIGAND-BINDING POCKET
1004, d1rk3A_, 0.7621, 2.82, 0.221, 240, 213, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 125-DIHYDROXYVITAMIN D3 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
1005, p5zwiA_, 0.7620, 2.62, 0.183, 232, 213, INTERACTION BETWEEN VITAMIN D RECEPTOR (VDR) AND A LIGAND HAVING A DIENONE GROUP 
1006, p5xpnA_, 0.7620, 3.20, 0.201, 238, 219, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 25RS-(HYDROXYPHENYL)-25- METHOXY-2-METHYLIDENE-19;26;27-TRINOR-1-HYDROXYVITAMIN D3 
1007, p4oniA_, 0.7620, 2.72, 0.182, 227, 214, STRUCTURE OF HUMAN ORPHAN RECEPTOR LRH1 BOUND TO TWO BACTERIAL PHOSPHOLIPIDS
1008, p3w5rA_, 0.7620, 3.29, 0.190, 240, 221, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
1009, p3o1eA_, 0.7620, 3.03, 0.155, 259, 220, STRUCTURE-FUNCTION OF GEMINI DERIVATIVES WITH TWO DIFFERENT SIDE CHAINS AT C-20 GEMINI-0072 AND GEMINI-0097.
1010, p2zxmA_, 0.7620, 3.09, 0.201, 240, 219, A NEW CLASS OF VITAMIN D RECEPTOR LIGANDS THAT INDUCE STRUCTURAL REARRANGEMENT OF THE LIGAND-BINDING POCKET
1011, d1xiuB_, 0.7619, 2.45, 0.248, 233, 206, CRYSTAL STRUCTURE OF THE AGONIST-BOUND LIGAND-BINDING DOMAIN OF BIOMPHALARIA GLABRATA RXR
1012, p5gtnA_, 0.7618, 2.85, 0.229, 233, 214, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH R35
1013, p3w0iA_, 0.7618, 3.14, 0.200, 240, 220, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
1014, p5awkA_, 0.7616, 3.12, 0.201, 239, 219, CRYSTAL STRUCTURE OF VDR-LBD/PARTIAL AGONIST COMPLEX: 22S-ETHYL ANALOGUE
1015, p4pleA_, 0.7616, 3.08, 0.201, 240, 219, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1016, d3plzB_, 0.7615, 3.06, 0.201, 239, 219, HUMAN LRH1 LBD BOUND TO GR470
1017, d1pk5A_, 0.7615, 2.83, 0.221, 241, 213, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR LRH-1
1018, p5ow7A_, 0.7614, 3.20, 0.200, 242, 220, VDR COMPLEX
1019, p3aunA_, 0.7614, 3.36, 0.199, 239, 221, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YR335 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
1020, p5syzA_, 0.7613, 3.13, 0.200, 240, 220, HUMAN LIVER RECEPTOR HOMOLOGUE-1 (LRH-1) BOUND TO A RJW100 STEREOISOMER AND A FRAGMENT OF TIF-2
1021, p5h1eA_, 0.7613, 2.87, 0.259, 224, 212, INTERACTION BETWEEN VITAMIN D RECEPTOR AND COACTIVATOR PEPTIDE SRC2-3
1022, d4g2iA_, 0.7613, 3.15, 0.174, 271, 218, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
1023, p3a2iA_, 0.7613, 3.09, 0.201, 242, 219, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR (H305F) LIGAND BINDING DOMAIN COMPLEXED WITH TEI-9647
1024, d2o4jA1, 0.7613, 3.16, 0.200, 240, 220, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH VITIII 17-20Z AND THE NR2 BOX OF DRIP 205
1025, p3vt5A_, 0.7612, 2.85, 0.225, 241, 213, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH R270L MUTATION
1026, d3a2jA_, 0.7612, 2.83, 0.216, 240, 213, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR (H305F/H397F) LIGAND BINDING DOMAIN COMPLEXED WITH TEI-9647
1027, d2o4rA1, 0.7612, 2.90, 0.224, 242, 214, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH VITIII 17-20E AND THE NR2 BOX OF DRIP 205
1028, p5xplA_, 0.7610, 3.21, 0.201, 240, 219, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22S-BUTYL-25- HYDROXYPHENYL-2-METHYLIDENE-19;26;27-TRINOR-25-OXO-1-HYDROXYVITAMIN D3 
1029, d1xvpD_, 0.7610, 3.21, 0.200, 238, 220, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
1030, p5nmbA_, 0.7609, 3.00, 0.214, 237, 215, 
1031, p3vtcA_, 0.7609, 3.08, 0.201, 239, 219, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO A PARTIAL AGONIST 26-ADAMANTYL-23-YNE-19-NORVITAMMIN D ADTK3
1032, p3vruA_, 0.7609, 3.00, 0.197, 253, 218, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 2-METHYLIDENE-1924-DINOR- 1ALPHA25-DIHYDROXY VITAMIND3
1033, d3kpzA_, 0.7609, 2.97, 0.194, 253, 217, CRYSTAL STRUCTURE OF A NOVEL VITAMIN D3 ANALOGUE ZK203278 SHOWING DISSOCIATED PROFILE
1034, d1xvpB_, 0.7609, 3.14, 0.201, 240, 219, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
1035, p3w5tA_, 0.7608, 3.19, 0.200, 240, 220, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
1036, d2zlcA_, 0.7608, 3.01, 0.197, 253, 218, 2-SUBSTITUTED-16-ENE-22-THIA-1ALPHA25-DIHYDROXY-2627- DIMETHYL-19-NORVITAMIN D3 ANALOGS: SYNTHESIS BIOLOGICAL EVALUATION AND CRYSTAL STRUCTURE
1037, p3vrvA_, 0.7607, 3.14, 0.201, 240, 219, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 2-METHYLIDENE-2627- DIMETHYL-1924-DINOR-1ALPHA25-DIHYDROXYVITAMIN D3
1038, d3tkcA_, 0.7606, 3.08, 0.195, 237, 220, DESIGN SYNTHESIS EVALUATION AND STRUCTURE OF VITAMIN D ANALOGUES WITH FURAN SIDE CHAINS
1039, d3ogtA_, 0.7606, 3.15, 0.200, 246, 220, DESIGN CHEMICAL SYNTHESIS FUNCTIONAL CHARACTERIZATION AND CRYSTAL STRUCTURE OF THE SIDECHAIN ANALOGUE OF 125-DIHYDROXYVITAMIN D3.
1040, d3d24A1, 0.7606, 3.14, 0.202, 238, 218, CRYSTAL STRUCTURE OF LIGAND-BINDING DOMAIN OF ESTROGEN- RELATED RECEPTOR ALPHA (ERRALPHA) IN COMPLEX WITH THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR COACTIVATOR- 1ALPHA BOX3 PEPTIDE (PGC-1ALPHA)
1041, d2zlaA_, 0.7606, 3.16, 0.200, 240, 220, 2-SUBSTITUTED-16-ENE-22-THIA-1ALPHA25-DIHYDROXY-2627- DIMETHYL-19-NORVITAMIN D3 ANALOGS: SYNTHESIS BIOLOGICAL EVALUATION AND CRYSTAL STRUCTURE
1042, p5ji0A_, 0.7605, 3.27, 0.200, 238, 220, PPARGAMMA-RXRALPHA(S427F) HETERODIMER IN COMPLEX WITH SRC-1 ROSIGLITAZONE AND 9-CIS-RETANOIC ACID
1043, p3wtqA_, 0.7605, 3.22, 0.191, 253, 220, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22S-BUTYL-2-METHYLIDENE- 19-NOR-1A25-DIHYDROXYVITAMIN D3
1044, p3vrtA_, 0.7605, 3.11, 0.200, 246, 220, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 2-MEHYLIDENE-19252627- TETRANOR-1ALPHA24-DIHYDROXYVITAMIND3
1045, p1zdtB_, 0.7605, 3.32, 0.190, 242, 221, THE CRYSTAL STRUCTURE OF HUMAN STEROIDOGENIC FACTOR-1
1046, p6fo7A_, 0.7604, 3.11, 0.201, 240, 219, VITAMIN D NUCLEAR RECEPTOR COMPLEX 3 
1047, d4j5wC1, 0.7604, 3.27, 0.200, 237, 220, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
1048, d2zmjA_, 0.7604, 3.04, 0.197, 254, 218, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO ADAMANTYL VITAMIN D ANALOGS: STRUCTURAL BASIS FOR VITAMIN D RECEPTOR ANTAGONISM AND/OR PARTIAL AGONISM
1049, d1rjkA_, 0.7604, 3.04, 0.197, 254, 218, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 2MD AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
1050, p5lgaA_, 0.7603, 2.00, 0.308, 209, 201, STRUCTURAL ANALYSIS AND BIOLOGICAL ACTIVITIES OF BXL0124 A GEMINI ANALOG OF VITAMIN D
1051, p3w5qA_, 0.7603, 3.26, 0.195, 238, 220, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
1052, p5nkyA_, 0.7602, 2.61, 0.282, 216, 209, STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF VITAMIN D ANALOGS WITH OXOLANE GROUP IN THEIR SIDE CHAIN
1053, p5l11A_, 0.7602, 3.11, 0.201, 240, 219, HUMAN LIVER RECEPTOR HOMOLOGUE-1 (LRH-1) BOUND TO RJW100 AND A FRAGMENT OF TIF-2
1054, p4g1dA_, 0.7601, 3.08, 0.201, 238, 219, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
1055, p3w0jA_, 0.7601, 2.74, 0.223, 239, 211, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
1056, p5ow9A_, 0.7600, 3.22, 0.201, 239, 219, VITAMIN D RECEPTOR COMPLEX
1057, d5hcvC_, 0.7599, 2.38, 0.282, 216, 206, IDENTIFICATION OF SPIROOXINDOLE AND DIBENZOXAZEPINE MOTIFS AS POTENT MINERALOCORTICOID RECEPTOR ANTAGONISTS
1058, p5gieA_, 0.7599, 3.14, 0.200, 240, 220, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-4P (P21 FORM)
1059, d3a2hA_, 0.7598, 3.14, 0.201, 239, 219, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH TEI-9647 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
1060, d2zmhA_, 0.7598, 3.15, 0.202, 238, 218, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO ADAMANTYL VITAMIN D ANALOGS: STRUCTURAL BASIS FOR VITAMIN D RECEPTOR ANTAGONISM AND/OR PARTIAL AGONISM
1061, p3vt3A_, 0.7597, 3.24, 0.195, 240, 220, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH R270L MUTATION
1062, d3b0tA1, 0.7597, 3.12, 0.202, 238, 218, HUMAN VDR LIGAND BINDING DOMAIN IN COMPLEX WITH MAXACALCITOL
1063, p5zweA_, 0.7596, 2.83, 0.211, 234, 213, COVALENT BOND FORMATION BETWEEN HISTIDINE OF VITAMIN D RECEPTOR (VDR) AND A FULL AGONIST HAVING A VINYL KETONE GROUP VIA CONJUGATE ADDITION REACTION 
1064, p3vrwA_, 0.7596, 3.27, 0.200, 239, 220, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 22S-BUTYL-2-METHYLIDENE-26 27-DIMETHYL-1924-DINOR-1ALPHA25-DIHYDROXYVITAMIN D3
1065, d2zl9A_, 0.7596, 3.10, 0.201, 242, 219, 2-SUBSTITUTED-16-ENE-22-THIA-1ALPHA25-DIHYDROXY-2627- DIMETHYL-19-NORVITAMIN D3 ANALOGS: SYNTHESIS BIOLOGICAL EVALUATION AND CRYSTAL STRUCTURE
1066, p5xppA_, 0.7595, 3.23, 0.201, 239, 219, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 25RS-(HYDROXYPHENYL)-2- METHYLIDENE-19;26;27-TRINOR-1;25-DIHYDROXYVITAMIN D3 
1067, p5nmaA_, 0.7595, 2.31, 0.240, 229, 204, STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF VITAMIN D ANALOGS WITH OXOLANE GROUP IN THEIR SIDE CHAIN
1068, p3vjsA_, 0.7595, 3.10, 0.202, 251, 218, VITAMIN D RECEPTOR COMPLEX WITH A CARBORANE COMPOUND
1069, d3a3zX_, 0.7594, 3.35, 0.195, 239, 221, CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND 2ALPHA-METHYL-AMCR277A(C23S)
1070, p6bnsB_, 0.7593, 3.11, 0.201, 240, 219, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND 25A AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES
1071, p4g1zA_, 0.7593, 3.32, 0.190, 239, 221, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
1072, p4dk8A_, 0.7592, 3.06, 0.197, 253, 218, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST 5
1073, p4g20A_, 0.7591, 3.12, 0.201, 240, 219, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
1074, p3vjtA_, 0.7591, 3.11, 0.201, 238, 219, VITAMIN D RECEPTOR COMPLEX WITH A CARBORANE COMPOUND
1075, d1xv9B_, 0.7591, 3.27, 0.191, 238, 220, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
1076, p5owdA_, 0.7590, 3.09, 0.201, 239, 219, VITAMIN D RECEPTOR COMPLEX
1077, d3p8xA_, 0.7590, 3.14, 0.202, 239, 218, SYNTHESIS STRUCTURE AND BIOLOGICAL ACTIVITY OF DES-SIDE CHAIN ANALOGUES OF 1ALPHA25-DIHYDROXYVITAMIN D3 WITH SUBSTITUENTS AT C-18
1078, d3cs4A_, 0.7590, 3.27, 0.200, 239, 220, STRUCTURE-BASED DESIGN OF A SUPERAGONIST LIGAND FOR THE VITAMIN D NUCLEAR RECEPTOR
1079, p5e7vA_, 0.7589, 3.05, 0.197, 255, 218, POTENT VITAMIN D RECEPTOR AGONIST
1080, p3w0gA_, 0.7589, 3.03, 0.151, 283, 218, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
1081, d1xv9D_, 0.7589, 3.22, 0.201, 239, 219, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
1082, p5zwfA_, 0.7588, 2.82, 0.181, 233, 216, COVALENT BOND FORMATION BETWEEN HISTIDINE OF VITAMIN D RECEPTOR (VDR) AND A FULL AGONIST HAVING A ENONE WITH A BETA METHYL GROUP VIA CONJUGATE ADDITION REACTION 
1083, p4rujA_, 0.7588, 3.23, 0.201, 237, 219, CRYSTAL STRUCTURE OF ZVDR L337H MUTANT-VD COMPLEX
1084, p4dosA_, 0.7587, 3.27, 0.200, 238, 220, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO DLPC AND A FRAGMENT OF TIF-2
1085, p3vtbA_, 0.7586, 3.13, 0.200, 246, 220, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO A PARTIAL AGONIST 25-ADAMANTYL-23-YNE-19-NORVITAMMIN D ADTK1
1086, p5xpmA_, 0.7584, 3.13, 0.200, 246, 220, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22S-BUTYL-25RS- (HYDROXYPHENYL)-25-METHOXY-2-METHYLIDENE-19;26;27-TRINOR-1- HYDROXYVITAMIN D3 
1087, p4pleG_, 0.7584, 3.16, 0.202, 238, 218, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1088, d2oaxE_, 0.7584, 3.05, 0.197, 255, 218, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1089, d1ie9A_, 0.7584, 3.05, 0.197, 254, 218, CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D LIGAND BINDING DOMAIN BOUND TO MC1288
1090, d1fm9D_, 0.7584, 3.14, 0.202, 239, 218, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES.
1091, p5z12B_, 0.7583, 3.22, 0.200, 242, 220, A STRUCTURE OF FXR/RXR 
1092, d3a78A_, 0.7583, 3.15, 0.200, 246, 220, CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE NATURAL METABOLITE 1ALPHA25-DIHYDROXY-3-EPI-VITAMIN D3
1093, p3w0hA_, 0.7582, 3.28, 0.200, 237, 220, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
1094, d3cs6A_, 0.7582, 3.23, 0.201, 240, 219, STRUCTURE-BASED DESIGN OF A SUPERAGONIST LIGAND FOR THE VITAMIN D NUCLEAR RECEPTOR
1095, d3a40X_, 0.7582, 2.96, 0.224, 242, 214, CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND 2ALPHA-METHYL-AMCR277B(C23R)
1096, d1zduA_, 0.7582, 3.15, 0.201, 240, 219, THE CRYSTAL STRUCTURE OF HUMAN LIVER RECEPTOR HOMOLOGUE-1
1097, p5zwhA_, 0.7581, 3.24, 0.200, 239, 220, COVALENT BOND FORMATION BETWEEN HISTIDINE OF VITAMIN D RECEPTOR (VDR) AND A FULL AGONIST HAVING AN ENE-YNONE GROUP VIA CONJUGATE ADDITION REACTION 
1098, p5awjA_, 0.7581, 2.92, 0.221, 241, 213, CRYSTAL STRUCTURE OF VDR-LBD/PARTIAL AGONIST COMPLEX: 22S-HEXYL ANALOGUE
1099, d2zmiA_, 0.7581, 2.44, 0.248, 234, 206, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO ADAMANTYL VITAMIN D ANALOGS: STRUCTURAL BASIS FOR VITAMIN D RECEPTOR ANTAGONISM AND/OR PARTIAL AGONISM
1100, p6fo9A_, 0.7580, 3.07, 0.197, 255, 218, VITAMIN D NUCLEAR RECEPTOR COMPLEX 2 
1101, p5aviA_, 0.7580, 3.07, 0.197, 255, 218, CRYSTAL STRUCTURE OF LXRALPHA IN COMPLEX WITH TERT-BUTYL BENZOATE ANALOG COMPOUND 4
1102, p4g21A_, 0.7580, 3.27, 0.174, 272, 219, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
1103, p6fo81_, 0.7579, 2.49, 0.280, 217, 207, VITAMIN D NUCLEAR RECEPTOR COMPLEX 4 
1104, d3plzA_, 0.7579, 3.07, 0.197, 255, 218, HUMAN LRH1 LBD BOUND TO GR470
1105, d1pk5B_, 0.7579, 3.31, 0.190, 247, 221, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR LRH-1
1106, p5hjsA_, 0.7578, 3.06, 0.197, 254, 218, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
1107, d2oaxB_, 0.7578, 3.28, 0.191, 255, 220, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1108, p3vt4A_, 0.7577, 2.67, 0.218, 233, 211, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH R270L MUTATION
1109, p3o1dA_, 0.7576, 3.19, 0.201, 237, 219, STRUCTURE-FUNCTION STUDY OF GEMINI DERIVATIVES WITH TWO DIFFERENT SIDE CHAINS AT C-20 GEMINI-0072 AND GEMINI-0097.
1110, d1r20D_, 0.7576, 3.14, 0.200, 240, 220, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO THE SYNTHETIC AGONIST BYI06830
1111, d5hcvB_, 0.7574, 3.15, 0.201, 242, 219, IDENTIFICATION OF SPIROOXINDOLE AND DIBENZOXAZEPINE MOTIFS AS POTENT MINERALOCORTICOID RECEPTOR ANTAGONISTS
1112, d3cdpA_, 0.7573, 3.24, 0.201, 239, 219, CRYSTAL STRUCTURE OF PPAR-GAMMA LBD COMPLEXED WITH A PARTIAL AGONIST ANALOGUE OF CLOFIBRIC ACID
1113, p6fobA_, 0.7572, 2.70, 0.183, 228, 213, VITAMIN D RECEPTOR COMPLEX 5 
1114, p4pleE_, 0.7572, 3.17, 0.202, 239, 218, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1115, d1ya3C_, 0.7572, 3.14, 0.202, 236, 218, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1116, p5xzfA_, 0.7569, 2.68, 0.223, 231, 211, VITAMIN D RECEPTOR WITH A SYNTHETIC LIGAND ADRO1 
1117, p5v39A_, 0.7568, 2.85, 0.217, 236, 212, CRYSTAL STRUCTURE OF HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A VDRM
1118, p5hjsB_, 0.7568, 2.64, 0.179, 226, 212, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
1119, p4ruoX_, 0.7567, 2.40, 0.249, 233, 205, CRYSTAL STRUCTURE OF ZVDR L337H MUTANT-GEMINI COMPLEX
1120, p4rupA_, 0.7566, 3.22, 0.200, 240, 220, CRYSTAL STRUCTURE OF ZVDR L337H MUTANT-GEMINI72 COMPLEX
1121, d2i4zA_, 0.7566, 3.25, 0.201, 240, 219, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). THIS STRUCTURE HAS BEEN OBTAINED FROM CRYSTALS SOAKED FOR 6 HOURS.
1122, p6fodA_, 0.7565, 2.69, 0.155, 228, 213, VITAMIN D NUCLEAR RECEPTOR COMPLEX 1 
1123, p4rwvA_, 0.7565, 2.36, 0.240, 232, 204, CRYSTAL STRUCTURE OF PIP3 BOUND HUMAN NUCLEAR RECEPTOR LRH-1 (LIVER RECEPTOR HOMOLOG 1 NR5A2) IN COMPLEX WITH A CO-REGULATOR DAX-1 (NR0B1) PEPTIDE AT 1.86 A RESOLUTION
1124, d1xdkE_, 0.7565, 3.04, 0.180, 270, 217, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
1125, d2zy0C_, 0.7564, 3.25, 0.201, 238, 219, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO A SYNTHETIC AGONIST COMPOUND AND A COACTIVATOR PEPTIDE
1126, d1xdkA_, 0.7564, 2.81, 0.222, 241, 212, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
1127, d1db1A_, 0.7564, 2.46, 0.239, 232, 205, CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D COMPLEXED TO VITAMIN D
1128, p5xzhA_, 0.7563, 3.29, 0.200, 237, 220, VITAMIN D RECEPTOR WITH A SYNTHETIC LIGAND ADRO2 
1129, d2zy0A_, 0.7563, 3.29, 0.209, 251, 220, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO A SYNTHETIC AGONIST COMPOUND AND A COACTIVATOR PEPTIDE
1130, p4qk4A_, 0.7562, 2.67, 0.184, 226, 212, CRYSTAL STRUCTURE OF HUMAN NUCLEAR RECEPTOR SF-1 (NR5A1) BOUND TO PIP2 AT 2.8 A RESOLUTION
1131, d3ozjC_, 0.7562, 3.23, 0.201, 239, 219, CRYSTAL STRUCTURE OF HUMAN RETINOIC X RECEPTOR ALPHA COMPLEXED WITH BIGELOVIN AND COACTIVATOR SRC-1
1132, d2p54A_, 0.7561, 3.26, 0.201, 239, 219, A CRYSTAL STRUCTURE OF PPAR ALPHA BOUND WITH SRC1 PEPTIDE AND GW735
1133, p5unjA_, 0.7560, 3.01, 0.180, 270, 217, STRUCTURE OF HUMAN LIVER RECEPTOR HOMOLOG 1 IN COMPLEX WITH PGC1A AND RJW100
1134, p4ia1A_, 0.7560, 3.26, 0.201, 239, 219, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
1135, p4fhiA_, 0.7560, 2.92, 0.211, 242, 213, DEVELOPMENT OF SYNTHETICALLY ACCESSIBLE NON-SECOSTEROIDAL HYBRID MOLECULES COMBINING VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITION
1136, p3ipsA_, 0.7560, 2.75, 0.278, 217, 209, X-RAY STRUCTURE OF BENZISOXAZOLE SYNTHETIC AGONIST BOUND TO THE LXR- ALPHA
1137, p6eu9A_, 0.7558, 2.40, 0.283, 215, 205, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
1138, d3r8iB_, 0.7558, 2.76, 0.278, 217, 209, CRYSTAL STRUCTURE OF PPARGAMMA WITH AN ACHIRAL UREIDOFIBRATE DERIVATIVE (RT86)
1139, p2hcdA_, 0.7558, 2.92, 0.195, 250, 215, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE VITAMIN D NUCLEAR RECEPTOR IN COMPLEX WITH GEMINI AND A COACTIVATOR PEPTIDE
1140, p5mk4C_, 0.7557, 3.30, 0.195, 239, 220, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 7 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1141, p4qjrA_, 0.7557, 2.38, 0.283, 215, 205, CRYSTAL STRUCTURE OF HUMAN NUCLEAR RECEPTOR SF-1 (NR5A1) BOUND TO ITS HORMONE PIP3 AT 2.4 A RESOLUTION
1142, p4fhhA_, 0.7557, 2.96, 0.221, 244, 213, DEVELOPMENT OF SYNTHETICALLY ACCESSIBLE NON-SECOSTEROIDAL HYBRID MOLECULES COMBINING VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITION
1143, p3ipsB_, 0.7557, 2.51, 0.282, 215, 206, X-RAY STRUCTURE OF BENZISOXAZOLE SYNTHETIC AGONIST BOUND TO THE LXR- ALPHA
1144, p5aviC_, 0.7556, 2.91, 0.159, 267, 214, CRYSTAL STRUCTURE OF LXRALPHA IN COMPLEX WITH TERT-BUTYL BENZOATE ANALOG COMPOUND 4
1145, d4bcrB_, 0.7555, 2.64, 0.225, 227, 209, STRUCTURE OF PPARALPHA IN COMPLEX WITH WY14643
1146, d3kdtB1, 0.7555, 3.27, 0.201, 239, 219, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-(METHOXYCARBONYL)GLYCINE
1147, p2hc4A_, 0.7554, 3.19, 0.202, 238, 218, CRYSTAL STRUCTURE OF THE LBD OF VDR OF DANIO RERIO IN COMPLEX WITH CALCITRIOL
1148, d3et1A_, 0.7553, 2.53, 0.181, 224, 210, STRUCTURE OF PPARALPHA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
1149, d2i4pA_, 0.7553, 3.05, 0.224, 227, 214, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 30 DAYS.
1150, d2prgA_, 0.7552, 2.98, 0.162, 270, 216, LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
1151, p2hbhA_, 0.7552, 3.27, 0.201, 239, 219, CRYSTAL STRUCTURE OF VITAMIN D NUCLEAR RECEPTOR LIGAND BINDING DOMAIN BOUND TO A LOCKED SIDE-CHAIN ANALOG OF CALCITRIOL AND SRC-1 PEPTIDE
1152, d4e4qA_, 0.7551, 2.40, 0.286, 215, 206, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND FS214
1153, d1k74D_, 0.7551, 2.97, 0.221, 244, 213, THE 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN PPARGAMMA AND RXRALPHA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH GW409544 AND 9-CIS RETINOIC ACID AND CO-ACTIVATOR PEPTIDES.
1154, p4ia7A_, 0.7550, 2.97, 0.221, 244, 213, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
1155, d4e4kA_, 0.7550, 3.19, 0.202, 239, 218, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND JO21
1156, d3qt0A_, 0.7550, 2.65, 0.193, 226, 212, REVEALING A STEROID RECEPTOR LIGAND AS A UNIQUE PPARGAMMA AGONIST
1157, d4is8A_, 0.7549, 2.60, 0.180, 226, 211, DIVERGENT SEQUENCE TUNES LIGAND SENSITIVITY IN PHOSPHOLIPID-REGULATED HORMONE RECEPTORS
1158, p4g2hA_, 0.7548, 2.98, 0.157, 265, 216, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
1159, p4iqrF2, 0.7547, 3.04, 0.153, 268, 216, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
1160, p4ia3A_, 0.7547, 3.18, 0.202, 239, 218, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
1161, d3r8iA_, 0.7547, 2.93, 0.153, 263, 215, CRYSTAL STRUCTURE OF PPARGAMMA WITH AN ACHIRAL UREIDOFIBRATE DERIVATIVE (RT86)
1162, d3ozjA_, 0.7547, 2.96, 0.181, 270, 216, CRYSTAL STRUCTURE OF HUMAN RETINOIC X RECEPTOR ALPHA COMPLEXED WITH BIGELOVIN AND COACTIVATOR SRC-1
1163, d3f5cA_, 0.7547, 3.15, 0.175, 271, 217, STRUCTURE OF DAX-1:LRH-1 COMPLEX
1164, p1ymtA_, 0.7547, 3.28, 0.201, 239, 219, MOUSE SF-1 LBD
1165, p4jygB_, 0.7546, 2.97, 0.181, 268, 216, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH AGONIST BMS411 [4- {[(55-DIMETHYL-8-PHENYL-56-DIHYDRONAPHTHALEN-2-YL) CARBONYL]AMINO}BENZOIC ACID]
1166, p3r5mA_, 0.7546, 3.16, 0.170, 272, 218, CRYSTAL STRUCTURE OF RXRALPHALBD COMPLEXED WITH THE AGONIST MAGNOLOL
1167, p3dr1A_, 0.7546, 3.18, 0.202, 238, 218, SIDE-CHAIN FLUORINE ATOMS OF NON-STEROIDAL VITAMIN D3 ANALOGS STABILIZE HELIX 12 OF VITAMIN D RECEPTOR
1168, d4is8B_, 0.7545, 3.15, 0.187, 268, 219, DIVERGENT SEQUENCE TUNES LIGAND SENSITIVITY IN PHOSPHOLIPID-REGULATED HORMONE RECEPTORS
1169, p3f7dA_, 0.7545, 3.16, 0.181, 267, 216, SF-1 LBD BOUND BY PHOSPHATIDYLCHOLINE
1170, d3cdsA_, 0.7545, 2.75, 0.223, 230, 211, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPAR-GAMMA AND THE AGONIST LT248 (CLOFIBRIC ACID ANALOGUE)
1171, d1yokA_, 0.7545, 3.20, 0.202, 239, 218, CRYSTAL STRUCTURE OF HUMAN LRH-1 BOUND WITH TIF-2 PEPTIDE AND PHOSPHATIDYLGLYCEROL
1172, d1ie8A_, 0.7544, 2.74, 0.216, 227, 208, CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D LIGAND BINDING DOMAIN BOUND TO KH1060
1173, d3wgpA_, 0.7543, 3.28, 0.201, 239, 219, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
1174, d3b3kA_, 0.7543, 3.09, 0.180, 270, 217, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE FULL AGONIST LT175
1175, p5mk4A_, 0.7542, 2.39, 0.283, 215, 205, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 7 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1176, p4nqaA2, 0.7542, 2.81, 0.222, 243, 212, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
1177, d4dm6A1, 0.7542, 2.70, 0.214, 235, 210, CRYSTAL STRUCTURE OF RARB LBD HOMODIMER IN COMPLEX WITH TTNPB
1178, d3hodA_, 0.7542, 3.05, 0.196, 240, 214, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
1179, d3d6dA_, 0.7541, 2.40, 0.283, 215, 205, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LT175(R-ENANTIOMER)
1180, p3a9eB_, 0.7541, 3.28, 0.201, 240, 219, CRYSTAL STRUCTURE OF A MIXED AGONIST-BOUND RAR-ALPHA AND ANTAGONIST- BOUND RXR-ALPHA HETERODIMER LIGAND BINDING DOMAINS
1181, d4prgC_, 0.7537, 2.74, 0.218, 230, 211, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
1182, p4g1yA_, 0.7537, 2.83, 0.223, 237, 211, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
1183, p4pleC_, 0.7535, 2.95, 0.181, 270, 216, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1184, p4ia2A_, 0.7535, 2.77, 0.218, 236, 211, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
1185, d3noaA_, 0.7535, 2.93, 0.195, 250, 215, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEX WITH A POTENCY IMPROVED AGONIST
1186, d3kdtA_, 0.7535, 3.16, 0.189, 250, 217, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-(METHOXYCARBONYL)GLYCINE
1187, d2i4jA_, 0.7535, 2.96, 0.181, 270, 216, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE AGONIST LT160 (UREIDOFIBRATE DERIVATIVE)
1188, d2g0gA_, 0.7535, 2.33, 0.288, 214, 205, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
1189, d4prgA_, 0.7534, 2.76, 0.281, 232, 210, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
1190, p3sp6A_, 0.7534, 2.99, 0.207, 239, 213, STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHA/DELTA AGONIST
1191, p4k6iA_, 0.7532, 2.97, 0.181, 270, 216, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH TARGRETIN AND THE COACTIVATOR PEPTIDE GRIP-1
1192, p4jyiB_, 0.7532, 2.97, 0.185, 270, 216, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE PARTIAL AGONIST BMS641 [3-CHLORO-4-[(E)-2-(55-DIMETHYL-8-PHENYL-56- DIHYDRONAPHTHALEN-2-YL)ETHENYL]BENZOIC ACID]
1193, d2rewA_, 0.7532, 3.07, 0.192, 239, 214, CRYSTAL STRUCTURE OF PPARALPHA LIGAND BINDING DOMAIN WITH BMS-631707
1194, d1pq9D_, 0.7532, 3.27, 0.183, 270, 219, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
1195, p4rmcA_, 0.7531, 3.30, 0.201, 239, 219, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB76 AND THE COACTIVATOR PEPTIDE GRIP-1
1196, p4dqmC_, 0.7531, 2.79, 0.227, 239, 211, REVEALING A MARINE NATURAL PRODUCT AS A NOVEL AGONIST FOR RETINOIC ACID RECEPTORS WITH A UNIQUE BINDING MODE AND ANTITUMOR ACTIVITY
1197, p4dm8B_, 0.7531, 3.21, 0.202, 239, 218, CRYSTAL STRUCTURE OF RARB LBD IN COMPLEX WITH 9CIS RETINOIC ACID
1198, d3ho0A_, 0.7531, 3.16, 0.181, 271, 216, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
1199, d1pqcD_, 0.7531, 3.01, 0.153, 264, 215, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
1200, d1fm6D_, 0.7530, 2.98, 0.181, 270, 216, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
1201, d4jl4A_, 0.7529, 3.22, 0.180, 271, 217, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570 [(2S)-3-(BIPHENYL-4-YL)-2-(BIPHENYL-4-YLOXY)PROPANOIC ACID]
1202, p3vn2A_, 0.7529, 3.18, 0.178, 270, 219, CRYSTAL STRUCTURE OF PPARGAMMA COMPLEXED WITH TELMISARTAN
1203, d3uvvB_, 0.7529, 2.96, 0.149, 270, 215, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE THYROID RECEPTOR:RETINOID X RECEPTOR COMPLEXED WITH 33 5 TRIIODO-L- THYRONINE AND 9-CIS RETINOIC ACID
1204, d2i4pB_, 0.7529, 2.38, 0.284, 214, 204, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 30 DAYS.
1205, d3fs1A_, 0.7528, 3.07, 0.196, 239, 214, CRYSTAL STRUCTURE OF HNF4A LBD IN COMPLEX WITH THE LIGAND AND THE COACTIVATOR PGC-1A FRAGMENT
1206, p4pohA_, 0.7527, 2.97, 0.150, 255, 214, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 8-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1207, p4fgyA_, 0.7527, 2.75, 0.180, 219, 211, IDENTIFICATION OF A UNIQUE PPAR LIGAND WITH AN UNEXPECTED BINDING MODE AND ANTIBETIC ACTIVITY
1208, d2abiA_, 0.7527, 2.22, 0.286, 214, 203, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE
1209, d2f4bA_, 0.7526, 3.09, 0.187, 234, 214, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH AN AGONIST
1210, d2zk0A_, 0.7525, 3.13, 0.205, 239, 215, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN
1211, d3oapA_, 0.7524, 3.07, 0.184, 270, 217, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9-CIS RETINOIC ACID AND THE COACTIVATOR PEPTIDE GRIP-1
1212, p5dwlA_, 0.7523, 2.76, 0.180, 219, 211, HUMAN PPARGAMMA LIGAND BINDING DMAIN IN COMPLEX WITH SR1664
1213, d2zk3A_, 0.7523, 3.22, 0.183, 272, 218, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 8-OXO- EICOSATETRAENOIC ACID
1214, p5q1iA_, 0.7522, 3.11, 0.180, 268, 217, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1215, d4jazA_, 0.7522, 3.18, 0.171, 261, 216, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND TRANS- RESVERATROL
1216, d3kduB1, 0.7522, 2.59, 0.280, 218, 207, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-((4-METHYLPHENOXY)CARBONYL)GLYCINE
1217, d2oaxC_, 0.7522, 3.34, 0.170, 270, 218, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1218, d1pzlA_, 0.7522, 2.79, 0.221, 230, 208, CRYSTAL STRUCTURE OF HNF4A LBD IN COMPLEX WITH THE LIGAND AND THE COACTIVATOR SRC-1 PEPTIDE
1219, p4m8eA_, 0.7521, 2.79, 0.221, 230, 208, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (S) 4-METHYL 9CUAB30 COACTIVATOR PEPTIDE GRIP-1
1220, p3ipqA_, 0.7521, 2.35, 0.284, 214, 204, X-RAY STRUCTURE OF GW3965 SYNTHETIC AGONIST BOUND TO THE LXR-ALPHA
1221, p4jyhB_, 0.7520, 3.12, 0.181, 265, 215, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE AGONIST BMS948 [4-{[(8-PHENYLNAPHTHALEN-2-YL)CARBONYL]AMINO}BENZOIC ACID]
1222, d3wj4A1, 0.7520, 2.47, 0.236, 230, 203, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIBUTYLTIN
1223, d3r5nA_, 0.7520, 3.14, 0.181, 271, 216, CRYSTAL STRUCTURE OF PPARGAMMALBD COMPLEXED WITH THE AGONIST MAGNOLOL
1224, d3gbkA_, 0.7520, 3.24, 0.174, 270, 218, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST
1225, d2npaC_, 0.7520, 2.39, 0.284, 214, 204, THE CRYSTAL STRUCTURE OF THE HUMAN PPARAPLPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A A-HYDROXYIMINO PHENYLPROPANOIC ACID
1226, d2g0hA_, 0.7520, 3.26, 0.170, 271, 218, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
1227, d1ya3B_, 0.7520, 3.17, 0.176, 274, 216, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1228, d1fbyA_, 0.7520, 2.86, 0.178, 227, 213, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO 9-CIS RETINOIC ACID
1229, d2nxxB_, 0.7519, 3.00, 0.181, 268, 216, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
1230, p4rmeA_, 0.7518, 2.95, 0.154, 268, 214, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB111 AND COACTIVATOR PEPTIDE GRIP-1
1231, d4r2uA_, 0.7518, 2.55, 0.248, 233, 206, CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1664
1232, d3w0cA_, 0.7518, 3.01, 0.202, 227, 213, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
1233, d2athA_, 0.7518, 2.39, 0.284, 214, 204, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IM COMPLEX WITH AN AGONIST
1234, d1m7wD_, 0.7518, 2.55, 0.177, 220, 209, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1235, p4m8hA_, 0.7517, 3.09, 0.196, 239, 214, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (R)4-METHYL 9CUAB30 AND COACTIVATOR PEPTIDE GRIP- 3 1
1236, p4rmdA_, 0.7516, 3.28, 0.175, 254, 217, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB110 AND COACTIVATOR PEPTIDE GRIP-1
1237, d3et3A1, 0.7516, 3.07, 0.172, 256, 215, STRUCTURE OF PPARGAMMA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
1238, d3az1A_, 0.7516, 3.15, 0.181, 271, 216, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
1239, d1prgA_, 0.7516, 3.07, 0.153, 267, 215, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
1240, p5dv6A_, 0.7515, 3.18, 0.184, 271, 217, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1404 IN A COVALENT BONDED FORM
1241, p4dk7C_, 0.7515, 2.48, 0.241, 230, 203, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH FULL AGONIST 1
1242, p4rfwA_, 0.7514, 2.64, 0.290, 217, 207, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB70 AND THE COACTIVATOR PEPTIDE GRIP-1
1243, p4pojA_, 0.7514, 3.36, 0.258, 228, 221, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 7-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1244, d4ci5A_, 0.7514, 2.23, 0.286, 214, 203, STRUCTURAL BASIS FOR GL479 A DUAL PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR GAMMA AGONIST
1245, p6eu9C_, 0.7513, 3.15, 0.176, 260, 216, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
1246, p4jyiA_, 0.7513, 3.18, 0.189, 250, 217, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE PARTIAL AGONIST BMS641 [3-CHLORO-4-[(E)-2-(55-DIMETHYL-8-PHENYL-56- DIHYDRONAPHTHALEN-2-YL)ETHENYL]BENZOIC ACID]
1247, d2npaA_, 0.7513, 3.16, 0.181, 271, 216, THE CRYSTAL STRUCTURE OF THE HUMAN PPARAPLPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A A-HYDROXYIMINO PHENYLPROPANOIC ACID
1248, d1k7lE_, 0.7513, 2.69, 0.232, 221, 207, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
1249, p5twoA_, 0.7512, 2.38, 0.284, 214, 204, PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGNAD BINDING DOMAIN IN COMPLEX WITH A NOVEL SELECTIVELY PPAR GAMMA-MODULATING LIGAND VSP- 51
1250, d3wj5A1, 0.7510, 2.25, 0.286, 214, 203, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPHENYLTIN
1251, d3gz9A_, 0.7510, 3.25, 0.171, 259, 216, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPARD) IN COMPLEX WITH A FULL AGONIST
1252, d2f4bB_, 0.7510, 2.97, 0.195, 250, 215, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH AN AGONIST
1253, d3v9yA_, 0.7509, 3.12, 0.180, 270, 217, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
1254, d3noaB_, 0.7509, 3.12, 0.181, 261, 215, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEX WITH A POTENCY IMPROVED AGONIST
1255, d3cs8A2, 0.7509, 2.67, 0.185, 224, 211, STRUCTURAL AND BIOCHEMICAL BASIS FOR THE BINDING SELECTIVITY OF PPARG TO PGC-1A
1256, d2fvjA_, 0.7509, 2.24, 0.286, 214, 203, A NOVEL ANTI-ADIPOGENIC PARTIAL AGONIST OF PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR-GAMMA (PPARG) RECRUITS PPARG-COACTIVATOR-1 ALPHA (PGC1A) BUT POTENTIATES INSULIN SIGNALING IN VITRO
1257, p5ji0D_, 0.7508, 2.39, 0.284, 214, 204, PPARGAMMA-RXRALPHA(S427F) HETERODIMER IN COMPLEX WITH SRC-1 ROSIGLITAZONE AND 9-CIS-RETANOIC ACID
1258, p4zshA_, 0.7508, 3.28, 0.171, 260, 217, RXR LBD IN COMPLEX WITH 9-CIS-1314-DIHYDRORETINOIC ACID
1259, d3u9qA_, 0.7508, 2.46, 0.223, 217, 206, LIGAND BINDING DOMAIN OF PPARGAMMA COMPLEXED WITH DECANOIC ACID AND PGC-1A PEPTIDE
1260, d3cwdB_, 0.7508, 3.16, 0.205, 239, 215, MOLECULAR RECOGNITION OF NITRO-FATTY ACIDS BY PPAR GAMMA
1261, d1zgyA_, 0.7508, 2.96, 0.164, 269, 214, STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP
1262, d1zeoA_, 0.7508, 2.83, 0.160, 267, 213, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH AN ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST
1263, p4pp3A_, 0.7507, 3.18, 0.181, 270, 216, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 6-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1264, p4nqaH2, 0.7507, 3.19, 0.167, 256, 216, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
1265, p4k4jA_, 0.7507, 3.19, 0.138, 262, 217, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1266, p4dqmA_, 0.7507, 3.26, 0.184, 271, 217, REVEALING A MARINE NATURAL PRODUCT AS A NOVEL AGONIST FOR RETINOIC ACID RECEPTORS WITH A UNIQUE BINDING MODE AND ANTITUMOR ACTIVITY
1267, d4dm6B_, 0.7507, 3.37, 0.170, 261, 218, CRYSTAL STRUCTURE OF RARB LBD HOMODIMER IN COMPLEX WITH TTNPB
1268, d3b0rA_, 0.7507, 3.20, 0.180, 271, 217, HUMAN PPAR GAMMA LIGAND BINDING DMAIN COMPLEXED WITH GW9662 IN A COVALENT BONDED FORM
1269, d2hwqA_, 0.7507, 3.00, 0.182, 265, 214, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
1270, d1uhlA_, 0.7507, 3.13, 0.172, 258, 215, CRYSTAL STRUCTURE OF THE LXRALFA-RXRBETA LBD HETERODIMER
1271, d1mznG_, 0.7507, 3.26, 0.185, 269, 216, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1272, d1fcyA_, 0.7507, 2.18, 0.287, 213, 202, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARBETA/GAMMA- SELECTIVE RETINOID CD564
1273, d2zk2A_, 0.7506, 3.20, 0.167, 257, 215, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH GLUTATHION CONJUGATED 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
1274, d1mznC_, 0.7506, 3.01, 0.178, 260, 214, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1275, d1fcxA_, 0.7506, 3.27, 0.180, 272, 217, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARGAMMA-SELECTIVE RETINOID BMS184394
1276, d3kduA_, 0.7505, 2.98, 0.178, 263, 214, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-((4-METHYLPHENOXY)CARBONYL)GLYCINE
1277, d3az2A_, 0.7505, 2.39, 0.284, 214, 204, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
1278, d1fczA_, 0.7505, 2.98, 0.264, 223, 212, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE PANAGONIST RETINOID BMS181156
1279, d1exxA_, 0.7505, 2.27, 0.286, 214, 203, ENANTIOMER DISCRIMINATION ILLUSTRATED BY CRYSTAL STRUCTURES OF THE HUMAN RETINOIC ACID RECEPTOR HRARGAMMA LIGAND BINDING DOMAIN: THE COMPLEX WITH THE INACTIVE S-ENANTIOMER BMS270395.
1280, d4lbdA_, 0.7504, 3.03, 0.188, 234, 213, LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO THE SYNTHETIC AGONIST BMS961
1281, d3az3A_, 0.7504, 3.24, 0.204, 239, 216, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
1282, d3w0aA_, 0.7503, 3.04, 0.178, 262, 214, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
1283, d5ttoA_, 0.7502, 3.23, 0.176, 261, 216, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1643
1284, d3r5mC_, 0.7502, 2.40, 0.294, 214, 204, CRYSTAL STRUCTURE OF RXRALPHALBD COMPLEXED WITH THE AGONIST MAGNOLOL
1285, d3lbdA_, 0.7502, 2.41, 0.286, 212, 203, LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO 9-CIS RETINOIC ACID
1286, p4jyhA_, 0.7501, 3.09, 0.206, 236, 214, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE AGONIST BMS948 [4-{[(8-PHENYLNAPHTHALEN-2-YL)CARBONYL]AMINO}BENZOIC ACID]
1287, d3et1B_, 0.7501, 3.27, 0.175, 274, 217, STRUCTURE OF PPARALPHA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
1288, d3bc5A1, 0.7501, 2.42, 0.286, 212, 203, X-RAY CRYSTAL STRUCTURE OF HUMAN PPAR GAMMA WITH 2-(5-(3-(2- (5-METHYL-2-PHENYLOXAZOL-4-YL)ETHOXY)BENZYL)-2-PHENYL-2H-1 23-TRIAZOL-4-YL)ACETIC ACID
1289, d2gtkA_, 0.7501, 2.98, 0.202, 235, 213, STRUCTURE-BASED DESIGN OF INDOLE PROPIONIC ACIDS AS NOVEL PPARAG CO-AGONISTS
1290, d2g0hB_, 0.7501, 2.97, 0.159, 264, 214, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
1291, d1k7lC_, 0.7501, 2.98, 0.195, 250, 215, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
1292, p4pp5A_, 0.7500, 2.99, 0.211, 235, 213, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 5-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1293, d3vjiA_, 0.7500, 3.07, 0.201, 236, 214, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL53
1294, d3h0aD_, 0.7500, 3.04, 0.206, 237, 214, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARG) AND RETINOIC ACID RECEPTOR ALPHA (RXRA) IN COMPLEX WITH 9-CIS RETINOIC ACID CO-ACTIVATOR PEPTIDE AND A PARTIAL AGONIST
1295, d2om9D_, 0.7500, 3.20, 0.189, 250, 217, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
1296, p4oc7A_, 0.7499, 3.20, 0.189, 250, 217, RETINOIC ACID RECEPTOR ALPHA IN COMPLEX WITH (E)-3-(3 -ALLYL-6- HYDROXY-[11 -BIPHENYL]-3-YL)ACRYLIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF2
1297, p2zxzA_, 0.7499, 3.00, 0.178, 260, 214, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO A SYNTHETIC AGONIST COMPOUND AND A COACTIVATOR PEPTIDE
1298, d2om9B_, 0.7499, 2.47, 0.284, 213, 204, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
1299, p1yowA_, 0.7499, 3.06, 0.215, 237, 214, HUMAN STEROIDOGENIC FACTOR 1 LBD WITH BOUND CO-FACTOR PEPTIDE
1300, d1xb7A1, 0.7498, 3.15, 0.205, 239, 215, X-RAY STRUCTURE OF ERRALPHA LBD IN COMPLEX WITH A PGC- 1ALPHA PEPTIDE AT 2.5A RESOLUTION
1301, d1fd0A_, 0.7497, 2.79, 0.160, 270, 213, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARGAMMA-SELECTIVE RETINOID SR11254
1302, p5lyqA_, 0.7496, 3.07, 0.172, 262, 215, CRYSTAL STRUCTURE OF THE RETINOIC ACID RECEPTOR ALPHA IN COMPLEX WITH A SYNTHETIC SPIROKETAL AGONIST AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1303, p5avlA_, 0.7496, 3.14, 0.172, 258, 215, CRYSTAL STRUCTURE OF LXRALPHA IN COMPLEX WITH TERT-BUTYL BENZOATE ANALOG COMPOUND 32B
1304, d2znoA_, 0.7496, 3.20, 0.176, 271, 216, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703
1305, p4jygA_, 0.7495, 2.89, 0.160, 267, 213, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH AGONIST BMS411 [4- {[(55-DIMETHYL-8-PHENYL-56-DIHYDRONAPHTHALEN-2-YL) CARBONYL]AMINO}BENZOIC ACID]
1306, d4em9A_, 0.7495, 2.27, 0.286, 214, 203, HUMAN PPAR GAMMA IN COMPLEX WITH NONANOIC ACIDS
1307, d4yt1A_, 0.7494, 3.04, 0.178, 262, 214, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT76
1308, d3a9eA_, 0.7494, 2.95, 0.183, 265, 213, CRYSTAL STRUCTURE OF A MIXED AGONIST-BOUND RAR-ALPHA AND ANTAGONIST- BOUND RXR-ALPHA HETERODIMER LIGAND BINDING DOMAINS
1309, d1k7lG_, 0.7494, 3.10, 0.172, 260, 215, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
1310, d3gbkB_, 0.7493, 2.19, 0.287, 213, 202, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST
1311, d3fejA_, 0.7493, 2.20, 0.287, 213, 202, DESIGN AND BIOLOGICAL EVALUATION OF NOVEL BALANCED DUAL PPARA/G AGONISTS
1312, d2zk6A_, 0.7493, 3.10, 0.172, 260, 215, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH C8-BODIPY
1313, d1exaA_, 0.7493, 2.89, 0.223, 230, 211, ENANTIOMER DISCRIMINATION ILLUSTRATED BY CRYSTAL STRUCTURES OF THE HUMAN RETINOIC ACID RECEPTOR HRARGAMMA LIGAND BINDING DOMAIN: THE COMPLEX WITH THE ACTIVE R-ENANTIOMER BMS270394.
1314, d3kmrA_, 0.7492, 2.15, 0.310, 207, 200, CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH AN AGONIST LIGAND (AM580) AND A COACTIVATOR FRAGMENT
1315, d2hwrA_, 0.7492, 3.00, 0.211, 235, 213, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
1316, p5y7xB_, 0.7491, 2.41, 0.286, 212, 203, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DELTA IN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST 
1317, d3d6dB_, 0.7491, 2.70, 0.176, 224, 210, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LT175(R-ENANTIOMER)
1318, d1mv9A_, 0.7491, 3.18, 0.177, 266, 215, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE EICOSANOID DHA (DOCOSA HEXAENOIC ACID) AND A COACTIVATOR PEPTIDE
1319, d1fm6X_, 0.7491, 3.18, 0.205, 239, 215, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
1320, p5iawB_, 0.7490, 3.22, 0.176, 259, 216, NOVEL NATURAL FXR MODULATOR WITH A UNIQUE BINDING MODE
1321, p5gtpA_, 0.7490, 3.05, 0.173, 261, 214, THE AGONIST-FREE STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN THE PRESENCE OF THE SRC-1 COACTIVATOR PEPTIDE
1322, d3furA_, 0.7490, 2.32, 0.291, 218, 203, CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH INT131
1323, p6f2lA_, 0.7489, 2.89, 0.164, 267, 213, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570: STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 15 DAYS.
1324, p5mmwA_, 0.7489, 3.14, 0.176, 271, 216, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 6 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1325, d3et2B_, 0.7489, 3.23, 0.176, 258, 216, STRUCTURE OF PPARDELTA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
1326, p5mj5A_, 0.7488, 3.21, 0.171, 274, 216, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETICHONOKIOL DERIVATIVE 3 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1327, p5dshA_, 0.7488, 2.99, 0.202, 236, 213, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1406 IN A COVALENT BONDED FORM
1328, d3adxA_, 0.7488, 3.07, 0.196, 234, 214, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN AND NITRO-233
1329, p5iawA_, 0.7487, 3.08, 0.177, 261, 215, NOVEL NATURAL FXR MODULATOR WITH A UNIQUE BINDING MODE
1330, p4y29A_, 0.7487, 3.01, 0.154, 262, 214, IDENTIFICATION OF A NOVEL PPARG LIGAND THAT REGULATES METABOLISM
1331, d5wr0A_, 0.7486, 3.15, 0.181, 270, 216, HUISGEN CYCLOADDITION FOR PPARG-LBD LABELING BY SOAKING METHOD
1332, d3ty0A1, 0.7486, 2.43, 0.286, 214, 203, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH (R)-5-(3- ((3-(6-METHOXYBENZO[D]ISOXAZOL-3-YL)-2-OXO-23-DIHYDRO-1H- BENZO[D]IMIDAZOL-1-YL)METHYL)PHENYL)-5-METHYLOXAZOLIDINE-24-DIONE
1333, d3cdsB_, 0.7486, 3.25, 0.183, 272, 219, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPAR-GAMMA AND THE AGONIST LT248 (CLOFIBRIC ACID ANALOGUE)
1334, d2g0gB_, 0.7485, 3.04, 0.173, 227, 214, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
1335, d3lmpA_, 0.7484, 3.05, 0.187, 261, 214, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
1336, p3hc6A_, 0.7484, 3.11, 0.178, 256, 214, FXR WITH SRC1 AND GSK088
1337, d1mvcA_, 0.7484, 3.05, 0.178, 259, 214, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1338, p6an1A_, 0.7483, 2.33, 0.286, 212, 203, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND AM-879
1339, p5xmxA_, 0.7483, 2.78, 0.151, 267, 212, CO-CRYSTAL STRUCTURE OF INHIBITOR COMPOUND IN COMPLEX WITH HUMAN PPARDELTA LBD 
1340, p5gieD_, 0.7483, 2.39, 0.284, 213, 204, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-4P (P21 FORM)
1341, p4s15B_, 0.7483, 3.13, 0.177, 258, 215, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORALPHA LIGAND- BINDING DOMAIN IN COMPLEX WITH 4ALPHA-CABOXYL 4BETA-METHYL- ZYMOSTEROL (4ACD8)
1342, d2q6rB_, 0.7483, 3.14, 0.181, 274, 216, CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED WITH PARTIAL AGONIST SF147
1343, d2pobA_, 0.7483, 2.99, 0.160, 228, 213, PPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A FARGLITAZAR ANALOGUE GW4709
1344, d1xiuA_, 0.7483, 3.26, 0.176, 257, 216, CRYSTAL STRUCTURE OF THE AGONIST-BOUND LIGAND-BINDING DOMAIN OF BIOMPHALARIA GLABRATA RXR
1345, d3et2A_, 0.7482, 3.20, 0.177, 257, 215, STRUCTURE OF PPARDELTA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
1346, d1k7lA_, 0.7482, 2.87, 0.183, 275, 213, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
1347, d2om9C_, 0.7481, 2.87, 0.183, 275, 213, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
1348, d2i4jB_, 0.7481, 3.13, 0.194, 270, 216, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE AGONIST LT160 (UREIDOFIBRATE DERIVATIVE)
1349, d2athB_, 0.7481, 3.10, 0.172, 271, 215, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IM COMPLEX WITH AN AGONIST
1350, d5wqxA_, 0.7480, 3.28, 0.171, 264, 217, COVALENT BOND FORMATION OF SYNTHETIC LIGAND WITH HPPARG-LBD
1351, p4iqrE2, 0.7480, 3.09, 0.167, 230, 216, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
1352, d3adwA_, 0.7480, 2.31, 0.287, 212, 202, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE AND 15-OXO-EICOSATETRAENOIC ACID
1353, d2om9A_, 0.7480, 3.08, 0.182, 261, 214, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
1354, d1xdkF_, 0.7480, 3.23, 0.153, 257, 216, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
1355, d1xdkB_, 0.7480, 2.97, 0.198, 230, 212, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
1356, d5lsgA_, 0.7479, 3.05, 0.169, 250, 213, PPARGAMMA COMPLEX WITH THE BETULINIC ACID
1357, p5gtoA_, 0.7479, 3.05, 0.169, 250, 213, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH S35
1358, p4f9mA_, 0.7479, 3.23, 0.190, 258, 216, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
1359, p4dm8A_, 0.7479, 3.19, 0.181, 255, 216, CRYSTAL STRUCTURE OF RARB LBD IN COMPLEX WITH 9CIS RETINOIC ACID
1360, d3peqB_, 0.7479, 2.73, 0.273, 221, 205, PPARD COMPLEXED WITH A PHENOXYACETIC ACID PARTIAL AGONIST
1361, d1fbyB_, 0.7479, 3.01, 0.150, 266, 214, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO 9-CIS RETINOIC ACID
1362, d3w0yA_, 0.7478, 2.89, 0.160, 267, 213, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
1363, d3vspA_, 0.7478, 3.19, 0.181, 270, 215, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT28
1364, p3t03A_, 0.7478, 3.17, 0.181, 270, 216, CRYSTAL STRUCTURE OF PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A NOVEL PARTIAL AGONIST GQ-16
1365, d2lbdA_, 0.7478, 3.23, 0.166, 271, 217, LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO ALL-TRANS RETINOIC ACID
1366, d1rdtD1, 0.7478, 3.09, 0.182, 257, 214, CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHA LIGAND BINDING DOAMIN IN THE RXRALPHA/PPARGAMMA HETERODIMER
1367, d3vjhA_, 0.7477, 2.64, 0.224, 228, 205, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL35
1368, d2i4zB_, 0.7477, 3.15, 0.176, 274, 216, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). THIS STRUCTURE HAS BEEN OBTAINED FROM CRYSTALS SOAKED FOR 6 HOURS.
1369, d5azvA_, 0.7476, 3.19, 0.172, 270, 215, CRYSTAL STRUCTURE OF HPPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 17-OXODHA
1370, d3g8iA_, 0.7476, 2.98, 0.198, 245, 212, ALEGLITAZAR A NEW POTENT AND BALANCED PPAR ALPHA/GAMMA AGONIST FOR THE TREATMENT OF TYPE II DIABETES
1371, d1prgB_, 0.7476, 2.98, 0.198, 245, 212, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
1372, d5wr1A_, 0.7475, 2.98, 0.198, 245, 212, COVALENT BOND FORMATION OF BIFUNCTIONAL LIGAND WITH HPPARG-LBD
1373, d5ttoB_, 0.7475, 3.06, 0.182, 256, 214, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1643
1374, p4dk7A_, 0.7475, 3.32, 0.166, 267, 217, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH FULL AGONIST 1
1375, d4a4vA_, 0.7475, 3.22, 0.171, 261, 216, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
1376, d3kmgA_, 0.7475, 2.99, 0.209, 238, 211, THE X-RAY CRYSTAL STRUCTURE OF PPAR-GAMMA IN COMPLEX WITH AN INDOLE DERIVATIVE MODULATOR GSK538 AND AN SRC-1 PEPTIDE
1377, d3gwxB_, 0.7475, 2.79, 0.146, 257, 212, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
1378, d2zvtA_, 0.7475, 2.34, 0.287, 212, 202, CYS285SER MUTANT PPARGAMMA LIGAND-BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
1379, d1gwxB_, 0.7475, 3.09, 0.194, 250, 216, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
1380, d4a4wA_, 0.7474, 3.08, 0.187, 265, 214, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
1381, d3kwyA_, 0.7474, 2.85, 0.179, 265, 212, CRYSTAL STRUCTURE OF RXRALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPHENYLTIN AND A COACTIVATOR FRAGMENT
1382, d1knuA_, 0.7474, 3.05, 0.216, 237, 213, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST
1383, p5q0wA_, 0.7473, 3.04, 0.178, 252, 213, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1384, d4emaA_, 0.7473, 2.97, 0.174, 261, 213, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH ROSIGLITAZONE
1385, d3x1iA_, 0.7473, 3.18, 0.181, 270, 216, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXO- TETRACOSAHEXAENOIC ACID
1386, d3uvvA1, 0.7473, 3.09, 0.178, 259, 214, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE THYROID RECEPTOR:RETINOID X RECEPTOR COMPLEXED WITH 33 5 TRIIODO-L- THYRONINE AND 9-CIS RETINOIC ACID
1387, d3g9eA_, 0.7473, 2.79, 0.161, 254, 211, ALEGLITAAR. A NEW. POTENT AND BALANCED DUAL PPARA/G AGONIST FOR THE TREATMENT OF TYPE II DIABETES
1388, d2yfeA_, 0.7473, 3.17, 0.194, 270, 216, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 1
1389, d2nxxD_, 0.7473, 3.11, 0.182, 257, 214, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
1390, d4pvuA_, 0.7472, 3.13, 0.168, 258, 214, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE R ENANTIOMER OF MBX-102 (METAGLIDASEN)
1391, p5q1eA_, 0.7471, 2.73, 0.190, 229, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1392, d3x1hA_, 0.7471, 3.05, 0.178, 264, 214, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-OXO- TRICOSAHEXAENOIC ACID
1393, d3po9A_, 0.7471, 3.02, 0.173, 259, 214, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPROPYLTIN
1394, d2zk4A_, 0.7471, 2.95, 0.144, 271, 215, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-OXO- EICOSATETRAENOIC ACID
1395, d2q61A_, 0.7471, 3.10, 0.177, 274, 215, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN BOUND TO PARTIAL AGONIST SR145
1396, d4xuhA_, 0.7470, 2.96, 0.149, 271, 215, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH SULINDAC SULFIDE
1397, d3vsoA_, 0.7470, 3.08, 0.173, 263, 214, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT21
1398, d2zk1A_, 0.7470, 2.33, 0.287, 210, 202, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214- PROSTAGLANDIN J2
1399, d3sz1A_, 0.7469, 3.13, 0.177, 265, 215, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH LUTEOLIN AND MYRISTIC ACID
1400, p3e00D2, 0.7469, 3.03, 0.173, 228, 214, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH GW9662 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1401, d3an4A_, 0.7469, 3.08, 0.178, 256, 214, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO4R
1402, d5y2oA_, 0.7467, 3.08, 0.178, 257, 214, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN-PIOGLITAZONE COMPLEX
1403, d5u5lA_, 0.7467, 3.29, 0.150, 249, 214, X-RAY CRYSTAL STRUCTURE OF THE PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH RIVOGLITAZONE
1404, d4ci5B_, 0.7467, 3.24, 0.171, 258, 216, STRUCTURAL BASIS FOR GL479 A DUAL PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR GAMMA AGONIST
1405, d3oswA_, 0.7467, 3.06, 0.182, 264, 214, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRABROMO-BISPHENOL A (TBBPA)
1406, d1i7gA_, 0.7467, 3.39, 0.259, 227, 220, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN FROM HUMAN PPAR-ALPHA IN COMPLEX WITH THE AGONIST AZ 242
1407, d5y2tA_, 0.7466, 3.14, 0.177, 257, 215, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN - LOBEGLITAZONE COMPLEX
1408, d3wmhA_, 0.7466, 3.12, 0.177, 224, 215, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT75
1409, d3p88A_, 0.7466, 3.18, 0.177, 256, 215, FXR BOUND TO ISOQUINOLINECARBOXYLIC ACID
1410, d3e94A_, 0.7466, 2.98, 0.174, 261, 213, CRYSTAL STRUCTURE OF RXRALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIBUTYLTIN AND A COACTIVATOR FRAGMENT
1411, d2vv1A_, 0.7466, 3.07, 0.178, 274, 214, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA
1412, d2hfpA_, 0.7466, 3.06, 0.178, 256, 214, CRYSTAL STRUCTURE OF PPAR GAMMA WITH N-SULFONYL-2-INDOLE CARBOXAMIDE LIGANDS
1413, p5q17A_, 0.7465, 3.26, 0.176, 264, 216, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1414, d5m24A_, 0.7465, 2.95, 0.183, 263, 213, RARG MUTANT-S371E
1415, d3cwdA_, 0.7465, 3.06, 0.178, 274, 214, MOLECULAR RECOGNITION OF NITRO-FATTY ACIDS BY PPAR GAMMA
1416, d2nxxC_, 0.7465, 2.98, 0.178, 258, 213, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
1417, d1n4hA_, 0.7465, 3.12, 0.181, 266, 215, CHARACTERIZATION OF LIGANDS FOR THE ORPHAN NUCLEAR RECEPTOR RORBETA
1418, d5hykA_, 0.7464, 3.09, 0.178, 262, 214, CRYSTAL STRUCTURE OF THE COMPLEX PPARALPHA/AL26-29
1419, p4pldA_, 0.7464, 3.15, 0.181, 262, 215, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 IN ITS APO STATE BOUND TO A FRAGMENT OF HUMAN TIF-2
1420, d4kziB_, 0.7464, 3.10, 0.178, 259, 214, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH DPDO
1421, d3peqA_, 0.7464, 3.11, 0.168, 260, 214, PPARD COMPLEXED WITH A PHENOXYACETIC ACID PARTIAL AGONIST
1422, d3adsA_, 0.7464, 3.10, 0.178, 261, 214, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
1423, p6fx0A_, 0.7463, 3.11, 0.140, 259, 215, STRUCTURE-BASED DESIGN OF TRIFAROTENE (CD5789); A POTENT AND SELECTIVE RAR GAMMA AGONIST FOR THE TREATMENT OF ACNE 
1424, d4xumA_, 0.7463, 3.14, 0.177, 261, 215, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
1425, d2xyjB_, 0.7463, 2.97, 0.188, 264, 213, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
1426, d4xldA1, 0.7462, 3.18, 0.171, 229, 216, CRYSTAL STRUCTURE OF THE HUMAN PPARG-LBD/ROSIGLITAZONE COMPLEX OBTAINED BY DRY CO-CRYSTALLIZATION AND IN SITU DIFFRACTION
1427, d2q5pA_, 0.7462, 2.27, 0.289, 211, 201, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST MRL24
1428, p5mkjA_, 0.7461, 3.09, 0.178, 256, 214, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 9 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1429, d3b3kB_, 0.7461, 3.25, 0.184, 272, 217, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE FULL AGONIST LT175
1430, d2xkwA_, 0.7461, 3.06, 0.178, 224, 214, LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE
1431, d2vsrA_, 0.7460, 3.07, 0.210, 236, 214, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE
1432, d1rdtA_, 0.7460, 3.01, 0.174, 257, 213, CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHA LIGAND BINDING DOAMIN IN THE RXRALPHA/PPARGAMMA HETERODIMER
1433, d1gwxA_, 0.7460, 3.25, 0.261, 225, 218, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
1434, d5f9bA_, 0.7459, 3.23, 0.195, 244, 215, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN THE COMPLEX WITH CAULOPHYLLOGENIN
1435, d3pbaA_, 0.7459, 2.94, 0.156, 255, 212, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MONOSULFATE TETRABROMO-BISPHENOL A (MONOTBBPA)
1436, d3an3A_, 0.7459, 2.90, 0.217, 239, 212, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO3S
1437, d5ickB_, 0.7458, 3.12, 0.213, 234, 211, A UNIQUE BINDING MODEL OF FXR LBD WITH FEROLINE
1438, d4oj4A_, 0.7458, 3.10, 0.150, 255, 214, CRYSTAL STRUCTURE OF V290M PPARGAMMA MUTANT IN COMPLEX WITH DICLOFENAC
1439, d2vstA_, 0.7458, 2.97, 0.174, 262, 213, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 13-(S)- HODE
1440, d4pwlA_, 0.7457, 3.12, 0.210, 238, 214, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE S ENANTIOMER OF MBX-102 (METAGLIDASEN)
1441, d3v3qB1, 0.7457, 3.07, 0.182, 260, 214, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH ETHYL 2-[234 TRIMETHOXY-6(1-OCTANOYL)PHENYL]ACETATE
1442, d3advA_, 0.7457, 2.85, 0.151, 259, 212, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH SEROTONIN
1443, d2zk5A_, 0.7457, 3.12, 0.177, 262, 215, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH NITRO-233
1444, d2q59A_, 0.7457, 3.02, 0.174, 256, 213, CRYSTAL STRUCTURE OF PPARGAMMA LBD BOUND TO FULL AGONIST MRL20
1445, p3vt9A_, 0.7456, 2.41, 0.287, 211, 202, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH W282R MUTATION
1446, d2vv0A_, 0.7456, 3.23, 0.185, 270, 216, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH DHA
1447, d1nq7A_, 0.7456, 3.09, 0.178, 261, 214, CHARACTERIZATION OF LIGANDS FOR THE ORPHAN NUCLEAR RECEPTOR RORBETA
1448, p6enqA_, 0.7455, 3.09, 0.178, 257, 214, STRUCTURE OF HUMAN PPAR GAMMA LBD IN COMPLEX WITH LANIFIBRANOR (IVA337)
1449, p3s9sA_, 0.7455, 2.42, 0.286, 211, 203, LIGAND BINDING DOMAIN OF PPARGAMMA COMPLEXED WITH A BENZIMIDAZOLE PARTIAL AGONIST
1450, d3b1mA_, 0.7455, 3.20, 0.143, 270, 217, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR CERCO-A
1451, d5u46A_, 0.7454, 3.10, 0.178, 254, 214, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH GW501516
1452, p5dv3A_, 0.7454, 3.00, 0.183, 262, 213, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1405 IN A COVALENT BONDED FORM
1453, d4r6sA_, 0.7454, 2.99, 0.183, 263, 213, CRYSTAL STRUCTURE OF PPARGAMMMA IN COMPLEX WITH SR1663
1454, p3vt8A_, 0.7454, 3.04, 0.160, 229, 213, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH W282R MUTATION
1455, d3osiA_, 0.7454, 3.47, 0.180, 260, 217, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRACHLORO-BISPHENOL A (TCBPA)
1456, p6b0fB_, 0.7453, 3.09, 0.178, 260, 214, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH LSZ102
1457, d3tkmA1, 0.7453, 3.12, 0.173, 255, 214, CRYSTAL STRUCTURE PPAR DELTA BINDING GW0742
1458, d3b0qA_, 0.7453, 3.24, 0.216, 238, 213, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MCC555
1459, d3aduA_, 0.7453, 3.00, 0.183, 262, 213, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE
1460, d2p1tA_, 0.7453, 3.03, 0.178, 274, 214, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH 3-(2 -METHOXY)- TETRAHYDRONAPHTYL CINNAMIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF-2
1461, p5aztA_, 0.7452, 3.04, 0.178, 254, 213, TERNARY COMPLEX OF HPPARALPHA LIGAND BINDING DOMAIN 17-OXODHA AND A SRC1 PEPTIDE
1462, d3fugA_, 0.7452, 3.13, 0.206, 233, 214, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST 3-[4-HYDROXY-3-(35 588-PENTAMETHYL-5678-TETRAHYDRONAPHTHALEN-2-YL)- PHENYL]ACRYLIC ACID
1463, d3dcuA_, 0.7452, 3.01, 0.174, 259, 213, FXR WITH SRC1 AND GSK8062
1464, d1nyxA_, 0.7452, 3.18, 0.195, 244, 215, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH AN AGONIST
1465, p5xuqA_, 0.7451, 2.92, 0.184, 256, 212, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH AN ANTAGONIST; 2- METHYLIDENE-19;26;27-TRINOR-22-(S)-BUTYL-1-HYDROXY-25-OXO-25-(1H- PYRROL-2-YL)- VITAMIN D3 
1466, d3pcuA_, 0.7451, 3.03, 0.174, 258, 213, CRYSTAL STRUCTURE OF HUMAN RETINOIC X RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH LX0278 AND SRC1 PEPTIDE
1467, d1wm0X1, 0.7451, 3.15, 0.167, 260, 215, PPARGAMMA IN COMPLEX WITH A 2-BABA COMPOUND
1468, d5u3sA_, 0.7450, 3.29, 0.148, 264, 216, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 3
1469, d4rzgB_, 0.7450, 3.00, 0.178, 263, 213, CRYSTAL STRUCTURE ANALYSIS OF THE DNPA-BOUNDED NUR77 LIGAND BINDING DOMAIN
1470, d3wj4B1, 0.7450, 3.07, 0.178, 262, 214, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIBUTYLTIN
1471, d2vv3A_, 0.7450, 3.12, 0.206, 233, 214, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-OXODHA
1472, d2q5sA_, 0.7450, 2.99, 0.178, 260, 213, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST NTZDPA
1473, d2nxxA_, 0.7450, 0.87, 0.989, 185, 185, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
1474, p5uanB2, 0.7449, 3.09, 0.145, 266, 214, CRYSTAL STRUCTURE OF MULTI-DOMAIN RAR-BETA-RXR-ALPHA HETERODIMER ON DNA
1475, d3v3eB_, 0.7449, 3.09, 0.178, 262, 214, CRYSTAL STRUCTURE OF THE HUMAN NUR77 LIGAND-BINDING DOMAIN
1476, d3dctA_, 0.7449, 3.06, 0.178, 259, 214, FXR WITH SRC1 AND GW4064
1477, d2b50B_, 0.7449, 2.29, 0.289, 211, 201, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 2
1478, d5u3rA_, 0.7448, 2.83, 0.167, 261, 210, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 2
1479, d5u3qB_, 0.7448, 2.15, 0.290, 211, 200, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 1
1480, d3vi8A_, 0.7448, 3.14, 0.167, 229, 216, HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST APHM13
1481, d3po9B_, 0.7448, 3.20, 0.172, 260, 215, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPROPYLTIN
1482, d3k8sB_, 0.7448, 3.43, 0.196, 231, 219, CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH T2384
1483, p5q0mA_, 0.7447, 2.29, 0.289, 211, 201, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1484, d4ci4A_, 0.7447, 3.19, 0.181, 268, 215, STRUCTURAL BASIS FOR GL479 A DUAL PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR ALPHA AGONIST
1485, d3feiA_, 0.7447, 3.30, 0.144, 271, 216, DESIGN AND BIOLOGICAL EVALUATION OF NOVEL BALANCED DUAL PPARA/G AGONISTS
1486, d3cdpB_, 0.7447, 3.00, 0.210, 235, 210, CRYSTAL STRUCTURE OF PPAR-GAMMA LBD COMPLEXED WITH A PARTIAL AGONIST ANALOGUE OF CLOFIBRIC ACID
1487, d3bejA_, 0.7447, 3.17, 0.173, 255, 214, STRUCTURE OF HUMAN FXR IN COMPLEX WITH MFA-1 AND CO- ACTIVATOR PEPTIDE
1488, d2p1vA_, 0.7447, 3.13, 0.182, 257, 214, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH 3-(2 -PROPOXY)- TETRAHYDRONAPHTYL CINNAMIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF-2
1489, d5u3yA_, 0.7446, 3.03, 0.178, 256, 213, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 9
1490, d3k8sA_, 0.7446, 3.20, 0.263, 224, 217, CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH T2384
1491, d2znnA_, 0.7446, 3.00, 0.213, 232, 211, HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703
1492, d2q8sA_, 0.7446, 3.23, 0.230, 237, 213, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
1493, p5ec9A_, 0.7445, 3.14, 0.167, 229, 216, RETINOIC ACID RECEPTOR ALPHA IN COMPLEX WITH CHIRAL DIHYDROBENZOFURAN BENZOIC ACID 9A AND A FRAGMENT OF THE COACTIVATOR TIF2
1494, d4r06A_, 0.7445, 3.14, 0.153, 263, 215, CRYSTAL STRUCTURE OF SR2067 BOUND TO PPARGAMMA
1495, d5u46B_, 0.7444, 3.13, 0.149, 270, 215, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH GW501516
1496, d4e4qB_, 0.7444, 3.08, 0.150, 270, 214, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND FS214
1497, d3hodB_, 0.7444, 2.97, 0.160, 258, 213, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
1498, d2vv4A_, 0.7444, 3.06, 0.165, 249, 212, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXOOTE
1499, d1k4wA_, 0.7443, 3.23, 0.181, 258, 215, X-RAY STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR BETA LIGAND-BINDING DOMAIN IN THE ACTIVE CONFORMATION
1500, p3rvfA_, 0.7442, 3.21, 0.177, 223, 215, FXR WITH SRC1 AND GSK2034
1501, p3rutA_, 0.7442, 2.87, 0.162, 248, 210, FXR WITH SRC1 AND GSK359
1502, d3oz0A_, 0.7442, 2.78, 0.167, 246, 210, PPAR DELTA IN COMPLEX WITH AZPPARD02
1503, p5q0rA_, 0.7441, 3.18, 0.194, 270, 216, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1504, p3gd2A_, 0.7441, 3.01, 0.169, 224, 213, ISOXAZOLE LIGAND BOUND TO FARNESOID X RECEPTOR (FXR)
1505, d2znqB1, 0.7441, 2.29, 0.289, 211, 201, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP401
1506, d5u3sB_, 0.7440, 3.13, 0.149, 263, 215, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 3
1507, p5q10A_, 0.7440, 3.32, 0.181, 262, 216, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1508, d1y0sB_, 0.7440, 2.85, 0.156, 258, 212, CRYSTAL STRUCTURE OF PPAR DELTA COMPLEXED WITH GW2331
1509, d1i7iA_, 0.7440, 3.18, 0.177, 253, 215, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242
1510, d5u3rB_, 0.7439, 2.24, 0.289, 210, 201, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 2
1511, d5hzcA_, 0.7439, 3.05, 0.178, 252, 213, CRYSTAL STRUCTURE OF THE COMPLEX PPARGAMMA/AL26-29
1512, d3ia6A_, 0.7439, 3.30, 0.148, 264, 216, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
1513, d1y0sA_, 0.7439, 3.05, 0.192, 268, 214, CRYSTAL STRUCTURE OF PPAR DELTA COMPLEXED WITH GW2331
1514, d3dy6A_, 0.7438, 3.11, 0.181, 270, 215, PPARDELTA COMPLEXED WITH AN ANTHRANILIC ACID PARTIAL AGONIST
1515, d2vv2A_, 0.7438, 3.10, 0.178, 254, 214, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-HEPA
1516, d3v9vA_, 0.7437, 3.08, 0.197, 244, 213, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
1517, d3adtA_, 0.7437, 3.18, 0.171, 228, 216, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-HYDROXY-INDOLE ACETATE
1518, d1s0xA1, 0.7437, 3.16, 0.171, 229, 216, CRYSTAL STRUCTURE OF THE HUMAN RORALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH CHOLESTEROL SULFATE AT 2.2A
1519, d1knuB_, 0.7437, 3.01, 0.146, 260, 213, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST
1520, d1kkqA_, 0.7437, 3.08, 0.168, 224, 214, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
1521, p5y7xA_, 0.7436, 3.15, 0.163, 227, 215, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DELTA IN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST 
1522, p5uanA2, 0.7436, 3.12, 0.149, 259, 215, CRYSTAL STRUCTURE OF MULTI-DOMAIN RAR-BETA-RXR-ALPHA HETERODIMER ON DNA
1523, d3v9tA_, 0.7436, 3.03, 0.150, 263, 213, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
1524, d2q6sA_, 0.7436, 3.08, 0.174, 227, 213, 2.4 ANGSTROM CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED TO BVT.13 WITHOUT CO-ACTIVATOR PEPTIDES
1525, d4xuhB_, 0.7435, 3.09, 0.145, 258, 214, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH SULINDAC SULFIDE
1526, d3ruuA_, 0.7434, 3.10, 0.178, 258, 214, FXR WITH SRC1 AND GSK237
1527, d3et0A1, 0.7434, 2.85, 0.151, 261, 212, STRUCTURE OF PPARGAMMA WITH 3-(5-METHOXY-1H-INDOL-3-YL)- PROPIONIC ACID
1528, d2p1uA_, 0.7434, 2.93, 0.175, 251, 212, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH 3-(2 -ETHOXY)- TETRAHYDRONAPHTYL CINNAMIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF-2
1529, d2gwxB_, 0.7434, 3.22, 0.177, 254, 215, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
1530, d2awhB_, 0.7434, 3.06, 0.150, 260, 214, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
1531, d2awhA_, 0.7434, 3.07, 0.150, 257, 214, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
1532, d5u3qA_, 0.7433, 3.08, 0.182, 256, 214, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 1
1533, p5dvcA_, 0.7433, 3.23, 0.167, 258, 216, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1453 IN A COVALENT BONDED FORM
1534, p5dv8A_, 0.7433, 3.08, 0.178, 259, 214, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1451 IN A COVALENT BONDED FORM
1535, d4bcrA_, 0.7433, 3.11, 0.188, 249, 213, STRUCTURE OF PPARALPHA IN COMPLEX WITH WY14643
1536, d3fxvA1, 0.7433, 3.24, 0.177, 258, 215, IDENTIFICATION OF AN N-OXIDE PYRIDINE GW4064 ANALOGUE AS A POTENT FXR AGONIST
1537, d4xumB_, 0.7432, 3.31, 0.148, 269, 216, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
1538, d4whgB_, 0.7432, 3.02, 0.150, 258, 213, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 3
1539, p3up0A_, 0.7432, 2.66, 0.289, 212, 204, NUCLEAR RECEPTOR DAF-12 FROM HOOKWORM ANCYLOSTOMA CEYLANICUM IN COMPLEX WITH (25S)-DELTA7-DAFACHRONIC ACID
1540, d3prgA_, 0.7432, 3.23, 0.172, 258, 215, LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR
1541, d3gwxA_, 0.7432, 3.12, 0.173, 254, 214, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
1542, d2q61B_, 0.7432, 3.26, 0.171, 258, 216, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN BOUND TO PARTIAL AGONIST SR145
1543, d1kkqC_, 0.7432, 3.20, 0.171, 229, 216, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
1544, p4s15A_, 0.7431, 3.18, 0.173, 258, 214, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORALPHA LIGAND- BINDING DOMAIN IN COMPLEX WITH 4ALPHA-CABOXYL 4BETA-METHYL- ZYMOSTEROL (4ACD8)
1545, d4r2uD_, 0.7431, 2.16, 0.290, 211, 200, CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1664
1546, d4prgD_, 0.7431, 2.87, 0.156, 267, 212, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
1547, d1xzxX1, 0.7431, 2.95, 0.156, 250, 212, THYROXINE-THYROID HORMONE RECEPTOR INTERACTIONS
1548, d5u42B_, 0.7430, 2.92, 0.156, 254, 212, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 11
1549, d4reeB_, 0.7430, 2.91, 0.156, 265, 212, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 6
1550, p4iqrB2, 0.7430, 3.16, 0.177, 268, 215, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
1551, d1nq2A1, 0.7430, 3.25, 0.176, 269, 216, TWO RTH MUTANTS WITH IMPAIRED HORMONE BINDING
1552, d1nq1A1, 0.7430, 3.27, 0.143, 263, 217, TR RECEPTOR MUTATIONS CONFERRING HORMONE RESISTANCE AND REDUCED COREPRESSOR RELEASE EXHIBIT DECREASED STABILITY IN THE NTERMINAL LBD
1553, p5t92B_, 0.7429, 2.99, 0.171, 221, 211, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- {4-[(1R)-2-(4-FLUOROPHENYL)-6-HYDROXY-1-METHY L-1234- TETRAHYDROISOQUINOLIN-1-YL]PHENYL}PROP-2-ENOIC ACID
1554, d4jl4B_, 0.7429, 3.31, 0.186, 260, 215, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570 [(2S)-3-(BIPHENYL-4-YL)-2-(BIPHENYL-4-YLOXY)PROPANOIC ACID]
1555, d4a4wB_, 0.7429, 3.12, 0.214, 232, 210, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
1556, d3ho0B_, 0.7429, 2.97, 0.154, 242, 214, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
1557, d1kkqD_, 0.7429, 2.97, 0.154, 242, 214, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
1558, p4zo1X_, 0.7427, 3.11, 0.168, 267, 214, CRYSTAL STRUCTURE OF THE T3-BOUND TR-BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH RXR-ALPHA
1559, d3r8aA_, 0.7427, 3.13, 0.144, 270, 215, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A COMPOUND WITH DUAL PPAR GAMMA AGONISM AND ANGIOTENSIN II TYPE I RECEPTOR ANTAGONISM ACTIVITY
1560, d2yfeB_, 0.7427, 3.37, 0.190, 259, 216, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 1
1561, p5q0xA_, 0.7426, 3.12, 0.160, 269, 213, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1562, p3dzuA2, 0.7425, 2.98, 0.189, 244, 212, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH BVT.13 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1563, d5u42A_, 0.7424, 3.11, 0.173, 257, 214, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 11
1564, d3sz1B_, 0.7423, 3.31, 0.189, 270, 217, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH LUTEOLIN AND MYRISTIC ACID
1565, p5ugmA_, 0.7422, 3.39, 0.140, 247, 215, CRYSTAL STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH EDAGLITAZONE
1566, d5u5lB_, 0.7422, 2.90, 0.151, 263, 212, X-RAY CRYSTAL STRUCTURE OF THE PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH RIVOGLITAZONE
1567, d4e4kB_, 0.7422, 3.11, 0.214, 233, 210, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND JO21
1568, d4a4vB_, 0.7422, 2.66, 0.220, 219, 205, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
1569, d3wj5B1, 0.7422, 3.26, 0.145, 251, 214, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPHENYLTIN
1570, d1y0xX1, 0.7422, 3.29, 0.145, 250, 214, THYROXINE-THYROID HORMONE RECEPTOR INTERACTIONS
1571, d1nyxB_, 0.7422, 0.43, 0.995, 183, 183, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH AN AGONIST
1572, p3up0B_, 0.7421, 3.03, 0.178, 267, 213, NUCLEAR RECEPTOR DAF-12 FROM HOOKWORM ANCYLOSTOMA CEYLANICUM IN COMPLEX WITH (25S)-DELTA7-DAFACHRONIC ACID
1573, d2xyjA_, 0.7421, 3.09, 0.183, 264, 213, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
1574, d2q6sB_, 0.7421, 3.22, 0.166, 270, 217, 2.4 ANGSTROM CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED TO BVT.13 WITHOUT CO-ACTIVATOR PEPTIDES
1575, d3ixpD_, 0.7420, 3.04, 0.165, 269, 212, CRYSTAL STRUCTURE OF THE ECDYSONE RECEPTOR BOUND TO BYI08346
1576, d5y2tB1, 0.7419, 3.38, 0.140, 242, 215, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN - LOBEGLITAZONE COMPLEX
1577, d3hc5A_, 0.7419, 3.14, 0.173, 251, 214, FXR WITH SRC1 AND GSK826
1578, d1nq0A1, 0.7419, 3.12, 0.178, 264, 213, TR RECEPTOR MUTATIONS CONFERRING HORMONE RESISTANCE AND REDUCED COREPRESSOR RELEASE EXHIBIT DECREASED STABILITY IN THE NTERMINAL LBD
1579, d5u43A_, 0.7418, 2.98, 0.171, 222, 211, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 12
1580, d5u3uA_, 0.7418, 2.38, 0.292, 209, 202, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 5
1581, d5u3yB_, 0.7417, 3.14, 0.150, 271, 214, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 9
1582, d5u3xA_, 0.7417, 3.30, 0.186, 258, 215, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 8
1583, d5ickA_, 0.7417, 3.23, 0.181, 271, 215, A UNIQUE BINDING MODEL OF FXR LBD WITH FEROLINE
1584, d4o8fA_, 0.7417, 3.32, 0.177, 254, 215, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA MUTANT R357A AND ROSIGLITAZONE
1585, d3kmgD_, 0.7417, 3.08, 0.178, 268, 214, THE X-RAY CRYSTAL STRUCTURE OF PPAR-GAMMA IN COMPLEX WITH AN INDOLE DERIVATIVE MODULATOR GSK538 AND AN SRC-1 PEPTIDE
1586, p4iqrA2, 0.7414, 3.12, 0.183, 265, 213, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
1587, p3up3A_, 0.7414, 3.31, 0.181, 253, 215, NUCLEAR RECEPTOR DAF-12 FROM HOOKWORM ANCYLOSTOMA CEYLANICUM IN COMPLEX WITH (25S)-CHOLESTENOIC ACID
1588, d3dy6B_, 0.7414, 3.40, 0.140, 247, 215, PPARDELTA COMPLEXED WITH AN ANTHRANILIC ACID PARTIAL AGONIST
1589, p5q0kA_, 0.7413, 3.41, 0.181, 258, 216, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1590, d2znqA_, 0.7413, 2.99, 0.154, 242, 214, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP401
1591, d2prgB_, 0.7413, 2.83, 0.147, 263, 211, LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
1592, d5u3vB_, 0.7412, 3.21, 0.178, 253, 214, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 6
1593, d4xtaA_, 0.7412, 2.67, 0.163, 220, 208, MECHANISMS OF PPARGAMMA ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
1594, d3x1hB_, 0.7412, 3.31, 0.172, 258, 215, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-OXO- TRICOSAHEXAENOIC ACID
1595, d3d5fB_, 0.7412, 3.22, 0.171, 229, 216, CRYSTAL STRUCTURE OF PPAR-DELTA COMPLEX
1596, d2zk3B_, 0.7412, 3.39, 0.144, 250, 215, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 8-OXO- EICOSATETRAENOIC ACID
1597, d5u44B_, 0.7411, 3.02, 0.150, 266, 213, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 13
1598, d4r6sB_, 0.7411, 3.27, 0.144, 255, 215, CRYSTAL STRUCTURE OF PPARGAMMMA IN COMPLEX WITH SR1663
1599, d2zk4B_, 0.7411, 3.00, 0.150, 255, 213, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-OXO- EICOSATETRAENOIC ACID
1600, d4jazB_, 0.7410, 2.90, 0.151, 262, 212, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND TRANS- RESVERATROL
1601, p3vt7A_, 0.7410, 3.19, 0.167, 229, 215, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH W282R MUTATION
1602, d2zk6B_, 0.7410, 3.14, 0.178, 252, 214, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH C8-BODIPY
1603, d2q5sB_, 0.7410, 3.11, 0.173, 256, 214, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST NTZDPA
1604, p5ugmB_, 0.7409, 2.71, 0.225, 226, 204, CRYSTAL STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH EDAGLITAZONE
1605, d4yt1B_, 0.7409, 3.11, 0.157, 242, 216, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT76
1606, d2q8sB_, 0.7409, 2.96, 0.151, 255, 212, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
1607, d1n83A1, 0.7409, 3.19, 0.172, 224, 215, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE ORPHAN NUCLEAR HORMONE RECEPTOR ROR(ALPHA)-LBD AND CHOLESTEROL
1608, d2pinB_, 0.7408, 3.06, 0.155, 262, 213, THYROID RECEPTOR BETA IN COMPLEX WITH INHIBITOR
1609, d1n46A_, 0.7407, 2.92, 0.180, 246, 211, CRYSTAL STRUCTURE OF HUMAN TR BETA LIGAND-BINDING DOMAIN COMPLEXED WITH A POTENT SUBTYPE-SELECTIVE THYROMIMETIC
1610, p5q12A_, 0.7406, 3.15, 0.150, 267, 214, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1611, d2vv0B_, 0.7406, 3.20, 0.174, 248, 213, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH DHA
1612, d3pbaB_, 0.7405, 3.20, 0.174, 254, 213, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MONOSULFATE TETRABROMO-BISPHENOL A (MONOTBBPA)
1613, d2q59B_, 0.7405, 3.08, 0.160, 254, 212, CRYSTAL STRUCTURE OF PPARGAMMA LBD BOUND TO FULL AGONIST MRL20
1614, d5u3zA_, 0.7404, 3.15, 0.183, 263, 213, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 10
1615, d3adtB_, 0.7404, 2.93, 0.151, 260, 212, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-HYDROXY-INDOLE ACETATE
1616, d5u3wA_, 0.7403, 3.18, 0.173, 254, 214, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 7
1617, d5lsgB_, 0.7403, 3.14, 0.178, 263, 213, PPARGAMMA COMPLEX WITH THE BETULINIC ACID
1618, d4prgB_, 0.7403, 3.14, 0.182, 267, 214, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
1619, d3an3B_, 0.7403, 3.05, 0.209, 230, 211, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO3S
1620, d3advB_, 0.7403, 3.15, 0.188, 262, 213, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH SEROTONIN
1621, d2vsrB_, 0.7403, 3.29, 0.191, 258, 215, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE
1622, d2j14A_, 0.7403, 3.24, 0.181, 271, 215, 345-TRISUBSTITUTED ISOXAZOLES AS NOVEL PPARDELTA AGONISTS: PART2
1623, d5u41B_, 0.7402, 3.16, 0.188, 257, 213, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 16
1624, d3ia6B_, 0.7402, 3.36, 0.172, 254, 215, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
1625, d3oswB_, 0.7401, 3.05, 0.189, 241, 212, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRABROMO-BISPHENOL A (TBBPA)
1626, d3b0rB_, 0.7401, 3.46, 0.140, 250, 215, HUMAN PPAR GAMMA LIGAND BINDING DMAIN COMPLEXED WITH GW9662 IN A COVALENT BONDED FORM
1627, d2xkwB_, 0.7401, 3.39, 0.140, 248, 215, LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE
1628, d1uhlB1, 0.7401, 3.19, 0.177, 228, 215, CRYSTAL STRUCTURE OF THE LXRALFA-RXRBETA LBD HETERODIMER
1629, d3h0aA_, 0.7400, 3.36, 0.181, 252, 215, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARG) AND RETINOIC ACID RECEPTOR ALPHA (RXRA) IN COMPLEX WITH 9-CIS RETINOIC ACID CO-ACTIVATOR PEPTIDE AND A PARTIAL AGONIST
1630, d2znpB1, 0.7400, 3.10, 0.179, 249, 212, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP204
1631, d5u45B_, 0.7399, 3.28, 0.173, 253, 214, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 14
1632, d5u3tB_, 0.7399, 2.96, 0.151, 268, 212, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 4
1633, d5u3vA_, 0.7397, 3.18, 0.174, 257, 213, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 6
1634, d2zk2B_, 0.7397, 3.11, 0.150, 266, 213, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH GLUTATHION CONJUGATED 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
1635, d2xyxB_, 0.7397, 3.11, 0.179, 260, 212, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
1636, p6an1B_, 0.7396, 3.15, 0.181, 270, 215, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND AM-879
1637, d5wr0B_, 0.7396, 3.15, 0.178, 256, 213, HUISGEN CYCLOADDITION FOR PPARG-LBD LABELING BY SOAKING METHOD
1638, p5mkuA_, 0.7396, 3.16, 0.178, 257, 213, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 4 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1639, d1xapA_, 0.7396, 3.20, 0.174, 255, 213, STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOIC ACID RECEPTOR BETA
1640, d1r6gA_, 0.7396, 3.07, 0.150, 253, 213, CRYSTAL STRUCTURE OF THE THYROID HORMONE RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BETA SELECTIVE COMPOUND
1641, d5wr1B_, 0.7395, 3.03, 0.150, 261, 213, COVALENT BOND FORMATION OF BIFUNCTIONAL LIGAND WITH HPPARG-LBD
1642, d5u45A_, 0.7395, 3.14, 0.169, 255, 213, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 14
1643, d5kyjB1, 0.7395, 3.28, 0.168, 248, 214, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1644, d4r06B_, 0.7395, 3.16, 0.170, 245, 212, CRYSTAL STRUCTURE OF SR2067 BOUND TO PPARGAMMA
1645, p3t03B_, 0.7395, 3.24, 0.178, 256, 214, CRYSTAL STRUCTURE OF PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A NOVEL PARTIAL AGONIST GQ-16
1646, d3d57B_, 0.7395, 2.82, 0.172, 218, 209, TR VARIANT D355R
1647, d3adwB_, 0.7395, 2.27, 0.284, 210, 201, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE AND 15-OXO-EICOSATETRAENOIC ACID
1648, p5q0qC_, 0.7394, 3.06, 0.154, 261, 214, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1649, p3dzyD2, 0.7394, 2.88, 0.152, 265, 211, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH ROSIGLITAZONE 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1650, d2zk5B_, 0.7394, 2.91, 0.156, 265, 211, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH NITRO-233
1651, d5u3xB_, 0.7393, 2.80, 0.152, 262, 210, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 8
1652, d5u3tA_, 0.7392, 3.12, 0.178, 263, 213, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 4
1653, d3d5fA_, 0.7392, 2.81, 0.152, 263, 210, CRYSTAL STRUCTURE OF PPAR-DELTA COMPLEX
1654, d1kkqB_, 0.7392, 3.12, 0.189, 253, 212, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
1655, d5wqxB_, 0.7391, 3.34, 0.173, 246, 214, COVALENT BOND FORMATION OF SYNTHETIC LIGAND WITH HPPARG-LBD
1656, d5y2oB1, 0.7390, 2.40, 0.294, 208, 201, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN-PIOGLITAZONE COMPLEX
1657, d3d57A_, 0.7390, 2.94, 0.201, 232, 209, TR VARIANT D355R
1658, d2pinA_, 0.7390, 3.46, 0.139, 239, 216, THYROID RECEPTOR BETA IN COMPLEX WITH INHIBITOR
1659, p4heeX_, 0.7389, 3.25, 0.169, 246, 213, CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH COMPOUND 13
1660, d2vv3B_, 0.7389, 2.81, 0.152, 262, 210, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-OXODHA
1661, d1naxA_, 0.7389, 2.45, 0.297, 208, 202, THYROID RECEPTOR BETA1 IN COMPLEX WITH A BETA-SELECTIVE LIGAND
1662, d1m7wA_, 0.7389, 3.31, 0.178, 252, 214, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1663, d2zvtB_, 0.7388, 2.99, 0.175, 249, 211, CYS285SER MUTANT PPARGAMMA LIGAND-BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
1664, d2xywA_, 0.7388, 3.39, 0.140, 248, 214, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
1665, d2vv2B_, 0.7388, 3.25, 0.182, 260, 214, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-HEPA
1666, d5u43B_, 0.7387, 3.17, 0.168, 223, 214, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 12
1667, p5q0iA_, 0.7386, 2.97, 0.171, 252, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1668, d5u3uB_, 0.7385, 3.16, 0.188, 263, 213, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 5
1669, d3b0qB_, 0.7385, 2.93, 0.152, 252, 211, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MCC555
1670, d2xywB_, 0.7384, 3.12, 0.150, 270, 213, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
1671, d3osiB_, 0.7383, 3.09, 0.160, 254, 212, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRACHLORO-BISPHENOL A (TCBPA)
1672, d5u3zB_, 0.7382, 3.17, 0.155, 269, 213, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 10
1673, d4l96A_, 0.7382, 3.25, 0.164, 246, 213, STRUCTURE OF THE COMPLEX BETWEEN THE F360L PPARGAMMA MUTANT AND THE LIGAND LT175 (SPACE GROUP I222)
1674, d3wmhB_, 0.7382, 3.29, 0.182, 253, 214, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT75
1675, d5u40A_, 0.7381, 3.40, 0.140, 245, 214, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 15
1676, d3aduB_, 0.7381, 3.40, 0.140, 245, 214, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE
1677, d2zk0B_, 0.7381, 3.14, 0.164, 251, 214, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN
1678, d4o8fB_, 0.7380, 3.35, 0.168, 246, 214, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA MUTANT R357A AND ROSIGLITAZONE
1679, d3vjhB_, 0.7379, 3.40, 0.140, 250, 215, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL35
1680, d3vspB_, 0.7378, 2.93, 0.212, 223, 208, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT28
1681, d2zk1B_, 0.7378, 3.47, 0.176, 263, 216, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214- PROSTAGLANDIN J2
1682, d1pduA1, 0.7378, 2.71, 0.153, 263, 209, LIGAND-BINDING DOMAIN OF DROSOPHILA ORPHAN NUCLEAR RECEPTOR DHR38
1683, d3p89A_, 0.7376, 3.12, 0.175, 257, 212, FXR BOUND TO A QUINOLINECARBOXYLIC ACID
1684, p5q1gA_, 0.7375, 2.82, 0.152, 262, 210, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1685, d5kyjF1, 0.7375, 3.22, 0.164, 227, 214, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1686, d3vjiB_, 0.7375, 2.81, 0.157, 250, 210, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL53
1687, d3ty0B1, 0.7375, 3.18, 0.170, 245, 212, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH (R)-5-(3- ((3-(6-METHOXYBENZO[D]ISOXAZOL-3-YL)-2-OXO-23-DIHYDRO-1H- BENZO[D]IMIDAZOL-1-YL)METHYL)PHENYL)-5-METHYLOXAZOLIDINE-24-DIONE
1688, d1xnxA_, 0.7375, 2.71, 0.144, 263, 209, CRYSTAL STRUCTURE OF CONSTITUTIVE ANDROSTANE RECEPTOR
1689, d5hjpC1, 0.7374, 3.10, 0.179, 245, 212, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
1690, d3okhA_, 0.7374, 3.07, 0.146, 261, 212, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 2-(4-CHLOROPHENYL)-1- [(1S)-1-CYCLOHEXYL-2-(CYCLOHEXYLAMINO)-2-OXOETHYL]-1H-BENZIMIDAZOLE- 6-CARBOXYLIC ACID
1691, d2j14B_, 0.7374, 3.16, 0.183, 260, 213, 345-TRISUBSTITUTED ISOXAZOLES AS NOVEL PPARDELTA AGONISTS: PART2
1692, d1i7iB_, 0.7374, 3.09, 0.165, 256, 212, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242
1693, d4refB_, 0.7373, 2.99, 0.151, 257, 212, CRYSTAL STRUCTURE OF TR3 LBD_L449W IN COMPLEX WITH MOLECULE 2
1694, d4l98B_, 0.7373, 3.44, 0.173, 261, 214, CRYSTAL STRUCTURE OF THE COMPLEX OF F360L PPARGAMMA MUTANT WITH THE LIGAND LT175
1695, d2znoB_, 0.7372, 3.28, 0.173, 259, 214, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703
1696, d2vv4B_, 0.7372, 3.30, 0.178, 249, 214, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXOOTE
1697, d2pobB_, 0.7372, 3.08, 0.166, 246, 211, PPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A FARGLITAZAR ANALOGUE GW4709
1698, d2o9iA_, 0.7371, 3.43, 0.181, 259, 215, CRYSTAL STRUCTURE OF THE HUMAN PREGNANE X RECEPTOR LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND T0901317
1699, d5u3wB_, 0.7370, 3.09, 0.179, 263, 212, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 7
1700, p5t92A_, 0.7369, 2.82, 0.181, 229, 210, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- {4-[(1R)-2-(4-FLUOROPHENYL)-6-HYDROXY-1-METHY L-1234- TETRAHYDROISOQUINOLIN-1-YL]PHENYL}PROP-2-ENOIC ACID
1701, d5a86A_, 0.7369, 3.10, 0.169, 223, 213, STRUCTURE OF PREGNANE X RECEPTOR IN COMPLEX WITH A SPHINGOSINE 1-PHOSPHATE RECEPTOR 1 ANTAGONIST
1702, d5azvB_, 0.7368, 3.18, 0.169, 224, 213, CRYSTAL STRUCTURE OF HPPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 17-OXODHA
1703, d1navA1, 0.7368, 2.47, 0.297, 207, 202, THYROID RECEPTOR ALPHA IN COMPLEX WITH AN AGONIST SELECTIVE FOR THYROID RECEPTOR BETA1
1704, p3e00A2, 0.7367, 3.20, 0.175, 245, 212, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH GW9662 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1705, d2vstB_, 0.7367, 3.14, 0.178, 275, 214, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 13-(S)- HODE
1706, d1bsxB_, 0.7367, 2.81, 0.186, 232, 210, STRUCTURE AND SPECIFICITY OF NUCLEAR RECEPTOR-COACTIVATOR INTERACTIONS
1707, d1bsxA_, 0.7367, 2.46, 0.300, 208, 200, STRUCTURE AND SPECIFICITY OF NUCLEAR RECEPTOR-COACTIVATOR INTERACTIONS
1708, p4qe8A_, 0.7366, 3.11, 0.170, 227, 212, FXR WITH DM175 AND NCOA-2 PEPTIDE
1709, d3sp9B_, 0.7366, 3.01, 0.152, 251, 211, STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHA/DELTA AGONIST
1710, d3adsB_, 0.7366, 3.29, 0.183, 258, 213, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
1711, d2hwrB_, 0.7366, 3.22, 0.214, 235, 210, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
1712, d3vsoB_, 0.7365, 3.21, 0.178, 258, 213, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT21
1713, d2q5pB_, 0.7365, 3.21, 0.184, 251, 212, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST MRL24
1714, d2p4yA_, 0.7365, 3.17, 0.170, 247, 212, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA-LIGAND BINDING DOMAIN COMPLEXED WITH AN INDOLE-BASED MODULATOR
1715, d2j4aA_, 0.7365, 3.15, 0.175, 247, 212, HUMAN THYROID HORMONE RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH KB131084
1716, d2bawB_, 0.7365, 3.39, 0.139, 279, 216, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
1717, d3an4B_, 0.7363, 2.91, 0.157, 261, 210, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO4R
1718, d5i4vB1, 0.7362, 1.05, 0.995, 183, 183, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
1719, d2gwxA_, 0.7362, 3.35, 0.140, 271, 215, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
1720, d1zeoB_, 0.7362, 3.39, 0.167, 246, 215, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH AN ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST
1721, p6f2lB_, 0.7361, 3.58, 0.144, 251, 216, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570: STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 15 DAYS.
1722, p3gytA_, 0.7361, 2.33, 0.295, 208, 200, NUCLEAR RECEPTOR DAF-12 FROM PARASITIC NEMATODE STRONGYLOIDES STERCORALIS IN COMPLEX WITH ITS PHYSIOLOGICAL LIGAND DAFACHRONIC ACID DELTA 4
1723, d1n46B_, 0.7361, 3.27, 0.169, 248, 213, CRYSTAL STRUCTURE OF HUMAN TR BETA LIGAND-BINDING DOMAIN COMPLEXED WITH A POTENT SUBTYPE-SELECTIVE THYROMIMETIC
1724, p5aztB_, 0.7360, 3.26, 0.150, 243, 213, TERNARY COMPLEX OF HPPARALPHA LIGAND BINDING DOMAIN 17-OXODHA AND A SRC1 PEPTIDE
1725, d1ovlB_, 0.7360, 3.26, 0.150, 243, 213, CRYSTAL STRUCTURE OF NURR1 LBD
1726, d3adxB_, 0.7358, 3.22, 0.168, 224, 214, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN AND NITRO-233
1727, d1lv2A1, 0.7356, 3.24, 0.149, 267, 215, HEPATOCYTE NUCLEAR FACTOR 4 IS A TRANSCRIPTION FACTOR THAT CONSTITUTIVELY BINDS FATTY ACIDS
1728, d2b50A_, 0.7355, 3.14, 0.189, 251, 212, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 2
1729, d1nrlA_, 0.7355, 3.06, 0.180, 253, 211, CRYSTAL STRUCTURE OF THE HUMAN PXR-LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND SR12813
1730, d2znpA_, 0.7353, 3.54, 0.171, 260, 216, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP204
1731, d5kyaB1, 0.7352, 3.23, 0.178, 245, 213, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1732, d4xtaB_, 0.7352, 2.98, 0.181, 244, 210, MECHANISMS OF PPARGAMMA ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
1733, d3sp9A_, 0.7351, 3.42, 0.140, 250, 215, STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHA/DELTA AGONIST
1734, p5q11A_, 0.7350, 2.91, 0.157, 248, 210, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1735, d5kyaF1, 0.7348, 3.36, 0.182, 257, 214, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1736, d4s0tB_, 0.7348, 2.46, 0.299, 207, 201, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND WITH ADNECTIN-1 AND COMPOUND-1
1737, d4emaB_, 0.7348, 3.31, 0.148, 265, 216, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH ROSIGLITAZONE
1738, p6c5tA_, 0.7347, 3.32, 0.172, 247, 215, PPARG LBD BOUND TO SR11023 
1739, p5uc1B_, 0.7347, 3.18, 0.189, 255, 212, STRUCTURAL ANALYSIS OF GLUCOCORTICOID RECEPTOR BETA LIGAND BINDING DOMAIN COMPLEXED WITH GLUCOCORTICOID ANTAGONIST RU-486: IMPLICATION OF HELIX 12 IN ANTAGONISM
1740, d5hzcB_, 0.7347, 3.08, 0.116, 242, 215, CRYSTAL STRUCTURE OF THE COMPLEX PPARGAMMA/AL26-29
1741, d5u40B_, 0.7346, 3.08, 0.116, 242, 215, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 15
1742, d3et0B1, 0.7346, 3.30, 0.146, 239, 213, STRUCTURE OF PPARGAMMA WITH 3-(5-METHOXY-1H-INDOL-3-YL)- PROPIONIC ACID
1743, p5uc1A_, 0.7345, 3.08, 0.146, 251, 213, STRUCTURAL ANALYSIS OF GLUCOCORTICOID RECEPTOR BETA LIGAND BINDING DOMAIN COMPLEXED WITH GLUCOCORTICOID ANTAGONIST RU-486: IMPLICATION OF HELIX 12 IN ANTAGONISM
1744, d2hwqB_, 0.7345, 3.04, 0.216, 233, 208, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
1745, d1ot7B_, 0.7344, 3.13, 0.184, 251, 212, STRUCTURAL BASIS FOR 3-DEOXY-CDCA BINDING AND ACTIVATION OF FXR
1746, d4rzeB_, 0.7343, 2.86, 0.214, 222, 206, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN L437W D594E MUTANT
1747, d1pduB_, 0.7342, 3.09, 0.145, 261, 214, LIGAND-BINDING DOMAIN OF DROSOPHILA ORPHAN NUCLEAR RECEPTOR DHR38
1748, d5ntqA_, 0.7341, 3.37, 0.140, 278, 215, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1749, d1osvB1, 0.7340, 3.02, 0.147, 259, 211, STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR
1750, p5q0tA_, 0.7339, 2.44, 0.299, 206, 201, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1751, d4rakA_, 0.7338, 3.00, 0.181, 243, 210, CRYSTAL STRUCTURE OF NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2 (LXRB) COMPLEXED WITH PARTIAL AGONIST
1752, d4ypqA_, 0.7337, 3.14, 0.150, 269, 214, CRYSTAL STRUCTURE OF THE ROR(GAMMA)T LIGAND BINDING DOMAIN IN COMPLEX WITH 4-(1-(2-CHLORO-6-(TRIFLUOROMETHYL)BENZOYL)-1H-INDAZOL-3-YL) BENZOIC ACID
1753, d4xaoA_, 0.7337, 3.19, 0.174, 221, 213, CRYSTAL STRUCTURE OF THE HPXR-LBD OBTAINED IN PRESENCE OF THE PESTICIDE TRANS-NONACHLOR
1754, p4qe8B_, 0.7337, 2.46, 0.299, 206, 201, FXR WITH DM175 AND NCOA-2 PEPTIDE
1755, d4pwlB_, 0.7337, 3.44, 0.138, 283, 217, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE S ENANTIOMER OF MBX-102 (METAGLIDASEN)
1756, d4whfB_, 0.7335, 3.34, 0.178, 244, 213, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH 1-(345- TRIHYDROXYPHENYL)DECAN-1-ONE
1757, d5f9bB_, 0.7334, 3.01, 0.196, 257, 209, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN THE COMPLEX WITH CAULOPHYLLOGENIN
1758, d4em9B_, 0.7334, 2.60, 0.276, 205, 203, HUMAN PPAR GAMMA IN COMPLEX WITH NONANOIC ACIDS
1759, p3dzyA2, 0.7334, 3.35, 0.183, 250, 213, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH ROSIGLITAZONE 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1760, d1m13A_, 0.7334, 3.16, 0.144, 259, 215, CRYSTAL STRUCTURE OF THE HUMAN PREGANE X RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH HYPERFORIN A CONSTITUENT OF ST. JOHN S WORT
1761, d5ntiC_, 0.7333, 3.34, 0.173, 257, 214, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1762, d4kzmB_, 0.7333, 2.60, 0.276, 205, 203, CRYSTAL STRUCTURE OF TR3 LBD S553A MUTANT
1763, p3dzuD2, 0.7333, 3.09, 0.185, 253, 211, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH BVT.13 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1764, d5lwpA1, 0.7331, 3.17, 0.164, 229, 214, DISCOVERY OF PHENOXYINDAZOLES AND PHENYLTHIOINDAZOLES AS RORG INVERSE AGONISTS
1765, d4s0tA_, 0.7331, 2.94, 0.218, 229, 206, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND WITH ADNECTIN-1 AND COMPOUND-1
1766, d1osvA1, 0.7331, 2.89, 0.176, 228, 210, STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR
1767, d4s0sB_, 0.7330, 2.97, 0.151, 234, 212, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH ADNECTIN-1
1768, d3x1iB_, 0.7330, 3.12, 0.170, 228, 212, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXO- TETRACOSAHEXAENOIC ACID
1769, d4x1gA_, 0.7328, 3.18, 0.160, 222, 212, CRYSTAL STRUCTURE OF THE HPXR-LBD IN COMPLEX WITH THE SYNTHETIC ESTROGEN 17ALPHA-ETHINYLESTRADIOL AND THE PESTICIDE TRANS-NONACHLOR
1770, d4qm0C1, 0.7328, 2.62, 0.190, 236, 205, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A TERTIARY SULFONAMIDE INVERSE AGONIST
1771, d4s0sA_, 0.7327, 3.25, 0.168, 243, 214, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH ADNECTIN-1
1772, d4rzfB_, 0.7326, 3.45, 0.140, 275, 215, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN S441W MUTANT
1773, d2bawA_, 0.7325, 3.32, 0.173, 223, 214, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
1774, d1ot7A_, 0.7325, 3.11, 0.161, 252, 211, STRUCTURAL BASIS FOR 3-DEOXY-CDCA BINDING AND ACTIVATION OF FXR
1775, d4pvuB_, 0.7324, 3.11, 0.217, 229, 207, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE R ENANTIOMER OF MBX-102 (METAGLIDASEN)
1776, d4l98A_, 0.7322, 3.27, 0.184, 250, 212, CRYSTAL STRUCTURE OF THE COMPLEX OF F360L PPARGAMMA MUTANT WITH THE LIGAND LT175
1777, d5u41A_, 0.7321, 3.26, 0.170, 243, 212, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 16
1778, d5hjpA1, 0.7321, 2.25, 0.298, 205, 198, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
1779, p5q13A_, 0.7319, 3.50, 0.139, 273, 216, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1780, d5ntiB_, 0.7319, 3.18, 0.175, 245, 212, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1781, d2o9iB_, 0.7318, 3.10, 0.222, 230, 207, CRYSTAL STRUCTURE OF THE HUMAN PREGNANE X RECEPTOR LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND T0901317
1782, d3bejB_, 0.7317, 2.94, 0.176, 257, 210, STRUCTURE OF HUMAN FXR IN COMPLEX WITH MFA-1 AND CO- ACTIVATOR PEPTIDE
1783, p6c5qA_, 0.7316, 3.12, 0.165, 242, 212, PPARG LBD BOUND TO SR10171 
1784, p6fzuA_, 0.7315, 3.33, 0.144, 279, 215, RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ( CPD-1 ) AND RIP140 PEPTIDE AT 1.80A 
1785, d5u44A_, 0.7313, 3.08, 0.179, 228, 212, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 13
1786, d2xyxA_, 0.7312, 3.45, 0.143, 273, 217, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
1787, d3r8aB1, 0.7311, 2.97, 0.178, 237, 208, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A COMPOUND WITH DUAL PPAR GAMMA AGONISM AND ANGIOTENSIN II TYPE I RECEPTOR ANTAGONISM ACTIVITY
1788, d1q4xA_, 0.7311, 3.36, 0.140, 279, 214, CRYSTAL STRUCTURE OF HUMAN THYROID HORMONE RECEPTOR BETA LBD IN COMPLEX WITH SPECIFIC AGONIST GC-24
1789, d1ilhA_, 0.7311, 2.82, 0.163, 233, 209, CRYSTAL STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TO SR12813
1790, d5ntiD_, 0.7310, 3.45, 0.143, 273, 217, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1791, p4wlbB_, 0.7309, 3.10, 0.222, 232, 207, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PARTIAL INVERSE AGONIST COMPOUND
1792, p4qe6A_, 0.7309, 3.07, 0.146, 250, 213, FXR WITH CDCA AND NCOA-2 PEPTIDE
1793, d2vv1B_, 0.7308, 3.08, 0.184, 229, 212, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA
1794, d4x1fA_, 0.7305, 3.17, 0.180, 252, 211, CRYSTAL STRUCTURE OF THE HPXR-LBD IN COMPLEX WITH THE SYNTHETIC ESTROGEN 17ALPHA-ETHINYLESTRADIOL
1795, d3r29A_, 0.7305, 3.10, 0.186, 244, 210, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2
1796, d3imyA_, 0.7305, 3.25, 0.144, 260, 215, STRUCTURE OF TR-BETA BOUND TO SELECTIVE THYROMIMETIC GC-1
1797, p5xmxB_, 0.7304, 2.33, 0.303, 207, 198, CO-CRYSTAL STRUCTURE OF INHIBITOR COMPOUND IN COMPLEX WITH HUMAN PPARDELTA LBD 
1798, d3gwsX_, 0.7304, 3.36, 0.168, 232, 214, CRYSTAL STRUCTURE OF T3-BOUND THYROID HORMONE RECEPTOR
1799, d1nrlB_, 0.7304, 3.16, 0.175, 244, 212, CRYSTAL STRUCTURE OF THE HUMAN PXR-LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND SR12813
1800, d5vb7A1, 0.7303, 3.46, 0.140, 279, 215, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH AN AGONIST AND SRC2 PEPTIDE
1801, d5vb6A1, 0.7303, 3.32, 0.159, 228, 214, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH AN INVERSE AGONIST AND SRC2 PEPTIDE
1802, d5ntnC_, 0.7303, 3.14, 0.181, 265, 210, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1803, d3l0lB_, 0.7303, 3.18, 0.175, 245, 212, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
1804, d1ovlD_, 0.7302, 3.07, 0.146, 257, 213, CRYSTAL STRUCTURE OF NURR1 LBD
1805, p5q0qA_, 0.7301, 2.91, 0.144, 261, 209, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1806, p3kmzB_, 0.7301, 3.26, 0.171, 238, 211, CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH THE INVERSE AGONIST BMS493 AND A COREPRESSOR FRAGMENT
1807, d1ovlE_, 0.7301, 3.35, 0.142, 239, 212, CRYSTAL STRUCTURE OF NURR1 LBD
1808, d1nuoA_, 0.7301, 3.51, 0.135, 270, 215, TWO RTH MUTANTS WITH IMPAIRED HORMONE BINDING
1809, d1ilgA_, 0.7301, 3.19, 0.175, 244, 212, CRYSTAL STRUCTURE OF APO HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN
1810, d5a86B_, 0.7300, 3.21, 0.164, 248, 213, STRUCTURE OF PREGNANE X RECEPTOR IN COMPLEX WITH A SPHINGOSINE 1-PHOSPHATE RECEPTOR 1 ANTAGONIST
1811, p3kmzA_, 0.7299, 3.13, 0.170, 228, 212, CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH THE INVERSE AGONIST BMS493 AND A COREPRESSOR FRAGMENT
1812, d5vb5A1, 0.7297, 2.97, 0.178, 239, 208, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH AN INVERSE AGONIST AND SRC2 PEPTIDE
1813, d5vb3A1, 0.7296, 3.30, 0.141, 271, 213, X-RAY STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN + SRC2 PEPTIDE
1814, d1ovlA_, 0.7295, 2.49, 0.295, 212, 200, CRYSTAL STRUCTURE OF NURR1 LBD
1815, d5x0rB_, 0.7293, 3.41, 0.146, 248, 212, CRYSTAL STRUCTURE OF PXR LBD COMPLEXED WITH SJB7
1816, d5g44A1, 0.7293, 2.77, 0.159, 245, 207, LIGAND COMPLEX OF RORG LBD
1817, p4wpfA_, 0.7292, 3.32, 0.142, 243, 211, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PHENYL SULFONAMIDE AGONIST
1818, p6eu9B_, 0.7291, 3.42, 0.136, 275, 214, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
1819, d4xhdA_, 0.7289, 3.32, 0.150, 249, 214, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH COMPOUND-1
1820, d3hzfA1, 0.7289, 3.40, 0.149, 249, 215, STRUCTURE OF TR-ALFA BOUND TO SELECTIVE THYROMIMETIC GC-1 IN C2 SPACE GROUP
1821, p4wpfD_, 0.7288, 3.22, 0.170, 245, 212, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PHENYL SULFONAMIDE AGONIST
1822, d2q5gA_, 0.7288, 3.22, 0.164, 248, 213, LIGAND BINDING DOMAIN OF PPAR DELTA RECEPTOR IN COMPLEX WITH A PARTIAL AGONIST
1823, p6g05B_, 0.7287, 3.05, 0.207, 228, 208, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-2  AND RIP140 PEPTIDE AT 1.90A 
1824, d5x8uA_, 0.7287, 3.39, 0.174, 221, 213, CRYSTAL STRUCTURE OF THE WILD HUMAN ROR GAMMA LIGAND BINDING DOMAIN.
1825, d4kzjB_, 0.7286, 3.06, 0.208, 221, 207, CRYSTAL STRUCTURE OF TR3 LBD L449W MUTANT
1826, d5ntiA_, 0.7285, 3.13, 0.225, 247, 209, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1827, d5x8wA_, 0.7284, 3.13, 0.225, 247, 209, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN.
1828, d4ny9A_, 0.7283, 3.38, 0.145, 247, 214, CRYSTAL STRUCTURE OF THE HUMAN PXR-LBD IN COMPLEX WITH N-{(2R)-1- [(4S)-4-(4-CHLOROPHENYL)-4-HYDROXY-33-DIMETHYLPIPERIDIN-1-YL]-3- METHYL-1-OXOBUTAN-2-YL}-3-HYDROXY-3-METHYLBUTANAMIDE
1829, p5ejvA_, 0.7281, 3.54, 0.138, 270, 217, RORY IN COMPLEX WITH T090131718 AND COACTIVATOR PEPTIDE EBI96
1830, d3r8dA_, 0.7277, 3.27, 0.142, 274, 212, ACTIVATION OF THE HUMAN NUCLEAR XENOBIOTIC RECEPTOR PXR BY THE REVERSE TRANSCRIPTASE-TARGETED ANTI-HIV DRUG PNU-142721
1831, d1skxA_, 0.7277, 3.06, 0.208, 221, 207, STRUCTURAL DISORDER IN THE COMPLEX OF HUMAN PXR AND THE MACROLIDE ANTIBIOTIC RIFAMPICIN
1832, p5iz0A_, 0.7276, 3.32, 0.150, 249, 214, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
1833, d5g43A1, 0.7276, 3.30, 0.154, 249, 214, LIGAND COMPLEX OF RORG LBD
1834, d4ymqA1, 0.7276, 3.19, 0.212, 226, 208, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT + SRC2 PEPTIDE WITH A BENZOTHIADIAZOLE DIOXIDE INVERSE AGONIST
1835, d1pq6C_, 0.7276, 3.19, 0.142, 257, 211, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
1836, d5g46A1, 0.7275, 3.17, 0.175, 243, 212, LIGAND COMPLEX OF RORG LBD
1837, d5c4tA_, 0.7275, 3.05, 0.152, 246, 210, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
1838, d3r29B_, 0.7275, 2.70, 0.213, 214, 202, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2
1839, d5g45A1, 0.7273, 3.29, 0.142, 268, 212, LIGAND COMPLEX OF RORG LBD
1840, d5ntnB_, 0.7272, 3.65, 0.140, 256, 215, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1841, d3l0jA_, 0.7272, 3.05, 0.152, 246, 210, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
1842, d2h77A_, 0.7272, 3.29, 0.160, 244, 213, CRYSTAL STRUCTURE OF HUMAN TR ALPHA BOUND T3 IN MONOCLINIC SPACE GROUP
1843, p6enqB_, 0.7271, 3.32, 0.169, 245, 213, STRUCTURE OF HUMAN PPAR GAMMA LBD IN COMPLEX WITH LANIFIBRANOR (IVA337)
1844, d5ntnD_, 0.7269, 3.28, 0.174, 244, 213, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1845, p4wlbA_, 0.7269, 3.13, 0.218, 229, 206, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PARTIAL INVERSE AGONIST COMPOUND
1846, d4lnwA1, 0.7269, 3.19, 0.175, 245, 212, CRYSTAL STRUCTURE OF TR-ALPHA BOUND TO T3 IN A SECOND SITE
1847, d5ntnA_, 0.7268, 3.28, 0.169, 244, 213, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1848, d3l0lA_, 0.7267, 3.34, 0.142, 260, 212, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
1849, d5apjA1, 0.7266, 3.17, 0.170, 245, 212, LIGAND COMPLEX OF RORG LBD
1850, d3jzcA_, 0.7266, 3.32, 0.142, 264, 212, CRYSTAL STRUCTURE OF TR-BETA BOUND TO THE SELECTIVE THYROMIMETIC TRIAC
1851, d5nu1A_, 0.7265, 3.32, 0.142, 242, 212, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1852, p5ejvB_, 0.7265, 3.31, 0.169, 244, 213, RORY IN COMPLEX WITH T090131718 AND COACTIVATOR PEPTIDE EBI96
1853, d2h6wX_, 0.7264, 3.27, 0.174, 243, 213,  
1854, p6fzuB_, 0.7262, 3.32, 0.169, 244, 213, RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ( CPD-1 ) AND RIP140 PEPTIDE AT 1.80A 
1855, d2qnvA_, 0.7262, 2.37, 0.190, 208, 200, CRYSTAL STRUCTURE OF THE PREGNANE X RECEPTOR BOUND TO COLUPULONE
1856, d4lnxA1, 0.7261, 3.28, 0.174, 243, 213, CRYSTAL STRUCTURE OF TR-ALPHA BOUND TO T4 IN A SECOND SITE
1857, d5g42A1, 0.7259, 3.15, 0.166, 241, 211, LIGAND COMPLEX OF RORG LBD
1858, p4nieB_, 0.7259, 2.63, 0.290, 212, 200, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH SMALL MOLECULE LIGAND
1859, p5yp5A_, 0.7258, 3.31, 0.174, 243, 213, CRYSTAL STRUCTURE OF RORGAMMA COMPLEXED WITH SRC2 AND COMPOUND 5D
1860, d5aphA1, 0.7258, 3.23, 0.170, 244, 212, LIGAND COMPLEX OF RORG LBD
1861, p5yp6A_, 0.7256, 3.28, 0.169, 243, 213, RORGAMMA (263-509) COMPLEXED WITH SRC2 AND COMPOUND 6
1862, d1xnxB_, 0.7256, 3.27, 0.147, 251, 211, CRYSTAL STRUCTURE OF CONSTITUTIVE ANDROSTANE RECEPTOR
1863, d5nu1B_, 0.7254, 2.89, 0.190, 232, 205, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1864, p4xt9A_, 0.7252, 3.26, 0.170, 244, 212, RORGAMMA (263-509) COMPLEXED WITH GSK2435341A AND SRC2
1865, p4nieA_, 0.7252, 3.17, 0.165, 248, 212, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH SMALL MOLECULE LIGAND
1866, d3jzbA1, 0.7251, 3.23, 0.152, 256, 210, CRYSTAL STRUCTURE OF TR-ALFA BOUND TO THE SELECTIVE THYROMIMETIC TRIAC
1867, d4re8B_, 0.7250, 3.28, 0.174, 245, 213, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 5
1868, p5q0zC_, 0.7249, 3.17, 0.165, 247, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1869, p6eu9D_, 0.7248, 3.27, 0.174, 243, 213, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
1870, d5x0rA_, 0.7248, 3.44, 0.142, 244, 211, CRYSTAL STRUCTURE OF PXR LBD COMPLEXED WITH SJB7
1871, d5jy3C_, 0.7248, 3.33, 0.169, 245, 213, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
1872, p5iz0D_, 0.7248, 3.30, 0.169, 245, 213, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
1873, d5ntwC_, 0.7246, 3.21, 0.148, 242, 209, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1874, d2qw4A1, 0.7244, 3.23, 0.175, 245, 212, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1875, p4s14A_, 0.7243, 3.25, 0.142, 249, 211, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORGAMMA LIGAND- BINDING DOMAIN IN COMPLEX WITH 4ALPHA-CABOXYL 4BETA-METHYL- ZYMOSTEROL (4ACD8)
1876, p6g07A_, 0.7240, 3.34, 0.152, 256, 211, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
1877, d5c4oA_, 0.7240, 3.28, 0.174, 243, 213, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
1878, d5apkB_, 0.7240, 3.25, 0.170, 245, 212, LIGAND COMPLEX OF RORG LBD
1879, d2h79A1, 0.7239, 3.35, 0.169, 243, 213, CRYSTAL STRUCTURE OF HUMAN TR ALPHA BOUND T3 IN ORTHORHOMBIC SPACE GROUP
1880, p5z12A_, 0.7237, 3.29, 0.169, 243, 213, A STRUCTURE OF FXR/RXR 
1881, d5c4uA_, 0.7234, 3.37, 0.169, 243, 213, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
1882, p6g07C_, 0.7233, 2.89, 0.187, 232, 208, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
1883, d5jy3A_, 0.7232, 3.33, 0.169, 245, 213, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
1884, d5ntwA_, 0.7231, 3.37, 0.169, 243, 213, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1885, d5c4sA_, 0.7231, 3.26, 0.170, 245, 212, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
1886, d3l1bA1, 0.7230, 3.37, 0.147, 256, 211, COMPLEX STRUCTURE OF FXR LIGAND-BINDING DOMAIN WITH A TETRAHYDROAZEPINOINDOLE COMPOUND
1887, d3fliA_, 0.7229, 3.14, 0.220, 227, 205, DISCOVERY OF XL335 A HIGHLY POTENT SELECTIVE AND ORALLY- ACTIVE AGONIST OF THE FARNESOID X RECEPTOR (FXR)
1888, p6b31A_, 0.7228, 3.42, 0.174, 230, 213, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 2 
1889, p3kytA_, 0.7226, 2.51, 0.216, 210, 199, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
1890, p5z12C_, 0.7224, 3.06, 0.145, 237, 207, A STRUCTURE OF FXR/RXR 
1891, d3ilzA1, 0.7224, 2.59, 0.198, 231, 202, STRUCTURE OF TR-ALFA BOUND TO SELECTIVE THYROMIMETIC GC-1 IN P212121 SPACE GROUP
1892, d5ntwD_, 0.7219, 3.35, 0.169, 243, 213, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1893, p6b31B_, 0.7216, 3.27, 0.170, 245, 212, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 2 
1894, p5z12D_, 0.7215, 3.07, 0.213, 230, 207, A STRUCTURE OF FXR/RXR 
1895, d5k3nA_, 0.7215, 3.20, 0.171, 245, 211, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
1896, d1m7wB_, 0.7213, 3.27, 0.170, 245, 212, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1897, p4zo1B_, 0.7212, 3.09, 0.167, 241, 210, CRYSTAL STRUCTURE OF THE T3-BOUND TR-BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH RXR-ALPHA
1898, p3r2aA_, 0.7212, 3.36, 0.152, 236, 211, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
1899, p5q0zA_, 0.7210, 3.27, 0.148, 256, 210, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1900, d4wqpA_, 0.7210, 3.55, 0.178, 223, 214, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A BENZYL SULFONAMIDE INVERSE AGONIST
1901, d5k3nC_, 0.7209, 3.09, 0.167, 241, 210, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
1902, p6g07B_, 0.7208, 3.29, 0.170, 246, 212, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
1903, d4qm0A_, 0.7207, 2.69, 0.187, 228, 203, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A TERTIARY SULFONAMIDE INVERSE AGONIST
1904, p6g07D_, 0.7205, 3.26, 0.170, 245, 212, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
1905, p3r2aB_, 0.7205, 3.10, 0.167, 241, 210, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
1906, p5iz0G_, 0.7204, 2.82, 0.172, 213, 203, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
1907, d4jgvB_, 0.7202, 3.35, 0.175, 221, 211, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH THPN
1908, p6g05A_, 0.7197, 2.83, 0.160, 228, 206, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-2  AND RIP140 PEPTIDE AT 1.90A 
1909, d5k6eB_, 0.7194, 3.22, 0.170, 243, 212, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0654919
1910, p5iz0B_, 0.7194, 2.26, 0.292, 203, 195, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
1911, p3r2aD_, 0.7191, 3.40, 0.147, 259, 211, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
1912, d5ntwB_, 0.7190, 3.40, 0.147, 259, 211, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1913, d3h52B_, 0.7190, 3.25, 0.170, 245, 212, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
1914, d6bn6A_, 0.7189, 2.83, 0.161, 227, 205, IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTS
1915, d1m7wC_, 0.7189, 3.52, 0.178, 223, 213, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1916, p5q18A_, 0.7186, 2.80, 0.160, 228, 206, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1917, p5t97A_, 0.7185, 2.63, 0.239, 218, 197, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- (4-{(1R)-6-HYDROXY-1-METHYL-2-[4-(PROPAN-2 -YL)PHENYL]-1234- TETRAHYDROISOQUINOLIN-1-YL}PHENYL)PROP-2-ENOIC ACID
1918, p6cvhA_, 0.7181, 2.37, 0.299, 199, 197, IDENTIFICATION AND BIOLOGICAL EVALUATION OF THIAZOLE-BASED INVERSE AGONISTS OF RORGT 
1919, d1oshA1, 0.7179, 2.09, 0.299, 197, 194, A CHEMICAL GENETIC AND STRUCTURAL ANALYSIS OF THE NUCLEAR BILE ACID RECEPTOR FXR
1920, p5q1bA_, 0.7178, 3.46, 0.174, 230, 213, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1921, p5q15C_, 0.7176, 3.32, 0.152, 234, 210, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1922, p5q0sC_, 0.7176, 2.80, 0.160, 228, 206, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1923, d1h9uB_, 0.7176, 3.24, 0.171, 245, 211, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
1924, d1h9uD_, 0.7175, 3.33, 0.152, 234, 210, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
1925, d5x8sB_, 0.7174, 3.28, 0.170, 245, 212, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH URSOLIC ACID.
1926, p5q1aC_, 0.7174, 2.02, 0.301, 195, 193, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1927, p5q0nC_, 0.7174, 3.32, 0.170, 246, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1928, d5k74A_, 0.7174, 2.92, 0.218, 226, 202, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0655870
1929, d1lbdA_, 0.7174, 3.29, 0.170, 245, 212, LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA
1930, d1h9uC_, 0.7174, 3.04, 0.168, 234, 208, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
1931, d1h9uA_, 0.7174, 3.23, 0.171, 245, 211, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
1932, p5q1dC_, 0.7173, 2.17, 0.299, 197, 194, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1933, p5q0pC_, 0.7172, 3.30, 0.170, 245, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1934, p5q14C_, 0.7171, 2.32, 0.246, 249, 195, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1935, d3ookC1, 0.7170, 2.95, 0.160, 228, 206, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-35-DIFLUOROBENZOIC ACID
1936, p5q0jA_, 0.7169, 2.69, 0.215, 220, 200, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1937, d3omkC1, 0.7169, 3.45, 0.175, 230, 212, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYL-N-(2- METHYLPHENYL)ETHANAMIDE
1938, d5k74B_, 0.7168, 0.43, 0.994, 177, 177, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0655870
1939, d2qmvA_, 0.7167, 2.72, 0.162, 227, 204, HIGH RESOLUTION STRUCTURE OF PEROXISONE PROLIFERATION-ACTIVATED RECEPTOR GAMMA AND CHARACTERISATION OF ITS INTERACTION WITH THE CO- ACTIVATOR TRANSCRIPTIONAL INTERMEDIARY FACTOR 2
1940, p5q0vC_, 0.7166, 2.73, 0.168, 213, 202, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1941, p5q18C_, 0.7164, 3.37, 0.175, 230, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1942, p5q1cA_, 0.7162, 3.40, 0.175, 229, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1943, p5q0oA_, 0.7162, 3.48, 0.175, 230, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1944, d3olfC1, 0.7159, 2.07, 0.319, 201, 191, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-METHYLBENZOIC ACID
1945, d3h52D_, 0.7159, 2.07, 0.319, 201, 191, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
1946, p5q1hE_, 0.7156, 3.12, 0.153, 232, 209, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1947, p5q15A_, 0.7155, 3.48, 0.175, 229, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1948, d2qw4B_, 0.7155, 3.48, 0.175, 228, 212, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1949, p5q1dA_, 0.7153, 3.08, 0.155, 227, 206, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1950, p5q1aA_, 0.7153, 3.34, 0.274, 238, 208, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1951, p5q16C_, 0.7153, 2.07, 0.319, 201, 191, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1952, p5q0jC_, 0.7153, 2.07, 0.319, 201, 191, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1953, d2p4yB_, 0.7153, 3.40, 0.175, 230, 211, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA-LIGAND BINDING DOMAIN COMPLEXED WITH AN INDOLE-BASED MODULATOR
1954, d4reeA_, 0.7152, 3.40, 0.175, 230, 211, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 6
1955, d3ommC1, 0.7152, 3.41, 0.175, 230, 211, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-FLUOROBENZOIC ACID
1956, d1ovlC_, 0.7152, 3.55, 0.174, 229, 213, CRYSTAL STRUCTURE OF NURR1 LBD
1957, d5x8sA_, 0.7151, 3.39, 0.175, 230, 211, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH URSOLIC ACID.
1958, p5q1bC_, 0.7150, 3.50, 0.175, 229, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1959, p5q19C_, 0.7150, 3.07, 0.155, 227, 206, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1960, d5k3nD_, 0.7150, 3.44, 0.157, 270, 217, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
1961, p5q0sA_, 0.7149, 3.41, 0.175, 230, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1962, d2qw4C_, 0.7149, 3.49, 0.175, 230, 212, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1963, p5q0yA_, 0.7148, 3.40, 0.175, 229, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1964, p5q0uC_, 0.7148, 3.41, 0.175, 230, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1965, d3omkA1, 0.7148, 3.41, 0.171, 229, 211, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYL-N-(2- METHYLPHENYL)ETHANAMIDE
1966, d1ovlF_, 0.7148, 2.31, 0.242, 234, 194, CRYSTAL STRUCTURE OF NURR1 LBD
1967, p5q1cC_, 0.7147, 3.49, 0.175, 230, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1968, d3oofC1, 0.7147, 3.41, 0.175, 230, 211, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)BENZOIC ACID
1969, p5q0yC_, 0.7146, 3.23, 0.212, 230, 208, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1970, d5k38A_, 0.7146, 3.34, 0.176, 230, 210, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN
1971, p5q13C_, 0.7140, 3.50, 0.175, 230, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1972, p5q1hA_, 0.7139, 3.43, 0.175, 230, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1973, d5k3lD_, 0.7138, 3.44, 0.175, 230, 211, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
1974, d3ookA1, 0.7138, 3.04, 0.185, 227, 205, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-35-DIFLUOROBENZOIC ACID
1975, p5q16A_, 0.7137, 3.25, 0.211, 234, 209, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1976, d1g1uC_, 0.7137, 3.43, 0.175, 229, 211, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
1977, p5q19A_, 0.7134, 2.99, 0.213, 223, 202, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1978, d3oofA1, 0.7134, 3.14, 0.153, 235, 209, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)BENZOIC ACID
1979, d4jgvA_, 0.7132, 3.42, 0.175, 230, 211, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH THPN
1980, d3okiC1, 0.7132, 3.42, 0.175, 230, 211, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-1H-BENZIMIDAZOL-1-YL]-N2-DICYCLOHEXYLETHANAMIDE
1981, p5q0vA_, 0.7131, 2.99, 0.155, 228, 206, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1982, p5q0uA_, 0.7130, 3.41, 0.175, 230, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1983, p5q0pA_, 0.7129, 3.20, 0.220, 227, 205, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1984, d5m96A_, 0.7129, 3.42, 0.175, 230, 211, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW TRIAZOLO AND IMIDAZOLOPYRIDINE RORGT INVERSE AGONISTS
1985, d5ufoA_, 0.7127, 3.43, 0.175, 230, 211, STRUCTURE OF RORGT BOUND TO
1986, p5q1fC_, 0.7126, 3.51, 0.175, 229, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1987, d5k38B_, 0.7126, 3.05, 0.213, 220, 202, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN
1988, d5k3lC_, 0.7125, 3.60, 0.182, 228, 214, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
1989, p5q1hG_, 0.7124, 3.40, 0.175, 229, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1990, d5m96B_, 0.7124, 3.43, 0.175, 230, 211, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW TRIAZOLO AND IMIDAZOLOPYRIDINE RORGT INVERSE AGONISTS
1991, d4rzfA_, 0.7123, 3.09, 0.155, 227, 206, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN S441W MUTANT
1992, d4kzmA_, 0.7122, 3.42, 0.175, 230, 211, CRYSTAL STRUCTURE OF TR3 LBD S553A MUTANT
1993, d2aclC_, 0.7121, 3.42, 0.175, 229, 211, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
1994, d1g1uB_, 0.7120, 3.00, 0.161, 226, 205, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
1995, p5q0oC_, 0.7118, 3.36, 0.176, 229, 210, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1996, p5q0nA_, 0.7118, 3.44, 0.175, 230, 211, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1997, d5k3lB_, 0.7118, 3.06, 0.305, 226, 200, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
1998, d4whgA_, 0.7115, 3.42, 0.175, 230, 211, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 3
1999, d4rzgA_, 0.7115, 3.46, 0.175, 229, 211, CRYSTAL STRUCTURE ANALYSIS OF THE DNPA-BOUNDED NUR77 LIGAND BINDING DOMAIN
2000, p5q14A_, 0.7114, 3.20, 0.207, 233, 208, LIGAND BINDING TO FARNESOID-X-RECEPTOR
2001, d5k3nB_, 0.7114, 3.46, 0.175, 229, 211, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
2002, d4re8A_, 0.7113, 3.43, 0.175, 230, 211, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 5
2003, d5k3lA_, 0.7112, 3.44, 0.175, 230, 211, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
2004, p4mddA_, 0.7111, 3.43, 0.175, 230, 211, CRYSTAL STRUCTURE OF THE GLUCOCORTICOID RECEPTOR BOUND TO A NON- STEROIDAL ANTAGONIST REVEALS REPOSITIONING AND PARTIAL DISORDERING OF ACTIVATION FUNCTION HELIX 12
2005, d2q5gB_, 0.7111, 2.74, 0.163, 225, 202, LIGAND BINDING DOMAIN OF PPAR DELTA RECEPTOR IN COMPLEX WITH A PARTIAL AGONIST
2006, d1g5yB_, 0.7111, 2.90, 0.163, 225, 203, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2007, d5ntqB_, 0.7109, 3.39, 0.176, 229, 210, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
2008, d5ntpA_, 0.7107, 2.94, 0.162, 226, 204, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
2009, p5q1hC_, 0.7106, 3.00, 0.161, 226, 205, LIGAND BINDING TO FARNESOID-X-RECEPTOR
2010, d3olfA1, 0.7106, 3.40, 0.179, 229, 212, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-METHYLBENZOIC ACID
2011, d2aclE_, 0.7106, 2.65, 0.165, 223, 200, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2012, d3v3eA_, 0.7105, 3.22, 0.212, 233, 208, CRYSTAL STRUCTURE OF THE HUMAN NUR77 LIGAND-BINDING DOMAIN
2013, d3okiA1, 0.7104, 3.23, 0.216, 233, 208, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-1H-BENZIMIDAZOL-1-YL]-N2-DICYCLOHEXYLETHANAMIDE
2014, p3gyuA_, 0.7104, 2.40, 0.299, 215, 194, NUCLEAR RECEPTOR DAF-12 FROM PARASITIC NEMATODE STRONGYLOIDES STERCORALIS IN COMPLEX WITH ITS PHYSIOLOGICAL LIGAND DAFACHRONIC ACID DELTA 7
2015, d3eybA_, 0.7103, 3.11, 0.303, 229, 201, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2016, d3v3qA1, 0.7100, 3.63, 0.174, 232, 213, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH ETHYL 2-[234 TRIMETHOXY-6(1-OCTANOYL)PHENYL]ACETATE
2017, d3ommA1, 0.7100, 3.63, 0.174, 232, 213, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-FLUOROBENZOIC ACID
2018, d2aclG_, 0.7100, 3.37, 0.176, 229, 210, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2019, d3eybB_, 0.7099, 3.00, 0.161, 226, 205, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2020, d3eybC_, 0.7096, 3.26, 0.206, 234, 209, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2021, d3eybD_, 0.7095, 3.20, 0.207, 233, 208, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2022, p5q1fA_, 0.7094, 3.38, 0.176, 230, 210, LIGAND BINDING TO FARNESOID-X-RECEPTOR
2023, d2aclA_, 0.7094, 2.92, 0.157, 226, 204, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2024, d4zomB_, 0.7088, 3.24, 0.212, 233, 208, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
2025, d4rzeA_, 0.7087, 2.89, 0.163, 225, 203, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN L437W D594E MUTANT
2026, d2qw4D_, 0.7084, 2.49, 0.249, 232, 193, HUMAN NR4A1 LIGAND-BINDING DOMAIN
2027, d1g5yC_, 0.7083, 2.95, 0.146, 235, 205, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2028, d1g1uA_, 0.7082, 3.26, 0.297, 229, 202, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2029, d1g5yD_, 0.7080, 2.66, 0.165, 223, 200, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2030, d1g1uD_, 0.7075, 2.98, 0.157, 230, 204, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2031, d4zomA_, 0.7073, 3.49, 0.175, 228, 211, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
2032, d3fc6A_, 0.7072, 3.38, 0.176, 229, 210, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
2033, d3h52A1, 0.7069, 2.24, 0.292, 214, 192, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2034, d4kziA_, 0.7068, 3.29, 0.211, 234, 209, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH DPDO
2035, d1g5yA_, 0.7067, 3.49, 0.175, 229, 211, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2036, d4refA_, 0.7062, 3.13, 0.120, 234, 208, CRYSTAL STRUCTURE OF TR3 LBD_L449W IN COMPLEX WITH MOLECULE 2
2037, d4nb6B_, 0.7059, 2.62, 0.296, 199, 196, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF RORC WITH T0901317
2038, p4mddB_, 0.7059, 3.31, 0.211, 234, 209, CRYSTAL STRUCTURE OF THE GLUCOCORTICOID RECEPTOR BOUND TO A NON- STEROIDAL ANTAGONIST REVEALS REPOSITIONING AND PARTIAL DISORDERING OF ACTIVATION FUNCTION HELIX 12
2039, d4kzjA_, 0.7058, 3.38, 0.176, 229, 210, CRYSTAL STRUCTURE OF TR3 LBD L449W MUTANT
2040, d3tx7B_, 0.7051, 2.25, 0.292, 214, 192, CRYSTAL STRUCTURE OF LRH-1/BETA-CATENIN COMPLEX
2041, d4zomC_, 0.7050, 2.63, 0.296, 199, 196, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
2042, d5apkA1, 0.7045, 2.63, 0.296, 199, 196, LIGAND COMPLEX OF RORG LBD
2043, d4whfA_, 0.7041, 2.63, 0.296, 199, 196, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH 1-(345- TRIHYDROXYPHENYL)DECAN-1-ONE
2044, d5ntkA_, 0.7039, 3.33, 0.177, 229, 209, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
2045, d6bn6B1, 0.7037, 2.25, 0.292, 214, 192, IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTS
2046, d2q6rA_, 0.7035, 2.78, 0.165, 222, 200, CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED WITH PARTIAL AGONIST SF147
2047, d4wqpB_, 0.7028, 3.20, 0.213, 232, 207, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A BENZYL SULFONAMIDE INVERSE AGONIST
2048, d4nb6A_, 0.7028, 3.00, 0.218, 227, 202, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF RORC WITH T0901317
2049, d5k6eA_, 0.7026, 3.39, 0.297, 226, 202, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0654919
2050, d5k3mB_, 0.7024, 3.08, 0.303, 228, 201, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH UUA
2051, d3h52C1, 0.7020, 3.14, 0.299, 229, 201, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2052, d3fc6C_, 0.7016, 3.14, 0.299, 229, 201, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
2053, p4dorA_, 0.7013, 2.72, 0.160, 223, 200, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 IN ITS APO STATE BOUND TO A FRAGMENT OF HUMAN SHP BOX1
2054, d4zjrB_, 0.7012, 2.31, 0.292, 207, 192, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
2055, d5k3mA_, 0.6996, 2.48, 0.247, 245, 194, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH UUA
2056, d2q60C_, 0.6995, 3.23, 0.208, 232, 207, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2057, d4zjrC1, 0.6993, 3.10, 0.303, 228, 201, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
2058, d5ufrA_, 0.6992, 3.22, 0.209, 231, 206, STRUCTURE OF RORGT BOUND TO
2059, p4wvdA_, 0.6991, 2.66, 0.156, 222, 199, IDENTIFICATION OF A NOVEL FXR LIGAND THAT REGULATES METABOLISM
2060, d5tbpC_, 0.6989, 1.86, 0.253, 202, 186, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2061, p4lsjA_, 0.6985, 3.23, 0.214, 231, 206, CRYSTAL STRUCTURE OF THE GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN BOUND TO A DIBENZOXAPINE SULFONAMIDE
2062, d5ntkB_, 0.6982, 2.77, 0.219, 218, 196, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
2063, d1yjeA_, 0.6982, 2.61, 0.162, 219, 197, CRYSTAL STRUCTURE OF THE RNGFI-B LIGAND-BINDING DOMAIN
2064, d5ufrB_, 0.6976, 2.71, 0.161, 222, 199, STRUCTURE OF RORGT BOUND TO
2065, d5tbpB_, 0.6967, 3.24, 0.214, 231, 206, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2066, p5uhiA_, 0.6962, 2.98, 0.163, 225, 203, STRUCTURE OF RORGT BOUND TO
2067, p4b7wA_, 0.6957, 2.73, 0.166, 222, 199, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2068, p4b7wC_, 0.6956, 3.16, 0.183, 235, 202, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2069, d4zjwB_, 0.6949, 2.77, 0.156, 221, 199, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 16
2070, d5x8qE_, 0.6948, 2.67, 0.157, 221, 198, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
2071, p4wvdB_, 0.6936, 2.70, 0.165, 226, 200, IDENTIFICATION OF A NOVEL FXR LIGAND THAT REGULATES METABOLISM
2072, d5x8qA_, 0.6934, 2.59, 0.167, 222, 198, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
2073, d3falC_, 0.6933, 2.82, 0.242, 236, 194, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
2074, d2xhsA1, 0.6933, 2.21, 0.295, 202, 190, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF FUSHI TARAZU FACTOR 1 OF DROSOPHILA MELANOGASTER.
2075, d3falA_, 0.6928, 2.75, 0.232, 216, 194, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
2076, d5x8qG_, 0.6927, 2.74, 0.167, 220, 198, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
2077, p5uhiB_, 0.6925, 2.77, 0.161, 222, 199, STRUCTURE OF RORGT BOUND TO
2078, d5x8qC_, 0.6913, 2.47, 0.321, 203, 190, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
2079, d5ethB_, 0.6913, 2.60, 0.163, 219, 196, RORY IN COMPLEX WITH INVERSE AGONIST 3.
2080, d4oztU_, 0.6913, 3.00, 0.159, 223, 201, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (PONA CRYSTAL)
2081, d2iz2A1, 0.6913, 2.95, 0.161, 210, 199,  
2082, d5aygB_, 0.6912, 2.88, 0.304, 213, 194, CRYSTAL STRUCTURE OF THE HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH 3G
2083, p5q0lA_, 0.6909, 2.47, 0.239, 225, 188, LIGAND BINDING TO FARNESOID-X-RECEPTOR
2084, d4zjrA_, 0.6901, 2.95, 0.163, 225, 202, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
2085, d2q60A_, 0.6901, 3.05, 0.219, 226, 201, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2086, d5ixkA_, 0.6893, 3.06, 0.159, 223, 201, RORGAMMA IN COMPLEX WITH INVERSE AGONIST BIO399.
2087, d5x8xE_, 0.6889, 2.85, 0.311, 213, 193, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
2088, d5x8xC_, 0.6889, 2.73, 0.162, 223, 198, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
2089, d5x8xA_, 0.6889, 2.43, 0.212, 202, 189, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
2090, d4zjrD1, 0.6889, 2.43, 0.212, 202, 189, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
2091, d4oivB_, 0.6884, 3.05, 0.154, 222, 201, STRUCTURAL BASIS FOR SMALL MOLECULE NDB AS A SELECTIVE ANTAGONIST OF FXR
2092, p5q0lC_, 0.6883, 2.92, 0.151, 228, 199, LIGAND BINDING TO FARNESOID-X-RECEPTOR
2093, d5x8xG_, 0.6881, 3.08, 0.171, 208, 199, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
2094, d2q60B_, 0.6876, 2.94, 0.151, 228, 199, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2095, d5ethA_, 0.6874, 2.27, 0.293, 198, 188, RORY IN COMPLEX WITH INVERSE AGONIST 3.
2096, d3b0wB_, 0.6869, 3.56, 0.182, 226, 203, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH DIGOXIN
2097, d4zjwA_, 0.6856, 2.06, 0.296, 196, 186, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 16
2098, d4n5gC_, 0.6856, 2.93, 0.151, 228, 199, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2099, d5ixkB_, 0.6854, 2.91, 0.156, 223, 199, RORGAMMA IN COMPLEX WITH INVERSE AGONIST BIO399.
2100, p5w4rB_, 0.6846, 2.95, 0.151, 228, 199, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
2101, p3r2aC_, 0.6843, 2.99, 0.156, 221, 199, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
2102, d4n5gB_, 0.6842, 2.62, 0.275, 195, 193, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2103, d2q60D_, 0.6841, 3.38, 0.179, 226, 201, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2104, p6br3A_, 0.6838, 3.38, 0.179, 226, 201, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST TAK-828.
2105, d4zomD_, 0.6837, 2.66, 0.159, 219, 195, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
2106, d5aygA_, 0.6826, 3.68, 0.163, 221, 208, CRYSTAL STRUCTURE OF THE HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH 3G
2107, p5wzxB_, 0.6813, 2.76, 0.164, 217, 195, STRUCTURAL BASIS FOR A PENTACYCLIC OLEANANE-TYPE TRITERPENOID AS A LIGAND OF FXR
2108, p3p0uA_, 0.6801, 2.65, 0.295, 198, 190, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN TESTICULAR RECEPTOR 4
2109, d2gl8C_, 0.6792, 2.95, 0.157, 219, 198, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2110, d3b0wA_, 0.6783, 2.96, 0.151, 228, 199, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH DIGOXIN
2111, p3n00A_, 0.6780, 3.07, 0.150, 228, 200, CRYSTAL STRUCTURE OF A DELETION MUTANT OF HUMAN REVERBA LIGAND BINDING DOMAIN BOUND WITH AN NCOR ID1 PEPTIDE DETERMINED TO 2.60A
2112, p6b30A_, 0.6768, 2.96, 0.151, 228, 199, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 1
2113, d3kfcC_, 0.6767, 2.77, 0.164, 217, 195, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
2114, p1z5xU_, 0.6765, 2.91, 0.177, 218, 198, HEMIPTERAN ECDYSONE RECEPTOR LIGAND-BINDING DOMAIN COMPLEXED WITH PONASTERONE A
2115, p6br2A_, 0.6761, 3.64, 0.164, 220, 207, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL ISOQUINOLINE INVERSE AGONIST.
2116, p3p0uB_, 0.6751, 2.96, 0.151, 224, 199, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN TESTICULAR RECEPTOR 4
2117, d2gl8B_, 0.6751, 2.33, 0.323, 198, 186, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2118, p5w4rA_, 0.6743, 2.78, 0.158, 218, 196, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
2119, d2gl8D_, 0.6742, 2.68, 0.165, 217, 194, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2120, d2gl8A_, 0.6717, 3.07, 0.150, 219, 200, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2121, p6br3B_, 0.6709, 2.76, 0.312, 209, 189, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST TAK-828.
2122, p5wzxA_, 0.6707, 3.07, 0.155, 220, 200, STRUCTURAL BASIS FOR A PENTACYCLIC OLEANANE-TYPE TRITERPENOID AS A LIGAND OF FXR
2123, p6br2B_, 0.6675, 2.59, 0.161, 217, 193, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL ISOQUINOLINE INVERSE AGONIST.
2124, d3cjwA1, 0.6660, 1.96, 0.311, 185, 183, CRYSTAL STRUCTURE OF THE HUMAN COUP-TFII LIGAND BINDING DOMAIN
2125, p6b30B_, 0.6653, 2.60, 0.316, 209, 187, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 1
2126, p4b7wD_, 0.6635, 2.70, 0.296, 197, 189, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2127, p4b7wB_, 0.6635, 2.67, 0.161, 216, 193, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2128, p5w4vB_, 0.6588, 2.62, 0.156, 215, 192, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
2129, p5w4vA_, 0.6575, 2.71, 0.155, 217, 193, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
2130, d4oivA_, 0.6558, 3.19, 0.165, 212, 200, STRUCTURAL BASIS FOR SMALL MOLECULE NDB AS A SELECTIVE ANTAGONIST OF FXR
2131, p4ozrE_, 0.6555, 3.03, 0.195, 222, 200, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (METHYLENE LACTAM CRYSTAL)
2132, p5gymB_, 0.6488, 3.03, 0.195, 222, 200, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2133, p5w4vC_, 0.6487, 2.39, 0.310, 194, 184, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
2134, p4n8rB_, 0.6487, 2.57, 0.162, 215, 191, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2135, p4n8rC_, 0.6480, 2.17, 0.208, 184, 183, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2136, p5w4vE_, 0.6475, 2.75, 0.156, 215, 192, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
2137, p4n5gA_, 0.6462, 2.22, 0.197, 186, 183, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2138, p5tbpA_, 0.6456, 2.83, 0.304, 193, 191, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2139, p4n5gD_, 0.6455, 2.86, 0.161, 215, 193, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2140, p5gymF_, 0.6448, 3.04, 0.181, 205, 199, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2141, p4n8rD_, 0.6448, 2.28, 0.324, 192, 182, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2142, d4ozrU_, 0.6437, 2.64, 0.158, 214, 190, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (METHYLENE LACTAM CRYSTAL)
2143, d3nsqB_, 0.6437, 2.37, 0.295, 195, 183, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD COMPLEXED WITH ANTAGONIST DANTHRON
2144, p4n8rA_, 0.6431, 2.32, 0.324, 190, 182, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2145, p5gymA_, 0.6423, 2.57, 0.164, 213, 189, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2146, p5tbpD_, 0.6421, 3.36, 0.161, 210, 199, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2147, p5gymG_, 0.6417, 2.70, 0.164, 212, 189, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2148, p4logB_, 0.6414, 3.59, 0.243, 203, 202, THE CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR PNR LIGAND BINDING DOMAIN FUSED WITH MBP
2149, p5gymD_, 0.6397, 3.59, 0.243, 203, 202, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2150, d3nspA_, 0.6396, 2.65, 0.160, 212, 188, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD
2151, p5gymE_, 0.6389, 2.24, 0.223, 182, 179, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2152, d3nsqA_, 0.6389, 2.24, 0.223, 182, 179, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD COMPLEXED WITH ANTAGONIST DANTHRON
2153, p5w4vD_, 0.6381, 2.64, 0.156, 209, 186, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
2154, p5gymH_, 0.6371, 2.66, 0.156, 209, 186, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2155, p4n73A_, 0.6370, 3.15, 0.183, 210, 191, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN (LBD) OF REV-ERB BETA BOUND TO COBALT PROTOPORPHYRIN IX
2156, p5w4vF_, 0.6351, 2.39, 0.190, 185, 179, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
2157, p5gymC_, 0.6343, 2.46, 0.311, 196, 177, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2158, p2v0vA_, 0.6285, 2.73, 0.161, 206, 186, CRYSTAL STRUCTURE OF REV-ERB BETA
2159, d3nspB_, 0.6281, 2.62, 0.311, 198, 177, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD
2160, p2v0vD_, 0.6273, 2.67, 0.311, 196, 177, CRYSTAL STRUCTURE OF REV-ERB BETA
2161, p2v0vB_, 0.6221, 2.66, 0.153, 206, 183, CRYSTAL STRUCTURE OF REV-ERB BETA
2162, p2v0vC_, 0.6210, 2.58, 0.309, 196, 178, CRYSTAL STRUCTURE OF REV-ERB BETA
2163, p4xajA3, 0.6206, 2.67, 0.309, 188, 178, CRYSTAL STRUCTURE OF HUMAN NR2E1/TLX
2164, p4xajC4, 0.6200, 2.59, 0.315, 196, 178, CRYSTAL STRUCTURE OF HUMAN NR2E1/TLX
2165, p4xajB3, 0.6178, 2.71, 0.307, 195, 176, CRYSTAL STRUCTURE OF HUMAN NR2E1/TLX
2166, p4xajD4, 0.6169, 2.59, 0.315, 197, 178, CRYSTAL STRUCTURE OF HUMAN NR2E1/TLX
2167, p4logA4, 0.6154, 2.85, 0.251, 196, 179, THE CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR PNR LIGAND BINDING DOMAIN FUSED WITH MBP
2168, p3f5cB_, 0.6124, 2.30, 0.316, 199, 174, STRUCTURE OF DAX-1:LRH-1 COMPLEX
2169, p3f5cC_, 0.6089, 2.61, 0.315, 197, 178, STRUCTURE OF DAX-1:LRH-1 COMPLEX
2170, p3cqvA_, 0.6068, 2.37, 0.316, 193, 174, CRYSTAL STRUCTURE OF REVERB BETA IN COMPLEX WITH HEME
2171, p4xaiA3, 0.6029, 2.63, 0.311, 188, 177, CRYSTAL STRUCTURE OF RED FLOUR BEETLE NR2E1/TLX
2172, p2v7cB_, 0.5978, 2.68, 0.309, 192, 175, CRYSTAL STRUCTURE OF REV-ERB BETA
2173, p4xaiB3, 0.5942, 3.42, 0.236, 232, 191, CRYSTAL STRUCTURE OF RED FLOUR BEETLE NR2E1/TLX
2174, p2v7cA_, 0.5756, 3.42, 0.236, 232, 191, CRYSTAL STRUCTURE OF REV-ERB BETA
2175, p4nufA3, 0.5729, 2.33, 0.312, 192, 173, CRYSTAL STRUCTURE OF SHP/EID1
